

DISEASE RELATED PROTEIN NETWORK

The present invention relates to a method for generating a network of direct and
5 indirect interaction partners of a disease-related (poly)peptide comprising the steps of
(a) contacting a selection of (poly)peptides suspected to contain one or several of
said direct or indirect interaction partners with said disease-related (poly)peptides
and optionally with known direct or indirect interaction partners of said disease-
related (poly)peptide under conditions that allow the interaction between interaction
10 partners to occur; (b) detecting (poly)peptides that interact with said disease-related
(poly)peptide or with said known direct or indirect interaction partners of said
disease-related (poly)peptide; (c) contacting (poly)peptides detected in step (b) with a
selection of (poly)peptides suspected to contain one or several (poly)peptides
interacting with said (poly)peptides detected in step (b) under conditions that allow
15 the interaction between interaction partners to occur; (d) detecting proteins that
interact with said (poly)peptides detected in step (b); (e) contacting said disease-
related (poly)peptide and optionally said known direct or indirect interaction partners
of said disease-related (poly)peptide, said (poly)peptides detected in steps (b) and
(d) and a selection of proteins suspected to contain one or several (poly)peptides
20 interacting with any of the afore mentioned (poly)peptides under conditions that allow
the interaction between interaction partners to occur; (f) detecting (poly)peptides that
interact with said disease-related (poly)peptide and optionally said known direct or
indirect interaction partners of said disease-related (poly)peptide or with said
(poly)peptides identified in step (b) or (d); and (g) generating a (poly)peptide -
25 (poly)peptide interaction network of said disease-related (poly)peptide and optionally
said known direct or indirect interaction partners of said disease-related (poly)peptide
and said (poly)peptides identified in steps (b), (d) and (f). Moreover, the present
invention relates to a protein complex comprising at least two proteins and to
methods for identifying compounds interfering with an interaction of said proteins.
30 Finally, the present invention relates to a pharmaceutical composition and to the use
of compounds identified by the present invention for the preparation of a
pharmaceutical composition for the treatment of Huntington's disease.

Several documents are cited throughout the text of this specification. The disclosure content of the documents cited herein (including any manufacture's specifications, instructions, etc.) is herewith incorporated by reference. The present invention is based on scientific experiments which have been performed on biological specimen
5 derived from diseased patients. Patients have given their consent to use the specimen for the study which is disclosed in the present invention. In case of deceased patients, the consent has been given by a relative.

With the identification of >35,000 genes in the human genome the challenge arises to
10 assign biological function to all proteins and to link these proteins to physiological pathways and disease processes. Since protein-protein interactions play a role in most events in a cell, clues to the function of an unknown protein can be obtained by investigating its interaction with other proteins whose function are already known. Thus, if the function of one protein is known, the function of the binding partners can
15 be inferred (deduced). This allows the researcher to assign a biological function to uncharacterized proteins by identifying protein-protein interactions. For example, several so far uncharacterized proteins in *Caenorhabditis elegans* were identified in a yeast two-hybrid screen for eukaryotic 26S proteasome interacting proteins and thereby could be linked to the ubiquitin-proteasome proteolytic pathway (Vidal et al.,
20 2001). Elucidation of protein-protein interactions is particularly desired when it comes to the generation of new drugs. For many diseases, the available drug portfolio is insufficient or inappropriate to provide a cure or to prevent onset of the disease. One such disease is Huntington's disease.

25 Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded polyglutamine (polyQ) tract in the multidomain protein huntingtin (htt). The elongated polyQ sequence is believed to confer a toxic gain of function to htt. It leads to htt aggregation primarily in neurons of the striatum and cortex and subsequently to the appearance of the disease phenotype. However, there is experimental evidence that
30 loss of htt function may also contribute to HD pathogenesis. Since huntingtin aggregation correlates with disease progression, it is crucial to develop methods for identifying factors that promote or inhibit aggregation of huntingtin.

Previously, a number of single interaction partners of huntingtin had been reported. In light of these reports, it is tempting to speculate that huntingtin is bound into a larger network of interacting partners, many of which might be capable of modulating huntingtin's activity and function by direct or indirect interaction. It is likely that an aberrant interaction of huntingtin with some of the members of said network will impair huntingtin's normal function. Moreover, this interaction might also be relevant for the conformation of huntingtin or for its solubility or state of aggregation. Interfering with the direct or indirect interactions of the protein-protein interaction network will provide an excellent basis for therapeutic intervention as it will allow to modulate huntingtin's activity or state of aggregation or both. The state of the art so far did not provide compounds capable of reducing or suppressing huntingtin aggregation since the factors promoting or suppressing huntingtin aggregation were not known.

Thus, the technical problem underlying the present invention was to provide novel approaches for identifying direct or indirect interaction partners of disease-related proteins, which must be seen as new targets for drug development. The solution to this technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to a method for generating a network of direct and indirect interaction partners of a disease-related (poly)peptide comprising the steps of (a) contacting a selection of (poly)peptides suspected to contain one or several of said direct or indirect interaction partners with said disease-related (poly)peptides and optionally with known direct or indirect interaction partners of said disease-related (poly)peptide under conditions that allow the interaction between interaction partners to occur; (b) detecting (poly)peptides that interact with said disease-related (poly)peptide or with said known direct or indirect interaction partners of said disease-related (poly)peptide; (c) contacting (poly)peptides detected in step (b) with a selection of (poly)peptides suspected to contain one or several (poly)peptides interacting with said (poly)peptides detected in step (b) under conditions that allow the interaction between interaction partners to occur; (d) detecting proteins that interact with said (poly)peptides detected in step (b); (e) contacting said disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide, said (poly)peptides

detected in steps (b) and (d) and a selection of proteins suspected to contain one or several (poly)peptides interacting with any of the afore mentioned (poly)peptides under conditions that allow the interaction between interaction partners to occur; (f) detecting (poly)peptides that interact with said disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide or with said (poly)peptides identified in step (b) or (d); and (g) generating a (poly)peptide-(poly)peptide interaction network of said disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide and said (poly)peptides identified in steps (b), (d) and (f).

In accordance with the present invention, the term "direct and indirect interaction partners" relates to (poly)peptides that either directly interact with the disease-related (poly)peptide (direct interaction) or that interact via a protein binding to/interacting with said disease-related (poly)peptide. In the latter case, there is no direct contact between the direct interaction partner and the disease-related protein. Rather, a further protein forms a "bridge" between these two proteins.

The term "known direct or indirect interaction partners" refers to the fact that for certain disease-related (poly)peptides, such interaction partners are known in the art. If such interaction partners are known in the art, it is advantageous to include them into the method of the invention. If no such interactions partners are known in the art, then the network may be generated starting solely from the known disease-related (poly)peptide.

The term "conditions that allow the interaction between interaction partners to occur" relates to conditions that would, as a rule, resemble physiological conditions. Conditions that allow protein actions are well known in the art and, can be taken, for example from Golemis, E.A. Ed., Protein-Protein Interactions, Cold Spring Harbor Laboratory Press, 2002.

The term "suspected to contain one or more of said direct or indirect interaction partners" relates to the fact that normally, a selection of (poly)peptides would be employed where the person skilled in the art would expect that interaction partners

are present. Examples of such selections of (poly)peptides are libraries of human origin such as cDNA libraries or genomic libraries.

The term "detecting proteins" refers to the fact that the (poly)peptides interacting with the "bait" (poly)peptides are identified within the selection of (poly)peptides. A further
5 characterization or isolation of the "prey" (poly)peptides at this stage may be advantageous but is not necessary. The term "detecting (poly)peptides" preferably also comprises characterizing said (poly)peptides or the nucleic acid molecules encoding said (poly)peptides. The skilled person knows that this can be done by a number of techniques, some of which are described for example in Sambrook et al.,
10 "Molecular Cloning, A Laboratory Manual"; CSH Press, Cold Spring Harbor, 1989 or Higgins and Hames (eds.). For example, the nucleotide sequence may be determined by DNA Sequencing, including PCR-Sequencing (see for example Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H., Cold Spring Harb Symp Quant Biol. 1986;51 Pt 1:263-73). Alternatively, the amino acid sequence of said
15 (poly)peptide may be determined. The skilled artisan knows various methods for sequencing proteins which include the method of Edman degradation, which is a preferred method of the present invention of determining the amino acid sequence of a protein. However, the amino acid sequence of a protein or (poly)peptide can also be reliably determined by methods such as for example Maldi-Tof, optionally in
20 combination with the method of Edman degradation. The interaction partner may be identified either as fusion with a DNA binding domain or as fusion with an activation domain. Preferably, if an interaction partner has been identified as a fusion molecule comprising a DNA binding domain, the interaction partner is cloned into a vector allowing the expression of the interaction partner as a fusion with an activation
25 domain. Consequently, protein interaction can be tested in the context the DNA activation or the DNA binding domain.

In accordance with the present invention, the first round of detecting (poly)peptides that interact with the "bait" (poly)peptides recited in step (a) wherein the detected (poly)peptides be considered as "prey" (poly)peptides is followed by the second
30 round of detecting further interacting (poly)peptides wherein the former "prey" (poly)peptides are now used as "bait" (poly)peptides. In certain preferred embodiments of the present invention such as in a two-hybrid detection system, a re-

cloning of the former "prey" (poly)peptides into vectors that are suitable for expressing "bait" (poly)peptides may be desired.

Accordingly, the invention describes a novel strategy to identify protein-protein interaction networks for human disease proteins. This strategy was applied to detect pair-wise protein-protein interactions for Huntington's disease and is useful for other hereditary diseases as well. Several human hereditary diseases are summarized in table 5.

A crucial step of the method of the invention is step (e). Here, the disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide are contacted under appropriate conditions, preferably at the same time, with both the (poly)peptides identified in steps (b) and (d) and further with a selection of (poly)peptides suspected to contain further interaction partners. Alternatively, the various baits, preys and further selection partners are added one after another, so that the final pool contains all baits and preys so far identified, in addition to the further selection partners. In other terms, in this step of the method of the invention, all "baits" and all "preys" are pooled and, additionally, further potential interaction partners are added. In this way, surprisingly the number of directed or indirect interactions partners of the previously identified "baits" and "preys" could significantly be enhanced. It is to be understood that various preys identified in one detection step may interact with each other and not only with the baits that were employed for the identification. For example, if a collection of baits detects preys "a" and "b", the invention does not exclude that "a" also interacts with "b". The same holds true mutatis mutandis for the baits used in accordance with the present invention. Wherever possible, baits and preys are exchangeable in the sense that bait (poly)peptides may be used as preys and vice versa. In a given case, however, the skilled person has to determine whether or not this exchange is possible on the basis of unfavourable site effects and limitations of the applied scientific approach. This can be done by the skilled person without undue burden by applying standard techniques known in the art.

It is further preferred in accordance with the present invention that the interaction of proteins is a specific interaction, such as a specific binding. This means that the

(poly)peptide being an interaction partner with a further (poly)peptide only or essentially only interacts with the interaction site(s) involved with this interaction partner. This does not exclude, of course, that further interaction sites of said (poly)peptide interact with further interaction partners, wherein in the corresponding
5 interaction is preferably also specific. The concept also embraces that, if a (poly)peptide has several identical interaction sites, which in nature bind to different interaction partners, these different interaction partners are also bound by the (poly)peptide in the method of the present invention.

In other terms, at least in the case of huntingtin, the number of interaction partners
10 found in step (e) was enhanced in an exponential rather than in a linear fashion.

The term "(poly)peptide" refers alternatively to peptide or to (poly)peptides. Peptides conventionally are covalently linked amino acids of up to 30 residues, whereas polypeptides (also referred to as "proteins") comprise 31 and more amino acid residues.

15 The term "huntingtin" refers to a protein with the data bank accession number P42858 which is referenced for the purpose of the present invention as "wild-type huntingtin protein". However, the term "huntingtin" also comprises proteins encoded by the nucleic acid sequence deposited under accession number L12392 or to proteins encoded by nucleic acid molecules which hybridize to the nucleic acid
20 molecule of L12392 under stringent conditions of hybridization. The present invention relates to all variants of the huntingtin protein. In particular, relevant for the present invention are those variants of huntingtin which comprise a polyglutamine tract (polyQ tract) or an elongated polyQ tract. A polyQ tract consists of two or more glutamines within the huntingtin protein. The insertion of additional glutamine codons
25 will result in huntingtin proteins with, for example 2, 51, 75 or 100 added glutamines in comparison to the sequence deposited under accession number P42858. In fact, the person skilled in the art knows that the huntingtin protein may have a glutamine tract with any random number of glutamines in the range of 1 to 200 added glutamines. All these proteins are comprised by the present invention.

30 The term "hybridizes under stringent conditions", as used in the description of the present invention, is well known to the skilled artisan and corresponds to conditions

of high stringency. Appropriate stringent hybridization conditions for each sequence may be established by a person skilled in the art on well-known parameters such as temperature, composition of the nucleic acid molecules, salt conditions etc.; see, for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual"; CSH Press, Cold Spring Harbor, 1989 or Higgins and Hames (eds.), "Nucleic acid hybridization, a practical approach", IRL Press, Oxford 1985, see in particular the chapter "Hybridization Strategy" by Britten & Davidson, 3 to 15. Stringent hybridization conditions are, for example, conditions comprising overnight incubation at 42° C in a solution comprising: 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°. Other stringent hybridization conditions are for example 0.2 x SSC (0.03 M NaCl, 0.003M Natriumcitrat, pH 7) bei 65°C. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC). Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

The skilled person knows that the presence of additional codons in the nucleic acid sequence of huntingtin might significantly reduce the capability of this nucleic acid molecule to hybridize to the nucleic acid molecule deposited under L12392 and referenced as wild-type huntingtin protein. Nevertheless, such proteins shall still be comprised by the present invention. In fact, computer programs such as the computer program Bestfit (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) or blast, capable of calculating homologies between two nucleic acid sequences, efficiently recognize nucleotide insertions and allow for an adjustment of gaps created by these insertions. The term "huntingtin" as used in the present invention, also includes those molecules of huntingtin, which have a

homology of more than 95% to wild-type huntingtin when analyzed with a program like bestfit under conditions not weighing gaps created by polyQ tracts (gap penalty=0).

5 The term "contacting" means bringing into contact so that two or more proteins or (poly)peptides can interact with each other, preferably under physiological conditions. The terms "interacting" or "binding" refer to a transient or permanent contact between two proteins or (poly)peptides. Preferably, the (poly)peptide or protein is provided by expression from a nucleic acid molecule, more preferably from a cDNA molecule within a cDNA library. Alternatively, said nucleic acid molecule is a genomic nucleic acid molecule of a genomic DNA library, or a nucleic acid molecule from a synthetic DNA or RNA library. Preferably, the nucleic acid molecule encoding the disease-related protein or its interaction partner is obtainable from nerve cells, brain tissue human adrenal gland, human bladder, human bone, human brain, human colon, human dorsal root ganglion, human heart, human HeLa cells, human kidney, human liver, human lung, human mammary gland, human ovary, human pancreas, human placenta, human prostate, human retina, human salivary gland, human skeletal muscle, human small intestine, human smooth muscle, human spinal cord, human spleen, human stomach, human testis, human thymus, human thyroid, human tonsil, human trachea, human uterus, human cell line HEP G2, human cell line MDA 435, human fetal brain, human fetal heart, human fetal kidney, human fetal liver, human fetal spleen, human fetal thymus, human breast tumor, human cervix tumor, human colon tumor, human kidney tumor, human lung tumor, human ovary tumor, human stomach tumor, human brain tumor and/or human uterus tumor.

25 The term "disease-related protein" refers to a protein known to be the causative agent of a disease or known to be involved in onset or progression of a disease. Preferably, said disease is CHOREA HUNTINGTON or the disease-related protein is huntingtin. More preferably, the disease-related protein is selected from table 6 and/or 7. The term "conditions that allow the interaction between interaction partners" means conditions that are similar to physiological conditions. Preferably, said conditions are physiological conditions.

The term "selection of (poly)peptides" refers to a library of (poly)peptides which comprises the above-mentioned libraries, but also includes libraries such as phage

display libraries. Preferably, the (poly)peptide is provided by expression from a nucleic acid molecule. Preferably, the protein or (poly)peptide expressed by said nucleic acid molecule is a (poly)peptide comprising a DNA binding domain (DBD) (in this case the fusion protein is termed "bait") or (b) a (poly)peptide comprising an activation domain capable of interacting with a transcription factor or an RNA polymerase and capable of activating transcription of a reporter or indicator gene (in this case the fusion protein is called "prey"). As used here, the terms "reporter gene" and "indicator gene" are to be understood as synonyms. It is important to note that one of the interaction partners will always comprise the amino acid sequence of a protein or (poly)peptide translated from said nucleic acid molecule while the other interaction partner will comprise the amino acid sequence of a protein or protein fragment. Preferably, a bait used for a method of the present invention is selected from the proteins listed in table 6 and/or 7. If, for example, the proteins encoded by the nucleic acid molecules contain a DNA binding domain fused in frame, the fusion protein can bind to the DNA recognition sequence of the DNA binding domain. Interaction of said fusion protein with a second fusion protein containing an activation domain can induce transcription of a nearby indicator gene. The indicator gene may encode a selection marker such as a protein that confers resistance to an antibiotic including ampicillin, kanamycin, chloramphenicol, tetracyclin, hygromycin, neomycin or methotrexate. Further examples of antibiotics are Penicillins: Ampicillin HCl, Ampicillin Na, Amoxycillin Na, Carbenicillin disodium, Penicillin G, Cephalosporins, Cefotaxim Na, Cefalexin HCl, Vancomycin, Cycloserine. Other examples include Bacteriostatic Inhibitors such as: Chloramphenicol, Erythromycin, Lincomycin, Tetracyclin, Spectinomycin sulfate, Clindamycin HCl, Chlortetracycline HCl. Additional examples are proteins that allow selection with Bacteriosidal inhibitors such as those affecting protein synthesis irreversibly causing cell death. Aminoglycosides can be inactivated by enzymes such as NPT II which phosphorylates 3'-OH present on kanamycin, thus inactivating this antibiotic. Some aminoglycoside modifying enzymes acetylate the compound and block their entry in to the cell. Gentamycin, Hygromycin B, Kanamycin, Neomycin, Streptomycin, G418, Tobramycin Nucleic Acid Metabolism Inhibitors, Rifampicin, Mitomycin C, Nalidixic acid, Doxorubicin HCl, 5-Fluorouracil, 6-Mercaptopurine, Antimetabolites, Miconazole, Trimethoprim, Methotrexate, Metronidazole, Sulfametoxazole. Alternatively, said indicator gene may encode a protein such as lacZ, GFP or luciferase, the expression

of which can be monitored by detection of a specific color. Other proteins commonly used as indicator proteins are beta-galactosidase, beta-glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). In general, however, the selection in the yeast two hybrid-system is based on a deficiency of the yeast strain to produce specific amino acids. The skilled person knows that any amino acid deficiency can be used for this selection strategy.

Preferably said preys and baits are expressed from two separate expression vectors contained in one host cell. The nucleic acid molecule encoding the preys and baits can be introduced into the host cell, for example, by transformation, transfection, transduction or microinjection which are common techniques known to the person skilled in the art and which require no additional explanation. In addition, the nucleic acid molecule contains a chromosomal or episomal nucleic acid sequence encoding the above-mentioned indicator protein. The expression of said indicator protein is under control of a recognition sequence which serves as a binding site for the bait protein. The nucleic acid molecule may be fused either to a DNA binding domain or to an activation domain. Co-expression of only those bait- and prey fusion proteins which are capable of interacting will induce the expression of one of the above-identified indicator proteins and thus allow the identification a nucleic acid molecule encoding a protein capable of interacting with huntingtin or an interaction or binding partner of huntingtin. The skilled person knows this system as the yeast two hybrid system. The yeast two hybrid system, which uses a bait protein-prey protein combination to induce transcription of the reporter gene, is a preferred method to identify proteins capable of interacting with huntingtin or with a direct or indirect interaction or binding partner of huntingtin. See for example Fields and Song, Nature 340:245 (1989) or Uetz et al., 2000 Nature 403(6770): 623-7. This is a useful way of determining protein-protein interactions. Another preferred method uses the yeast three hybrid system, as described in U.S. Pat. No. 5,928,868. Preferably, steps (a) to (d) of the method for generating a network of direct and indirect interaction partners comprise the yeast two hybrid system. Preferably, steps (e) and (f) of the method for generating a network of direct and indirect interaction partners comprise yeast interaction mating. Preferably, said "interaction mating" comprises the interaction of

all interaction partners identified in steps (a) to (d). Also preferred is that the interaction partners identified in steps (a) to (d) interact as prey and bait proteins, so that all prey proteins are contacted with all bait proteins. Using the array mating system, each bait is tested individually for interaction with every prey in the array.

5 Alternatively, steps (e) and (f) of the method for generating a network of direct and indirect interaction partners comprise testing all interaction partners identified in steps (a) to (d) in interaction assays such as biacore or coimmunoprecipitation. When performing such an assay, it is preferred that the interaction partners are tested as prey and/or bait fusion proteins or contain no fused (poly)peptides. Preferably, all
10 interaction partners are contacted in the biacore or coimmunoprecipitation assay by themselves and by all other remaining interaction partners identified in steps (a) to (d).

The method for generating a network of direct and indirect interaction partners of a disease related protein or (poly)peptide has proven to be an effective tool for
15 unveiling the protein-protein interactions (PPI) of preferably monogenic diseases. This is exemplified by the analysis of the disease related protein of Chorea Huntington, the analysis of which has demonstrated that the method of the present invention will be useful in an approach to identify potential drugs in the treatment of CHOREA HUNTINGTON. Moreover, this method will also be effective in unveiling
20 the protein-protein interactions of other disease related proteins and in identifying novel targets for treatment of these diseases. Using a preferred combination of library and matrix yeast two-hybrid screens, based on the methods of the present invention, a highly connected network was generated among 70 proteins involved in 117 protein-protein interactions, 99 of which had not been described previously. As
25 progression of Huntington's disease (HD) appears to be linked to huntingtin aggregation, a set of network proteins was tested for their potential to modulate this process. By using the methods of the present invention, it was discovered that the GTPase activating protein GIT1 strongly promotes huntingtin aggregation *in vivo*. GIT1 also localises to huntingtin aggregates in brains of transgenic mice and HD
30 patients. Therefore, a combination of the methods of the present invention has proven to provide effective means for the identification of potential targets for therapeutic intervention. GIT1 is a selected example of a modulator interaction partner of huntingtin. The other proteins in the network of interaction partners

disclosed by the present invention are further modulator interaction partners of huntingtin.

Preferably, the interaction mating comprises using an array mating system. In general, for this screen, MAT α yeast cultures are transformed with plasmids encoding prey proteins and arrayed on a microtiter plate for interaction mating with individual MAT α strains expressing bait proteins. Using this test system, each bait can be tested individually for interaction with every prey in the array. Diploid yeast clones, formed by mating on YPD plates and expressing both, bait and prey proteins, are selected on agar SDII plates, and further transferred for example by a spotting robot on SDIV plates to select for protein-protein interactions. In a more preferred embodiment of the method, plasmids encoding bait and prey proteins are transformed into strains L40ccua and L40cca α , respectively. L40cca α clones are arrayed on microtitre plates and mixed with a single L40ccua clone for interaction mating. These cells are transferred, preferably by a robot onto YPD medium plates and, after incubation for 20h to 28h at approximately 30°C, for selection of the cells, were transferred onto SDII medium plates, where mating takes place, for additional 60h to 80h at approximately 30°C. For two-hybrid selection diploid cells are transferred onto SDIV medium plates with and without nylon or nitrocellulose membranes and incubated for approximately 5 days at about 30°C. The nylon or nitrocellulose membranes are subjected to the β -GAL assay. Positive clones can be verified by cotransformation assays using plasmids encoding respective bait and prey proteins. Other preferred methods for studying protein-protein interactions according to the present invention are colocalization, coimmunoprecipitation, screening of protein or (poly)peptide arrays, library screens, in vivo and in vitro binding experiments using different tags such as HIS6, TAP or FLAG.

In a preferred embodiment of the present invention's method for generating a network of direct and indirect interaction partners of a disease related protein or (poly)peptide, plasmids encoding bait proteins are transformed into a strain such as L40ccua, tested for the absence of reporter gene activity and co-transformed with a human fetal brain cDNA library. Independent transformants are plated onto minimal medium lacking tryptophan, leucine, histidine and uracil (SDIV medium) and incubated at about 30°C for 5 to 10 days. Clones are transferred into microtitre

plates, optionally using a picking robot, and grown over night in liquid minimal medium lacking tryptophan and leucine (SDII medium). Subsequently, the clones are spotted onto nylon or nitrocellulose membranes placed on SDIV medium plates. After incubation for about 4 days membranes are subjected to a β -galactosidase (β -GAL) assay. Plasmids are prepared from positive clones and characterised, for example by restriction analyses and sequencing. For retransformation assays plasmids encoding bait and prey proteins are cotransformed in the yeast strain L40ccua and plated onto SDIV medium.

The term "generating a protein-protein interaction (PPI) network" means listing the interactions of all proteins interacting or binding directly or indirectly interacting the disease related (poly)peptide or protein. Preferably, this can be done by displaying the information in a matrix or a network representation. In a more preferred embodiment of the present invention's method, the protein-protein interaction network is generated by using Pivot 1.0 (Prof. Ron Shamir, Prof. Yossi Shilo, Nir Orlev; Tel Aviv University (TAU); Dep. of computer science; Ramat Aviv; Tel Aviv 69978; Israel).

In a preferred embodiment of the invention, interactions are detected by using the yeast two-hybrid system, MALDI-TOF MS or electro spray MS. Preferably, yeast strains such as strains L40ccua and L40cc α , are transformed with an expression selected from the group consisting of pBTM116, pBTM117, pBTM117c, pACT2, pAS2-1, pGAD10, pGAD424, pGAD425, pGAD426, pGAD427, pGAD428.

In another preferred embodiment of the present invention's method for generating a network of direct and indirect interaction partners of a disease-related polypeptide, the method contains after step (d) the additional steps of isolating a nucleic acid molecule with homology to said nucleic acid molecule expressing the encoded protein and testing it for its activity as a modulator of huntingtin, wherein said nucleic acid molecule is DNA, RNA, cDNA, or genomic DNA. Said testing can be done in several different assays. Preferably, the testing is performed in a co-immunoprecipitation assay or an affinity chromatography-based technique. Generally, co-immunoprecipitation is performed by purifying an interacting protein complex with a single antibody specific for one protein in the protein complex and by detecting the proteins in the protein complex. The step of detection can involve the

use of additional antibodies directed against proteins suspected of being trapped in the purified protein complex. Alternatively, at least one protein in the protein complex is fused to a tag sequence with affinity to a compound fixed to a solid matrix. By contacting the solid matrix with said tagged protein, further proteins binding to said protein can be purified and binding can be detected. GST or HA are preferred tags in accordance with the present invention.

In a preferred embodiment of the present invention's method, said contacting step (e) is effected in an interaction mating two hybrid approach.

In another preferred embodiment of the present invention's method, said method comprises after step (d) and before step (e) the steps of: (d') contacting (poly)peptides detected in step (d) with a selection of (poly)peptides suspected to contain one or several (poly)peptides interacting with said (poly)peptides detected in step (d) under conditions that allow the interaction between interaction partners to occur; and (d'') detecting proteins that interact with said (poly)peptides detected in step (d').

This preferred embodiment of the invention, an additional step of identifying further interaction partners is carried out prior to the contacting of all "baits" and "preys" in one pool (step (e)). Optionally, further steps of selecting interaction partners in analogy to steps (d') and (d'') may be effected prior to the pooling/interaction step.

Diseases of particular interest for which interrelationships of disease-related proteins may be analyzed in accordance with the invention are provided in Table 5.

In yet another preferred embodiment of the present invention's method, said disease related protein is a protein suspected of being a causative agent of a hereditary (see Table 5), such as a monogenic disease.

In another preferred embodiment of the present invention's method, said disease related protein is huntingtin and said interaction partners are the interaction partners as shown in table 6,7 and/or 9

In another preferred embodiment of the present invention's method, said method comprises the step of determining the nucleotide sequence of a nucleic acid molecule encoding a direct or indirect interaction partner of the disease related protein.

- 5 In another preferred embodiment of the present invention's method, said selections of proteins are translated from a nucleic acid library.

In another preferred embodiment of the present invention's method, said selection of proteins in step (a) and/or (c) and/or (d') and/or (e) is the same selection or a selection from the same source. In another preferred embodiment of the present
10 invention's method, said selection of proteins in step (a) and/or (c) and/or (d') and/or (e) is a different selection or a selection from a different source.

Preferably, said source is selected from nerve cells, brain tissue, human adrenal gland, human bladder, human bone, human brain, human colon, human dorsal root ganglion, human heart, human HeLa cells, human kidney, human liver, human lung,
15 human mammary gland, human ovary, human pancreas, human placenta, human prostate, human retina, human salivary gland, human skeletal muscle, human small intestine, human smooth muscle, human spinal cord, human spleen, human stomach, human testis, human thymus, human thyroid, human tonsil, human trachea, human uterus, human cell line HEP G2, human cell line MDA 435, human fetal brain,
20 human fetal heart, human fetal kidney, human fetal liver, human fetal spleen, human fetal thymus, human breast tumor, human cervix tumor, human colon tumor, human kidney tumor, human lung tumor, human ovary tumor, human stomach tumor, human brain tumor and/or human uterus tumor.

In another preferred embodiment of the present invention's method, said method is
25 performed by contacting the proteins on an array. Preferably, said array is an array allowing to detect protein-protein interaction by the principle of a biacore detector.

In another preferred embodiment of the present invention's method, said interactions are detected by using the yeast two-hybrid system. Preferably, said inteactions detected by using MALDI-TOF, MS, electro spray MS or biacore.

In another preferred embodiment of the present invention's method, said method contains after step of (b), (d), (d'') or (f) the additional steps of isolating a nucleic acid molecule with homology to said cDNA expressing the encoded protein and testing it for its activity as a modulator of huntingtin, wherein said nucleic acid molecule is DNA, or RNA, and preferably cDNA, or genomic or synthetic DNA, or mRNA.

By using the methods disclosed herein, a rate of success or fidelity of at least 70% validatable protein-protein interactions (PPI) (of proteins within the protein interaction network of huntingtin) can be achieved. This level of consistency is well above the level described in the art. In order to increase the rate of success or fidelity, the skilled person can, when carrying out the methods of the present invention, combine the methods of the present invention with additional steps of testing. For example, a step of co-immunoprecipitation and/or an in vitro binding assay may be carried out, in cases when initially the interaction was determined by using the yeast-two-hybrid system (or vice versa). Such additional steps may be carried out at any stage of the methods of the present invention. For example, after but also prior to step (f) of the method of the present invention, PPIs may be verified using in-vitro binding and/or immunoprecipitation assays in order to increase the stringency of the method. By performing these additional steps of testing, the skilled person can increase the rate of success or fidelity to at least 50%, more preferably to at least 60%. For the additional validation, any method may be employed that is available to the skilled artisan for testing the protein interaction. For example, the skilled artisan may simply repeat the step(s) initially carried out, optionally by (slightly) altering the reaction conditions, preferably to more stringent reaction conditions, i.e. conditions that could be expected to further reduce the number of false positive interactions. Alternatively, a different method may be carried out in the validation process. For example, if the method of the invention employed two hybrid systems, the validation might be carried out by precipitation steps as outlined elsewhere in the specification. Whereas the method of the invention provides valid results without the additional validation step(s), the inclusion of such additional validation steps may be advantageous for certain purposes, e.g. drug target identification. In the case that a first validation step does not confirm that the protein in question is a member of the interaction network, further steps in this regard should be carried out. For example, it should be excluded that the validation step(s) do/does not catch weak protein interactions that

nevertheless are part of the network. The present invention also relates to a nucleic acid molecule encoding a modulator of huntingtin, wherein said modulator is a protein selected from table 8. Figure 6 provides the amino acid sequences of the new proteins or (poly)peptides listed in table 8. The term "modulator protein of huntingtin" comprises two types of proteins within the network of proteins interacting with huntingtin. Direct interaction or binding partners of huntingtin are those proteins in the PPI network of huntingtin that directly interact with or bind to huntingtin (see figure 2). Examples of these proteins are IKAP, HYPA, CA150, HIP1, HIP11, HIP13, HIP15, CGI-125, PFN2, HP28, DRP-1, SH3GL3, HZFH, HIP5, PIASy, HIP16, GIT1, Ku70 and FEZ1. Table 7 and figure 6 provides a reference allowing to identify these proteins. The second class of proteins are indirect interaction or binding partners of huntingtin, i.e. those proteins in the PPI network of huntingtin that do not directly interact with or bind to huntingtin. Such proteins require a mediator, i.e. a direct binding partner of huntingtin to exert their huntingtin modulating function. Examples of these proteins are BARD1 or VIM, which bind to direct interaction partners of huntingtin. However, complexes of huntingtin and a direct interaction or binding partner are likely to interact with additional indirect interaction or binding partners. To summarize the above, modulator proteins of huntingtin can exert their function by direct or indirect contact to huntingtin.

The term "modulator protein", as used in the present invention, refers to a protein capable of modulating the function or physical state of a second protein and comprises proteins that enhance or reduce (inhibit) the function or activity of huntingtin. Preferably, the modulator protein is a protein having an activity selected from the group consisting of oxidoreductase activity (acting on the CH-OH group of donors, acting on the aldehyde or oxo group of donors, acting on the CH-CH group of donors, acting on the CH-NH(2) group of donors, acting on the CH-NH group of donors, acting on NADH or NADPH, acting on other nitrogenous compounds as donors, acting on a sulfur group of donors, acting on a heme group of donors, acting on diphenols and related substances as donors, acting on a peroxide as acceptor, acting on hydrogen as donor, acting on single donors with incorporation of molecular oxygen, acting on the CH-OH group of donors, acting on superoxide as acceptor, oxidizing metal ions, acting on -CH(2) groups, acting on iron-sulfur proteins as donors, acting on reduced flavodoxin as donor, acting on phosphorus or arsenic in

donors, acting on x-H and y-H to form an x-y bond, other oxidoreductases), transferase activity (transferring one-carbon groups, transferring aldehyde or ketone residues, acyltransferases, glycosyltransferases, transferring alkyl or aryl groups, other than methyl groups, transferring nitrogenous groups, transferring phosphorous-containing groups, transferring sulfur-containing groups, transferring selenium-containing groups), hydrolase activity (glycosylase activity, acting on ether bonds, acting on peptide bonds, acting on carbon-nitrogen bonds (other than peptide bonds), acting on acid anhydrides, acting on carbon-carbon bonds, acting on halide bonds, acting on phosphorus-nitrogen bonds, acting on sulfur-nitrogen bonds, acting on carbon-phosphorus bonds, acting on sulfur-nitrogen bonds, acting on carbon-phosphorus bonds, acting on sulfur-sulfur bonds, acting on carbon-sulfur bonds, lyases (carbon-carbon lyases, carbon-oxygen lyases, carbon-nitrogen lyases, carbon-sulfur lyases, carbon-halide lyases, phosphorus-oxygen lyases, other lyases), isomerases (racemases and epimerases, cis-trans-isomerases, intramolecular oxidoreductases, intramolecular transferases, intramolecular lyases, other isomerases), ligases activity (forming carbon-oxygen bonds, forming carbon-sulfur bonds, forming carbon-nitrogen bonds, forming carbon-carbon bonds, forming phosphoric ester bonds), transcription factor activity, filament protein, membrane protein and structural protein.

In a preferred embodiment, the present invention's nucleic acid molecule is DNA, or RNA, and preferably cDNA, or genomic DNA or synthetic DNA or mRNA

In another preferred embodiment of the invention, the nucleic acid molecule is double stranded or single stranded.

In another preferred embodiment of the invention, the nucleic acid molecule is of vertebrate, nematode, insect, bacterium or yeast. Preferably, the nematode is *Caenorhabditis elegans*. In another more preferred embodiment of the present invention, the insect is *Drosophila*, preferably *Drosophila melanogaster*. In another more preferred embodiment of the present invention, the vertebrate is human, mouse, rat, *Xenopus laevis*, zebrafish.

In yet another preferred embodiment of the present invention, the nucleic acid molecule is fused to a heterologous nucleic acid molecule. In a further preferred

embodiment of the present invention, the heterologous (poly)peptide encoded by said heterologous nucleic acid molecule is an immunoglobulin Fc domain.

In another preferred embodiment of the present invention the nucleic acid molecule is labeled. Labeled nucleic acid molecules may be useful for purification or detection.

5 Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine(ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA),
10 radioactive labels, e.g. ^{32}P , ^{35}S , ^3H ; etc. The label may also be a two stage system, where the DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner is conjugated to a detectable label. In the case of amplification the label may be conjugated to one or both of the primers. The pool of nucleotides used in the amplification may also be
15 labeled, so as to incorporate the label into the amplification product. Alternatively, the double strand formed after hybridization can be detected by anti-double strand DNA specific antibodies or aptamers etc.

In a more preferred embodiment said heterologous nucleic acid molecule encodes a heterologous polypeptide. Preferably said heterologous (poly)peptide, fused to the
20 (poly)peptide encoded by the nucleic acid molecule of the present invention, is a DNA binding protein selected from the group consisting of GAL4 (DBP) and LexA (DBP). Also preferred in accordance with the present invention are activation domains selected from the group consisting of GAL4(AD) and VP16(AD). Also preferred are (poly)peptides selected from the group consisting of GST, His Tag, Flag Tag, Tap Tag, HA Tag and Protein A Tag.
25

Thus, the sequence encoding the (poly)peptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused (poly)peptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in
30 a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz *et al.*, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for

convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson *et al.*, *Cell* 37: 767 (1984).

- 5 The (poly)peptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the (poly)peptide to improve stability and persistence in the host cell, during purification, or during
- 10 subsequent handling and storage. Also, peptide moieties may be added to the (poly)peptide to facilitate purification. Such regions may be removed prior to final preparation of the (poly)peptide. The addition of peptide moieties to (poly)peptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion
- 15 protein comprises a heterologous region from immunoglobulin that is useful to stabilize and purify proteins.

The present invention also relates to a method of producing a vector comprising the nucleic acid molecule the present invention. Furthermore, the present invention relates to a vector produced said method.

- 20 The present invention also relates to a vector comprising the nucleic acid molecule of the present invention. Preferably said vector is a transfer or expression vector selected from the group consisting of pACT2; pAS2-1; pBTM116; pBTM117; pcDNA3.1; pcDNA1; pECFP; pECFP-C1; pECFP-N1; pECFP-N2; pECFP-N3; pEYFP-C1; pFLAG-CMV-5 a, b, c; pGAD10; pGAD424; pGAD425; pGAD427;
- 25 pGAD428; pGBT9; pGEX-3X1; pGEX-5X1; pGEX-6P1; pGFP; pQE30; pQE30N; pQE30-NST; pQE31; pQE31N; pQE32; pQE32N; pQE60; pSE111; pSG5; pTET-CMV-AS; pTET-CMV-F^o-AS; pTET-CMV-F^o-S; pTET-CMV-MCS; pTET-CMV-S; pTK-Hyg; pTL1; pTL10; pTL-HA0; pTL-HA1; pTL-HA2; pTL-HA3; pBTM118c; pGEX-6P3; pACGHLT-C; pACGHLT-A; pACGHLT-B; pUP; pcDNA3.1-V5His; pMalc2x. Said
- 30 expression vectors may particularly be plasmids, cosmids, viruses or bacteriophages used conventionally in genetic engineering plasmids, cosmids, viruses and bacteriophages used conventionally in genetic engineering that comprise the

aforementioned nucleic acid. Preferably, said vector is a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the nucleic acid into targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel et al., Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989).

In yet a further preferred embodiment of the invention the vector contains an additional expression cassette for a reporter protein, selected from the group consisting of β -galactosidase, luciferase, green fluorescent protein and variants thereof.

Preferably, said vector comprises regulatory elements for expression of said nucleic acid molecule. Consequently, the nucleic acid of the invention may be operatively linked to expression control sequences allowing expression in eukaryotic cells. Expression of said nucleic acid molecule comprises transcription of the sequence nucleic acid molecule into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and, optionally, a poly-A signal ensuring termination of transcription and stabilization of the transcript, and/or an intron further enhancing expression of said nucleic acid. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally-associated or heterologous promoter regions. Possible regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the nucleic acid molecule. Furthermore, depending on the expression system used leader sequences capable of directing the (poly)peptide to a cellular compartment or

secreting it into the medium may be added to the coding sequence of the
aforementioned nucleic acid and are well known in the art. The leader sequence(s) is
(are) assembled in appropriate phase with translation, initiation and termination
sequences, and preferably, a leader sequence capable of directing secretion of
5 translated protein, or a portion thereof, into the periplasmic space or extracellular
medium. Optionally, the heterologous sequence can encode a fusion protein
including an C- or N-terminal identification peptide imparting desired characteristics,
e.g., stabilization or simplified purification of expressed recombinant product. In this
context, suitable expression vectors are known in the art such as Okayama-Berg
10 cDNA expression vector pcDVI (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3,
the EchoTM Cloning System (Invitrogen), pSPORT1 (GIBCO BRL) or pRevTet-
On/pRevTet-Off or pCI (Promega).

The present invention also relates to a method of producing a host cell comprising
genetically engineering cells with the nucleic acid molecule or the vector of the
15 present invention. The present invention also relates to a host cell produced said
method. Furthermore, the present invention relates to a host cell comprising the
vector of the present invention. Preferably, said host cell contains an endogenous
nucleic acid molecule which is operably associated with a heterologous regulatory
control sequence, including the regulatory elements contained in the vector of the
20 present invention.

The present invention also relates to a method of producing a (poly)peptide,
comprising culturing the host cell of the present invention under conditions such that
the (poly)peptide encoded by said polynucleotide is expressed and recovering said
(poly)peptide.

25 The present invention also relates to a (poly)peptide comprising an amino acid
sequence encoded by a nucleic acid molecule of the present invention, or which is
chemically synthesized, or is obtainable from the host cell of the present invention, or
which is obtainable by a method of the present invention or which is obtainable from
an in vitro translation system by expressing the nucleic acid molecule of the present
30 invention or the vector of the present invention.

In another preferred embodiment of the invention, the (poly)peptide or protein is of vertebrate, nematode, insect, bacterium or yeast. Preferably, the nematode is *Caenorhabditis elegans*. In another more preferred embodiment of the present invention, the insect is *Drosophila*, preferably *Drosophila melanogaster*. In another more preferred embodiment of the present invention, the vertebrate is human, mouse rat, *Xenopus laevis*, zebrafish.

In another preferred embodiment, the (poly)peptide of the present invention is fused to a heterologous (poly)peptide. Such a fusion protein may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the (poly)peptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the (poly)peptide to facilitate purification. Such regions may be removed prior to final preparation of the (poly)peptide. The addition of peptide moieties to (poly)peptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to stabilize and purify proteins.

In a preferred embodiment of the present invention, the (poly)peptide of the present invention is fused to a heterologous (poly)peptide which is an immunoglobulin Fc domain or Protein A domain. In another preferred embodiment of the present invention, the (poly)peptide the (poly)peptide is labelled. Preferably, the label is selected from the group consisting of fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine(ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. ^{32}P , ^{35}S , ^3H ; etc. The label may also be a two stage system, where the protein or (poly)peptide is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner is conjugated to a detectable label. In another preferred embodiment of the present invention the label is a toxin, radioisotope, or fluorescent label.

In another preferred embodiment of the present invention, the (poly)peptide contains or lacks an N-terminal methionine. It is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

The present invention also relates to a protein complex comprising at least two proteins, wherein said at least two proteins are selected from the group of interaction partners listed in table 9. The term "protein complex" refers to a compound stably comprising at least two proteins. Preferably, said stability allows to purify said protein complex.

In a preferred embodiment of the present invention, the protein complex comprises GIT1 and huntingtin.

The present invention also relates to the protein network of huntingtin which is described herein. In one embodiment, said protein network is formed by the interaction partners shown in table 6. Preferably, the protein network of the present invention is a validated protein network as described herein.

The present invention also relates to an antibody specifically recognizing the (poly)peptide of the present invention or specifically reacting with the protein complex of the present invention. This antibody is characterized in not recognizing the individual components of the protein complex but rather the complex itself. As such, said antibody recognizes a combined epitope, composed of amino acids of two different proteins within the protein complex. Dissociation of the complex will be detrimental to antibody recognition. Therefore, antibody binding depends on the integrity of the protein complex. In a preferred embodiment of the present invention, the antibody is specific for a protein complex comprising GIT1 and huntingtin.

In a preferred embodiment, the antibody of the present invention is polyclonal, monoclonal, chimeric, single chain, single chain Fv, human antibody, humanized antibody, or Fab fragment

In a more preferred embodiment of the present invention the antibody is labeled. Preferably, the label is selected from the group consisting of fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-
 5 carboxyfluorescein (JOE), 6-carboxy-X-rhodamine(ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. ^{32}P , ^{35}S , ^3H ; etc. The label may also be a two stage system, where the antibody is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where
 10 the binding partner is conjugated to a detectable label. In another preferred embodiment of the present invention the label is a toxin, radioisotope, or fluorescent label.

In a preferred embodiment of the present invention, the antibody is immobilized to a solid support. Preferably, the solid support may be the surface of a cell, a microtiter
 15 plate, beads or the surface of a sensor capable of detecting binding of the antibody or to the antibody.

The present invention also relates to a method of identifying whether a protein promotes huntingtin aggregation, comprising (a) transfecting a first cell with a nucleic acid molecule encoding a variant of the huntingtin protein or a fragment thereof
 20 capable of forming huntingtin aggregates; (b) co-transfecting a second cell with (i) a nucleic acid molecule encoding a variant of the huntingtin protein or a fragment thereof capable of forming huntingtin aggregates; and (ii) a nucleic acid molecule encoding a candidate modulator protein identified by the methods of the present invention or a nucleic acid molecule encoding a modulator protein selected from table
 25 6 or table 7 (c) expressing the proteins encoded by the transfected nucleic acid molecule of (a) and (b); (d) isolating insoluble aggregates of huntingtin from the transfected cell of (a) and (b); and (e) determining the amount of insoluble huntingtin aggregates from the transfected cell of (a) and (b), wherein an increased amount of huntingtin aggregates isolated from the transfected cells of (b) in comparison with the
 30 amount of huntingtin aggregates isolated from the transfected cells of (a) is indicative of a protein's activity as an enhancer of huntingtin aggregation. Preferably, the huntingtin protein or protein fragment of step (a) is HD169Q68 or HD510Q68.

The present invention also relates to a method of identifying whether a protein inhibits huntingtin aggregation, comprising (a) transfecting a first cell with a nucleic acid molecule encoding a variant of the huntingtin protein or a fragment thereof capable of forming huntingtin aggregates; (b) co-transfecting a second cell with (i) a nucleic acid molecule encoding a variant of the huntingtin protein or a fragment thereof capable of forming huntingtin aggregates; and (ii) a nucleic acid molecule encoding a candidate modulator protein identified by the methods of the present invention or a nucleic acid molecule encoding a modulator protein selected from table 6 or table 7 (c) expressing the proteins encoded by the transfected nucleic acid molecule of (a) and (b); (d) isolating insoluble aggregates of huntingtin from the transfected cell of (a) and (b); and (e) determining the amount of insoluble huntingtin aggregates from the transfected cell of (a) and (b), wherein a reduced amount of huntingtin aggregates isolated from the transfected cells of (b) in comparison with the amount of huntingtin aggregates isolated from the transfected cells of (a) is indicative of a protein's activity as an inhibitor of huntingtin aggregation. Preferably, the huntingtin protein or protein fragment of step (a) is HD169Q68 or HD510Q68 or HdexQ51.

The term "promotes" means increasing the amount of huntingtin aggregation.

Preferably said huntingtin protein or the fragments thereof is selected from the proteins listed in table 6 and/or 7. Preferably said insoluble aggregates are isolated by using a filter retardation method comprising lysing cells and boiling in 2%SDS for 5min in the presence of 100mM DDT followed by a filtration step. The presence of aggregates is detected by using specific antibodies.

In a preferred embodiment of the present invention, determining the amount of insoluble huntingtin is performed by using light scattering or size exclusion chromatography. In another preferred embodiment of the present invention prior to step (d) the cells are treated with an ionic detergent. In yet another preferred embodiment of the methods of the present invention, the huntingtin aggregates are filtered or transferred onto a membrane.

The present invention also relates to a method for identifying compounds affecting, e.g. interfering or enhancing the interaction of huntingtin or of a direct or indirect

interaction partner of huntingtin comprising (a) contacting interacting proteins selected from the group of interacting proteins listed in table 6 in the presence or absence of a potential modulator of interaction; and (b) identifying compounds capable of modulating said interaction. The contacting is performed under conditions that permit the interaction of the two proteins. Sometimes more than two interacting proteins might be present in a single reaction as additional interaction partners of those listed under table 6, can be tested. However, the compound may also be a small molecule. Preferably said compounds are antibodies directed to huntingtin or to said interaction partner listed in table 6, wherein these antibodies are capable of interfering with the interaction with huntingtin. Alternatively, said compound is a peptide fragment of 10 to 25 amino acid residues of an interaction partner listed in table 7, wherein said peptide fragment is capable of interfering with the interaction with huntingtin. In a more preferred embodiment of the present invention, said antibody is an antibody directed to GIT1. In another more preferred embodiment of the invention, said peptide fragment is a peptide fragment of GIT1 of 10 to 25 capable of interfering with the interaction of GIT1 with huntingtin. Said interfering peptide may contain additional modifications in order to increase cellular uptake, solubility or to increase stability. Such modifications are known to the person skilled in the art and need not be listed here in detail. In a preferred embodiment of the present invention, the methods for identifying a compound further comprise the steps of modeling said compound by peptidomimetics and chemically synthesizing the modeled compound.

In another preferred embodiment of the present invention, the methods for identifying a compound further comprise producing said compound. In yet another preferred embodiment of the present invention, the method for identifying said compound further comprise modifying to achieve (i) modified site of action, spectrum of activity, organ specificity, and/or (ii) improved potency, and/or (iii) decreased toxicity (improved therapeutic index), and/or (iv) decreased side effects, and/or (v) modified onset of therapeutic action, duration of effect, and/or (vi) modified pharmacokinetic parameters (resorption, distribution, metabolism and excretion), and/or (vii) modified physico-chemical parameters (solubility, hygroscopicity, color, taste, odor, stability, state), and/or (viii) improved general specificity, organ/tissue specificity, and/or (ix) optimized application form and route by (i) esterification of

carboxyl groups, or (ii) esterification of hydroxyl groups with carbon acids, or (iii) esterification of hydroxyl groups to, e.g. phosphates, pyrophosphates or sulfates or hemi succinates, or (iv) formation of pharmaceutically acceptable salts, or (v) formation of pharmaceutically acceptable complexes, or (vi) synthesis of
 5 pharmacologically active polymers, or (vii) introduction of hydrophilic moieties, or (viii) introduction/exchange of substituents on aromates or side chains, change of substituent pattern, or (ix) modification by introduction of isosteric or bioisosteric moieties, or (x) synthesis of homologous compounds, or (xi) introduction of branched side chains, or (xii) conversion of alkyl substituents to cyclic analogues, or (xiii)
 10 derivatisation of hydroxyl group to ketals, acetals, or (xiv) N-acetylation to amides, phenylcarbamates, or (xv) synthesis of Mannich bases, imines, or transformation of ketones or aldehydes to Schiff's bases, oximes, acetals, ketals, enolesters, oxazolidines, thiozolidines or combinations thereof.

The present invention also relates to a method of diagnosing Huntington's disease in
 15 a biological sample comprising the steps of (a) contacting the sample with an antibody specific for a protein of table 6 or 7 or an antibody specific for the protein complex of the present invention; and (b) detecting binding of the antibody to a protein complex, wherein the detection of binding is indicative of Huntington's disease or of a predisposition to develop Huntington's disease. Preferably, binding is
 20 detected by measuring the presence of a fluorescent label bound to the protein complex.

In a preferred embodiment of the present invention's method protein complex contains (a) GIT1 or (b) said antibody is specific for a protein complex containing
 25 GIT1.

In a preferred embodiment of the present invention, said protein complex contains (a) at least one protein selected from htt, HIP15 or HP28 or (b) said antibody is specific for a protein complex containing at least one protein selected from htt, HIP15 or
 30 HP28.

The present invention also relates to a diagnostic agent/composition comprising the nucleic acid molecule of the present invention, the (poly)peptide of the present invention including/or the (poly)peptide mentioned in table 6 or 7, the antibody of the

present invention, an antibody specifically reacting with a protein selected from table 7 and/or a protein selected from table 7.

Moreover, the present invention also relates to a pharmaceutical composition comprising the nucleic acid molecule of the present invention, the (poly)peptide of the present invention, the interfering compound identified with a method of the present invention, the antibody of the present invention, an antibody specifically reacting with a protein selected from table 7 and/or a protein selected from table 7.

The pharmaceutical composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient, the site of delivery of the pharmaceutical composition, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" of the pharmaceutical composition for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of pharmaceutical composition administered parenterally per dose will be in the range of about 1 μ g protein /kg/day to 10 mg protein /kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg protein /kg/day, and most preferably for humans between about 0.01 and 1 mg protein /kg/day for the peptide. If given continuously, the pharmaceutical composition is typically administered at a dose rate of about 1 μ g/kg/hour to about 50 μ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions of the invention may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), buccally, or as an oral or nasal spray. By "pharmaceutically acceptable carrier" is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include

intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The pharmaceutical composition is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release pharmaceutical composition also include liposomally entrapped protein, antibody, (poly)peptide, peptide or nucleic acid. Liposomes containing the pharmaceutical composition are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. (USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal therapy.

For parenteral administration, in one embodiment, the pharmaceutical composition is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to (poly)peptides.

Generally, the formulations are prepared by contacting the components of the pharmaceutical composition uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier

vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes. The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) (poly)peptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG. The proteinaceous components of the pharmaceutical composition are typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation protein or (poly)peptide salts.

The components of the pharmaceutical composition to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic components of the pharmaceutical composition (poly)peptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The components of the pharmaceutical composition ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous protein solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized protein using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical/diagnostic pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical/diagnostic compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency
5 regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the (poly)peptides of the components of the pharmaceutical composition invention may be employed in conjunction with other therapeutic compounds.

10

Finally, the present invention relates to the use of the nucleic acid molecule of the present invention, the interfering compound identified with a method of the present invention, the (poly)peptide of the present invention including/or the (poly)peptide mentioned in table 6 or 7, the antibody of the present invention, an antibody
15 specifically reacting with a protein selected from table 7 and/or a protein selected from table 7 for the preparation of a pharmaceutical composition for the treatment of Huntington's disease.

Tables:

Table 1:

PROTEIN-PROTEIN INTERACTIONS IN THE PPI OF HUNTINGTIN	
Baits (DBD)	Preys (AD)
BARD1	PLIP
EF1G	EF1G
HD1.7	CA150
HD1.7	HIP1
HD1.7	HYP A
HD1.7	SH3GL3
HDexQ20	CA150
HDexQ20	HYP A
HDexQ20	SH3GL3
HDexQ51	CA150
HDexQ51	HYP A
HDexQ51	SH3GL3
mp53	p53
mp53	PIASy
PIASy	SUMO-2
PIASy	SUMO-3
VIM	NEFL
VIM	VIMc
BARD1	BAIP1
BARD1	BAIP2
BARD1	BAIP3
BARD1	FEZ1
BARD1	GIT1
BARD1	HBO1
BARD1	HIP5
BARD1	HZFH
BARD1	IKAP
BARD1	mHAP1
BARD1	NAG4
BARD1	PIASy
BARD1	PTN
BARD1	SETBD1

BARD1	ZHX1
CLH-17	Ku70
CLK1	PIASy
GADD45G	BAIP3
GADD45G	CGI-125
GADD45G	CGI-74
GADD45G	EF1A
GADD45G	EF1G
GADD45G	G45IP1
GADD45G	G45IP2
GADD45G	G45IP3
GADD45G	HIP16
GADD45G	HIP5
GADD45G	LUC7B1
GADD45G	PIASy
GADD45G	PLIP
GADD45G	PTN
GADD45G	PTPK
hADA3	BAIP1
hADA3	Ku70
hADA3	MAGEH1
hADA3	PIASy
HD1.7	CGI-125
HD1.7	DRP-1
HD1.7	FEZ1
HD1.7	GIT1
HD1.7	HIP11
HD1.7	HIP13
HD1.7	HIP15
HD1.7	HIP16
HD1.7	HIP5
HD1.7	HZFH
HD1.7	IKAP
HD1.7	Ku70
HD1.7	PIASy
HDd1.0	FEZ1
HDd1.0	GIT1
HDd1.0	IKAP
HDd1.3	HZFH

HDd1.3	IKAP
HDd1.3	Ku70
HDd1.3	PIASy
HDexQ20	CGI-125
HDexQ20	HIP13
HDexQ20	HP28
HDexQ20	PFN2
HDexQ51	CGI-125
HDexQ51	HIP13
HDexQ51	HIP15
HDexQ51	HP28
HDexQ51	PFN2
HIP2	PIASy
HIP5	APP1
HIP5	BAIP1
HIP5	BAIP2
HIP5	CGI-74
HIP5	FEZ1
HIP5	GIT1
HIP5	HBO1
HIP5	HMP
HIP5	KPNA2
HIP5	mHAP1
HIP5	NAG4
HIP5	PLIP
IMPD2	PIASy
KPNB1	PIASy
KPNB1	PTN
mp53	HZFH
mp53	ZHX1
PIASy	MAP1c3
TAL1	ZHX1
TCP1G	Ku70
VIM	ALEX2
VIM	BAIP1
VIM	DRP-1
VIM	G45IP1
VIM	HBO1
VIM	HSPC232

VIM	HZFH
VIM	PIASy
VIM	SETBD1
VIM	SH3GL3
ZNF33B	mHAP1
ZNF33B	ZHX1

Table 2 Classification of proteins in Huntington's disease interaction network

ID	NAME	FUSION	ACCESSION	IDEN	aa MATCH	LOC
Huntingtin fragments						
HD1.7	huntingtin	DBD	P42858	100	1-506	N, C
HDd1.0	huntingtin	DBD	P42858	100	1-320	N, C
HDd1.3	huntingtin	DBD	P42858	100	166-506	N, C
HdexQ20	huntingtin	DBD	P42858	96	1-90	N, C
HdexQ51	huntingtin	DBD	P42858	75	1-82	N, C
Transcriptional control and DNA maintenance						
BARD1	BRCA1 associated ring domain protein 1	DBD	Q99728	99	1-379	N
CA150	putative transcription factor CA150	AD	O14776	93	299-629	N
GADD45G	growth arrest and DNA damage inducible protein GADD45 gamma	DBD	O95257	100	18-159	N
hADA3	ADA3 like protein	DBD	O75528	100	235-432	N
HBO1	histone acetyltransferase binding to ORC	AD	O95251	100	1-611	N
PIASy	protein inhibitor of activated STAT protein gamma (PIASy)	AD, DBD	Q8N2W9	100	5-510	N, C
HYP4	huntingtin interacting protein HYP4/FBP11 (fragment)	AD	O75400	100	8-422	C, N
HZFH	zinc finger helicase HZFH	AD, DBD	Q9Y4I0	100	1830-2000	N
IKAP	IKK complex associated protein	AD	O95163	100	1207-1332	N, C
Ku70	ATP dependent DNA helicase II, 70 kDa subunit	AD	P12956	100	298-608	N
NAG4	bromodomain containing protein NAG4	AD	Q9NPI1	100	94-651	N
p53	cellular tumor antigen p53	AD	P04637	100	1-393	N
p53c	cellular tumor antigen p53 (C-terminus)	AD	P04637	100	248-393	N
mp53	cellular tumor antigen p53 (mouse)	DBD	P02340	100	73-390	N
PLIP	cPLA2 interacting protein	AD	O95624	100	5-461	N, PN
SETDB1	histone-lysine N-methyltransferase, H3 lysine-9 specific 4	AD	Q15047	100	1023-1291	N
SUMO-2	ubiquitin like protein SMT3A (SUMO-2)	AD	P55854	100	1-103	C, N
SUMO-3	ubiquitin like protein SMT3B (SUMO-3)	AD	P55855	100	1-95	C, N
ZHX1	zinc finger homeobox protein ZHX1	AD	Q9UKY1	100	145-873	N
ZNF33B	zinc finger protein 33b	DBD	Q8NDW3	100	527-778	N
Cellular organization and protein transport						
APP1	amyloid like protein 1 precursor	AD	P51693	100	243-555	PM, EC
CLH-17	clathrin heavy chain 1	DBD	Q00610	100	1-289	PM, V
HP28	axonemal dynein light chain (hp28)	AD	Q9BQZ6	100	3-258	CN
mHAP1	huntingtin associated protein 1 (mouse)	AD	O35668	100	3-471	C, EE
HIP1	huntingtin interacting protein 1	AD	O00291	100	245-631	C, GN
HMP	mitofilin	AD	Q16891	100	212-758	Mit
MAP1lc3	microtubule associated proteins 1A/1B light chain 3	AD	Q9H491	100	58-170	CN, MT
NEFL	light molecular weight neurofilament protein	AD	Q8IU72	100	1-543	CN, IF

PFN2	profilin II	AD	P35080	100	1-140	CN
PTN	pleiotrophin precursor (exon 1 included)	AD	P21246	100	1-168	PM, EC
SH3GL3	SH3 containing GRB2 like protein 3	AD	Q99963	100	3-347	V
KPNA2	karyopherin alpha-2 subunit	AD	P52292	100	141-529	C, N
KPNB1	karyopherin beta-1 subunit	DBD	Q14974	100	668-876	C, N
VIM	vimentin	DBD	P08670	100	1-466	CN, IF
VIMc	vimentin (C-terminus)	AD	P08670	100	190-466	CN, IF

Cell signaling and fate

ALEX2	armadillo repeat protein ALEX2	AD	O60267	100	127-632	C, PM
CLK1	protein kinase CLK1	DBD	P49759	100	209-484	N
FEZ1	fasciculation and elongation protein zeta 1	AD	Q99689	100	131-392	C, PM
GIT1	ARF GTPase activating protein GIT1	AD	Q9Y2X7	98	249-761	PM, V
PTPK	protein-tyrosine phosphatase kappa precursor	AD	Q15262	100	1227-1439	PM, AJ

Cellular metabolism

DRP-1	dihydropyrimidinase related protein 1 (C-terminus)	AD	Q14194	100	345-572	C
IMPD2	inosine-5'-monophosphate dehydrogenase 2	DBD	P12268	100	34-514	C
TAL1	transaldolase	DBD	P37837	100	3-337	C

Protein synthesis and turnover

EF1A	translation elongation factor 1 alpha 1	AD	P04720	100	294-462	C, MT
EF1G	elongation factor 1 gamma	AD, DBD	P26641	100	2-437	C, MT
EF1Gc	elongation factor 1 gamma (C-terminus)	AD	P26641	100	123-437	C, MT
HIP2	ubiquitin conjugating enzyme E2-25 kDa	DBD	P27924	100	1-200	C, N
TCPG	T-complex protein 1, gamma subunit	DBD	P49368	100	252-544	C

Uncharacterized proteins

BAIP1	BARD1 interacting protein 1[similar to RIKEN cDNA 1810018M11]	AD	Q9BS30	100	1-226	UN
BAIP2	BARD1 interacting protein 2 [hypothetical protein]	AD	Q9H0I6	100	107-684	UN
BAIP3	BARD1 interacting protein 3 [hypothetical protein]	AD	Q96HT4	100	152-436	UN
CGI-74	CGI-74 protein	AD	Q9Y383	100	159-270	UN
CGI-125	CGI-125 protein	AD	Q9Y3C7	100	1-131	UN
G45IP1	GADD45G interacting protein 1[hypothetical protein]	AD	Q9H0V7	100	1-340	UN
G45IP2	GADD45G interacting protein 2 [B2 gene partial cDNA, clone B2E]	AD	Q9NYA0	100	566-926	UN
G45IP3	GADD45G interacting protein 3 [OK/SW-CL.16]	AD	Q8NI70	100	3-134	UN
HIP5	huntingtin interacting protein 5 [hypothetical protein KIAA1377]	AD, DBD	Q9P2H0	100	445-988	N, C
HIP11	huntingtin interacting protein 11[hypothetical protein]	AD	Q96EZ9	100	176-328	UN
HIP13	huntingtin interacting protein 13 [metastasis suppressor protein]	AD	Q96RX2	100	512-755	UN
HIP15	huntingtin interacting protein 15 [similar to KIAA0443 gene product]	AD	Q96D09	100	663-838	UN
HIP16	huntingtin interacting protein 16 [similar to KIAA0266 gene product]	AD	Q9BVJ6	100	585-771	UN
HSPC232	HSPC232	AD	Q9P0P6	92	1-319	UN
LUC7B1	putative SR protein LUC7B1 (SR+89)	AD	Q9NQ29	99	116-371	ER
MAGEH1	melanoma associated antigen H1	AD	Q9H213	100	1-219	UN

Abbreviations: aa, amino acids; IDEN, Identity; LOC, localisation; AD, activation domain; DBD, DNA binding domain; AJ, adherens junctions; C, cytosol; CN, cytoskeleton; EC, extracellular space; EE, early endosomes; ER, endoplasmic reticulum; IF, intermediate filaments; GN, Golgi network; Mit, mitochondria; MT, microtubules; N, nucleus; PM, plasma membrane; PN, perinuclear; UN, unknown; V, vesicles; [], database annotation

Table 3 New proteins in Huntington's disease interaction network

ID	NAME	FUSION	ACCESSION	IDEN	aa MATCH	LOC
Transcriptional control and DNA maintenance						
BARD1	BRCA1 associated ring domain protein 1	DBD	Q99728	99	1-379	N
CA150	putative transcription factor CA150	AD	O14776	93	299-629	N
Cell signaling and fate						
GIT1	ARF GTPase activating protein GIT1	AD	Q9Y2X7	98	249-761	PM, V
HSPC232	HSPC232	AD	Q9P0P6	92	1-319	UN
LUC7B1	putative SR protein LUC7B1 (SR+89)	AD	Q9NQ29	99	116-371	ER

Abbreviations: aa, amino acids; IDEN, identity; LOC, localisation; AD, activation domain; DBD, DNA binding domain; AJ, adherens junctions; C, cytosol; CN, cytoskeleton; EC, extracellular space; EE, early endosomes; ER, endoplasmic reticulum; IF, intermediate filaments; GN, Golgi network; Mit, mitochondria; MT, microtubules; N, nucleus; PM, plasma membrane; PN, perinuclear; UN, unknown; V, vesicles; [], database annotation

Table 4:

New protein-protein interactions, found	
Baits (DBD)	Preys (AD)
BARD1	BAIP1
BARD1	BAIP2
BARD1	BAIP3
BARD1	FEZ1
BARD1	GIT1
BARD1	HBO1
BARD1	HIP5
BARD1	HZFH
BARD1	IKAP
BARD1	mHAP1
BARD1	NAG4
BARD1	PIASy
BARD1	PTN
BARD1	SETBD1
BARD1	ZHX1
CLH-17	Ku70
CLK1	PIASy
GADD45G	BAIP3
GADD45G	CGI-125
GADD45G	CGI-74

GADD45G	EF1A
GADD45G	EF1G
GADD45G	G45IP1
GADD45G	G45IP2
GADD45G	G45IP3
GADD45G	HIP16
GADD45G	HIP5
GADD45G	LUC7B1
GADD45G	PIASy
GADD45G	PLIP
GADD45G	PTN
GADD45G	PTPK
hADA3	BAIP1
hADA3	Ku70
hADA3	MAGEH1
hADA3	PIASy
HD1.7	CGI-125
HD1.7	DRP-1
HD1.7	FEZ1
HD1.7	GIT1
HD1.7	HIP11
HD1.7	HIP13
HD1.7	HIP15
HD1.7	HIP16
HD1.7	HIP5
HD1.7	HZFH
HD1.7	IKAP
HD1.7	Ku70
HD1.7	PIASy
HDd1.0	FEZ1
HDd1.0	GIT1
HDd1.0	IKAP
HDd1.3	HZFH
HDd1.3	IKAP
HDd1.3	Ku70
HDd1.3	PIASy
HDexQ20	CGI-125
HDexQ20	HIP13
HDexQ20	HP28

HDexQ20	PFN2
HDexQ51	CGI-125
HDexQ51	HIP13
HDexQ51	HIP15
HDexQ51	HP28
HDexQ51	PFN2
HIP2	PIASy
HIP5	APP1
HIP5	BAIP1
HIP5	BAIP2
HIP5	CGI-74
HIP5	FEZ1
HIP5	GIT1
HIP5	HBO1
HIP5	HMP
HIP5	KPNA2
HIP5	mHAP1
HIP5	NAG4
HIP5	PLIP
IMPD2	PIASy
KPNB1	PIASy
KPNB1	PTN
mp53	HZFH
mp53	ZHX1
PIASy	MAPlc3
TAL1	ZHX1
TCP1G	Ku70
VIM	ALEX2
VIM	BAIP1
VIM	DRP-1
VIM	G45IP1
VIM	HBO1
VIM	HSPC232
VIM	HZFH
VIM	PIASy
VIM	SETBD1
VIM	SH3GL3
ZNF33B	mHAP1
ZNF33B	ZHX1

Table 5:

	* Aarskog syndrome
	* Achromatopsia
	* Acoustic neuroma
5	* Adrenal hyperplasia
	* Adrenoleukodystrophy
	* Agenesis of corpus callosum
	* Aicardi syndrome
	* Alagille syndrome
10	* Albinism
	* Alopecia areata
	* Alstrom syndrome
	* Alpha-1-antitrypsin deficiency
	* Alzheimer
15	* Ambiguous genitalia
	* Androgen insensitivity syndrome(s)
	* Anorchia
	* Angelman syndrome
	* Anophthalmia
20	* Apert syndrome
	* Arthrogryposis
	* Ataxia
	* Autism
	* Bardet-Biedl syndrome
25	* Basal cell carcinoma
	* Batten disease
	* Beckwith-Wiedemann syndrome
	* Blepharophimosis
	* Blind
30	* Branchio-Oto-Renal (BOR) syndrome
	* Canavan
	* Cancer: (ataxia telangiectasia, basal cell nevus, brain /spine, breast, colon / bowel, leukemia / lymphoma, lung, melanoma / skin, multiple endocrine neoplasia, oral, ovarian, prostate, retinoblastoma, testicular, von Hippel-Lindau, xeroderma pigmentosa)
35	* Cardiofaciocutaneous syndrome
	* Celiac sprue
	* Charcot-Marie-Tooth
	* CHARGE association
40	* Chromosome anomalies - trisomy, deletions, inversions, duplications, translocations, 4p- (Wolf-Hirshhorn), 5 (cri-du-chat, 5p-), 6, 8p, 9 (trisomy 9, 9p-), 11 (11q, 11;22), 13 (trisomy 13, Patau), 15, 16 (mosaic), 18 (18q-, 18p-, ring 18, trisomy 18, tetrasomy 18p, Edwards), 21 (Down syndrome, trisomy 21), 22, X & Y [sex chromosome anomalies, Klinefelter (XXY, other), Turner (XO, other), fragile-X, other]
45	* Cleft lip and/or cleft palate
	* Cockayne syndrome
	* Coffin-Lowry syndrome
	* Coffin-Siris syndrome
50	* Congenital heart defects

- * Connective tissue conditions
- * Cooley anemia
- * Conjoined twins
- * Cornelia de Lange syndrome
- 5 * Costello syndrome
- * Craniofacial conditions
- * Cri-du-Chat (5p-)
- * Cystic fibrosis
- * Cystinosis
- 10 * Cystinuria
- * Dandy-Walker syndrome
- * Deaf / hard of hearing
- * Dermatological (skin) conditions
- * Developmental delay / mental retardation
- 15 * DiGeorge syndrome
- * Down syndrome
- * DRPLA
- * Dubowitz syndrome
- * Dwarfism/ short stature
- 20 * Dysautonomia
- * Dystonia
- * Ectodermal dysplasia
- * Ehlers Danlos syndrome
- * Endocrine Conditions
- 25 * Epidermolysis bullosa
- * Facial anomalies, disfigurement
- * Fanconi anemia
- * Fetal alcohol syndrome and effects
- * FG syndrome
- 30 * Fragile-X syndrome
- * Friedreich ataxia
- * Freeman Sheldon syndrome
- * Galactosemia
- * Gardner syndrome
- 35 * Gastroenterology conditions
- * Gaucher disease
- * Glycogen storage disease
- * Goldenhar syndrome
- * Gorlin syndrome
- 40 * Hallerman Streiff syndrome
- * Hearing problems
- * Heart conditions
- * Hemochromatosis
- * Hemophilia
- 45 * Hemoglobinopathies
- * Hereditary hemorrhagic telangiectasia
- * Hereditary spastic paraplegia
- * Hermansky-Pudlak syndrome
- * Hirschsprung anomaly
- 50 * Holoprosencephaly

- * Huntington disease
- * Hydrocephalus
- * Ichthyosis
- * Immune deficiencies
- 5 * Incontinentia pigmenti
- * Infertility
- * Intestinal problems
- * Joseph disease
- * Joubert syndrome
- 10 * Kabuki syndrome
- * Kidney conditions
- * Klinefelter syndrome
- * Klippel-Feil syndrome
- * Klippel-Trenaunay syndrome
- 15 * Langer-Giedion syndrome
- * Laurence-Moon-Biedl syndrome
- * Leber Optic Atrophy
- * Leigh disease
- * Lesch-Nyhan syndrome
- 20 * Leukodystrophy [Adrenoleukodystrophy (ALD), Alexanders Disease, CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts & Leukoencephalopathy), Canavan Disease (Spongy Degeneration), Cerebrotendinous Xanthomatosis (CTX), Globoid Cell (Krabbes) Leukodystrophy, Metachromatic Leukodystrophy (MLD), Ovarioleukodystrophy, Pelizaeus-Merzbacher Disease, Refsum Disease, van der Knaap syndrome, Zellweger syndrome]
- 25 * Limb anomalies [missing arm(s) or leg(s), Poland anomaly, other]
- * Lissencephaly [Isolated Sequence (ILS), X-Linked (XLIS), Subcortical Band Heterotopia (SBH), Miller-Dieker syndrome (MDS), Microcephaly, Micro-lissencephaly (MLIS), Norman-Roberts syndrome (NRS), With Cerebellar Hypoplasia (LCH), Polymicrogyria (PMG), Schizencephaly (SCH), Muscle-Eye-Brain (MEB) Disease, and Walker-Warburg syndrome (WWS), 17p13.3 deletion]
- 30 * Liver conditions (biliary atresia, Alagille syndrome, alpha-1 antitrypsin, tyrosinemia, neonatal hepatitis, Wilson disease)
- 35 * Lowe syndrome
- * Lung / pulmonary conditions
- * Lymphedema
- * Maffucci syndrome (Ollier, multiple cartilaginous enchondromatosis)
- * Malignant hyperthermia
- 40 * Maple syrup urine disease
- * Marinesco-Sjogren Syndrome
- * Marfan syndrome
- * Menke syndrome
- * Mental retardation / developmental delay
- 45 * Metabolic conditions (carbohydrate deficient glycoprotein syndrome (CDGS), diabetes insipidus, Fabry, galactosemia, glucose-6-phosphate dehydrogenase (G6PD), fatty acid oxidation disorders, glutaric aciduria, hypophosphatemia, Krabbe, lactic acidosis, lysosomal storage diseases, mannosidosis, maple syrup urine, mitochondrial, neuro-metabolic, organic acidemias, PKU, purine, pyruvate dehydrogenase deficiency, urea cycle conditions, vitamin D deficient rickets)
- 50

- * Miscarriage, stillbirth, infant death
- * Mitochondrial conditions (Alpers, Barth, beta-oxidation defects, carnitine deficiency, CPEO, Kearns-Sayre, lactic acidosis, Leber optic neuropathy, Leigh, LCAD, Luft, MCAD, MAD, glutaric aciduria, MERRF, MNGIE, NARP, Pearson, PHD, SCAD, NADH-CoQ reductase, succinate dehydrogenase, Complex III, Complex IV, COX, Complex V, other)
- * Moebius syndrome
- * Mucopolidosis, type IV (ML4)
- * Mucopolysaccharidosis (Hunter syndrome, Hurler syndrome, Maroteaux-Lamy syndrome, Sanfilippo syndrome, Scheie syndrome, Morquio syndrome, other)
- * Multiple hereditary exostoses
- * Muscular dystrophy /atrophy (neuromuscular conditions including: Duchenne, facioscapulohumeral, Charcot Marie Tooth, spinal muscular atrophy, other)
- * Myotonic dystrophy
- * Nager & Miller syndromes
- * Nail Patella syndrome
- * Narcolepsy
- * Neurologic conditions (neuro-metabolic, neurogenetics, neuromuscular, other)
- * Neurofibromatosis (von Recklinghausen)
- * Neuromuscular conditions
- * Niemann-Pick disease
- * Noonan syndrome
- * Opitz syndromes [Opitz-Frias, Opitz FG (Opitz-Kaveggia), Opitz-C (Trigonocephaly)]
- * Organic acidemias
- * Osler-Weber-Rendu syndrome
- * Osteogenesis imperfecta
- * Oxalosis & hyperoxaluria
- * Pallister-Hall syndrome
- * Pallister-Killian syndrome (tetrasomy 12p, Teschler-Nicola syndrome)
- * Parkinson's disease
- * Periodic paralysis
- * Phenylketonuria (PKU)
- * Polycystic kidney disease
- * Popliteal pterygium syndrome
- * Porphyrria
- * Prader-Willi syndrome
- * Progeria (Werner, Hutchinson-Gilford, Cockayne, Rothmond-Thomson syndromes)
- * Proteus syndrome
- * Prune belly syndrome
- * Pseudoxanthoma elasticum (PXE)
- * Psychiatric conditions
- * Refsum disease
- * Retinal degeneration
- * Retinitis pigmentosa (retinal degenerative diseases, Usher syndrome)
- * Retinoblastoma
- * Rett syndrome
- * Robinow syndrome
- * Rubinstein-Taybi syndrome
- * Russell-Silver syndrome

- * SBMA
- * SCA
- * Schizencephaly
- * Sex chromosome anomalies (47,XXY, 47,XXX, 45,X and variants, 47,XYY)
- 5 * Shwachman syndrome
- * Sickle cell anemia
- * Skeletal dysplasia
- * Smith-Lemli-Opitz syndrome (RHS syndrome)
- * Smith-Magenis syndrome (17p-)
- 10 * Sotos syndrome
- * Spina bifida (myelomeningocele, neural tube defects)
- * Spinal muscular atrophy (Werdnig-Hoffman, Kugelberg-Welander)
- * Stickler / Marshall syndrome
- * Sturge-Weber
- 15 * Tay-Sachs disease / other (dysautonomia, dystonia, Gaucher, Niemann Pick, Canavan, Bloom)
- * Thalassemia (Cooley anemia)
- * Thrombocytopenia absent radius syndrome
- * Tourette syndrome
- 20 * Treacher Collins syndrome (craniofacial)
- * Trisomy (21, 18, 13, 9, other, see chromosome syndromes)
- * Tuberous sclerosis
- * Turner syndrome
- * Twins / triplets / multiple births
- 25 * Unknown disorders
- * Urea cycle conditions
- * Usher syndrome
- * VATER association
- * Velo-cardio-facial syndrome (Shprintzen, DiGeorge, 22q deletion)
- 30 * Visual impairment / blind
- * Von Hippel-Lindau syndrome
- * Waardenburg syndrome
- * Weaver syndrome
- * Werner syndrome
- 35 * Williams syndrome
- * Wilson disease (hepatolenticular degeneration)
- * Xeroderma pigmentosum
- * Zellweger syndrome

TABLE 6

PROTEIN-PROTEIN INTERACTIONS IN THE PROTEIN NETWORK OF HUNTINGTIN

BAIT	PREY
SETDB1	SUMO-3
PIASy	SUMO-3
HZFH	SUMO-3
PIASy	HYP
HZFH	HYP
MAP1lc3	HYP
ZHX1	HYP
PIASy	HZFH
HZFH	HZFH
GIT1	HZFH
VIM	HZFH
PIASy	ZHX1
HZFH	ZHX1
VIM	ZHX1
FEZ1	HMP
HZFH	HMP
HMP	HMP
PIASy	HMP
HZFH	PTN
HIP15	PTN
PIASy	PTN
PTN	PTN
FEZ1	PTN
KPNA2	G45IP3
GIT1	G45IP3
BAIP1	G45IP3
FEZ1	G45IP3
SH3GL3	G45IP3
EF1A	APP1
SETDB1	APP1
HIP16	APP1
GDF9	APP1
G45IP1	APP1
BAIP1	APP1
HIP5	BAIP3
GIT1	BAIP3
BAIP2	BAIP3
APP1	BAIP3

FEZ1	BAIP3
NAG4	BAIP3
SETDB1	BAIP3
HBO1	BAIP3
HIP15	BAIP3
BAIP3	BAIP3
HZFH	BAIP3
PLIP	BAIP3
mHAP1	BAIP3
PIASy	BAIP3
HMP	BAIP3
NAG4	NEFL
HZFH	NEFL
VIM	NEFL
PIASy	NEFL
HMP	HIP5
PLIP	HIP5
mHAP1	HIP5
HBO1	HIP5
KPNA2	HIP5
VIM	HIP5
APP1	HIP5
HIP15	HIP5
NAG4	HIP5
GIT1	HIP5
BAIP1	HIP5
FEZ1	HIP5
CGI-74	HIP5
BAIP2	HIP5
ALEX2	ALEX2
PIASy	MAGEH1
KPNA2	MAGEH1
SETDB1	CA150
LUC7B1	CA150
HZFH	CA150
PIASy	CA150
PIASy	hADA3
BAIP1	hADA3
MAGEH1	hADA3
Ku70	hADA3
GIT1	BARD1

BAIP3	BARD1
SETDB1	BARD1
CA150	BARD1
NAG4	BARD1
HIP15	BARD1
HIP5	BARD1
PTN	BARD1
FEZ1	BARD1
IKAP	BARD1
BAIP1	BARD1
mHAP1	BARD1
HBO1	BARD1
BAIP2	BARD1
PLIP	BARD1
PIASy	BARD1
HZFH	BARD1
ZHX1	BARD1
SH3GL3	HDexQ20
HIP13	HDexQ20
CGI-125	HDexQ20
PFN2	HDexQ20
CA150	HDexQ20
HYP A	HDexQ20
HP28	HDexQ51
HYP A	HDexQ51
CA150	HDexQ51
SH3GL3	HDexQ51
HIP13	HDexQ51
HIP15	HDexQ51
PFN2	HDexQ51
CGI-125	HDexQ51
LUC7B1	GADD45G
GDF9	GADD45G
PTN	GADD45G
BAIP3	GADD45G
G45IP2	GADD45G
HIP16	GADD45G
G45IP3	GADD45G
CGI-125	GADD45G
G45IP1	GADD45G
HIP5	GADD45G

EF1G	GADD45G
EF1A	GADD45G
PLIP	GADD45G
PIASy	GADD45G
CGI-74	GADD45G
PTPK	GADD45G
MAP1lc3	PIASy
SUMO-2	PIASy
SUMO-3	PIASy
HYP A	HD1.7
HIP16	HD1.7
DRP-1	HD1.7
HZFH	HD1.7
SH3GL3	HD1.7
HIP13	HD1.7
CGI-125	HD1.7
CA150	HD1.7
HIP11	HD1.7
Ku70	HD1.7
HIP1	HD1.7
IKAP	HD1.7
PFN2	HD1.7
FEZ1	HD1.7
GIT1	HD1.7
HIP5	HD1.7
PIASy	HD1.7
GIT1	HDd1.0
IKAP	HDd1.0
FEZ1	HDd1.0
PIASy	HDd1.3
IKAP	HDd1.3
HZFH	HDd1.3
Ku70	HDd1.3
PIASy	HIP2
Ku70	CLH-17
HZFH	mp53
ZHX1	mp53
p53	mp53
PIASy	mp53
PLIP	GAPD

PIASy	IMPD2
EF1G	EF1G
HIP11	EF1G
HZFH	TAL1
ZHX1	TAL1
Ku70	TCPG
PIASy	CLK1
mHAP1	ZNF33B
ZHX1	ZNF33B
HZFH	KPNB1
PIASy	KPNB1
PTN	KPNB1
ALEX2	VIM
SH3GL3	VIM
PIASy	VIM
HIP16	VIM
HBO1	VIM
BAIP1	VIM
DRP-1	VIM
G45IP1	VIM
MOV34	VIM
VIM	VIM
NEFL	VIM
HSPC232	VIM
SETDB1	VIM
HIP15	HD1.7
HP28	HDexQ20

Table 7 Classification of proteins in Huntington's disease interaction network

ID	NAME	FUSION	LOCUS ID	ACCESSION	IDEN	aa MATCH	LOC
Huntingtin fragments							
HD1.7	huntingtin	DBD	3064	P42858	100	1-506	N, C
HDd1.0	huntingtin	DBD	3064	P42858	100	1-320	N, C
HDd1.3	huntingtin	DBD	3064	P42858	100	166-506	N, C
HDexQ20	huntingtin	DBD	3064	P42858	96	1-90	N, C
HDexQ51	huntingtin	DBD	3064	P42858	75	1-82	N, C
Transcriptional control and DNA maintenance							
BARD1	BRCA1 associated ring domain protein 1	DBD	580	Q99728	99	1-379	N
CA150	putative transcription factor CA150	AD, DBD	10915	O14776	93	299-629	N
GADD45G	growth arrest and DNA damage inducible protein GADD45 gamma	DBD	10912	O95257	100	18-159	N
hADA3	ADA3 like protein	DBD	10474	O75528	100	235-432	N
HBO1	histone acetyltransferase binding to ORC	AD, DBD ²	11143	O95251	100	1-611	N
HYP4	huntingtin interacting protein HYP4/FBP11 (fragment)	AD, DBD	55660	O75400	100	8-422	C, N
HZFH	zinc finger helicase HZFH	AD, DBD	11107	Q9Y410	100	1830-2000	N
IKAP	IKK complex associated protein	AD, DBD ²	8518	O95163	100	1207-1332	N, C
Ku70	ATP dependent DNA helicase II, 70 kDa subunit	AD, DBD ¹	2547	P12956	100	298-608	N
NAG4	bromodomain containing protein NAG4	AD	29117	Q9NP11	100	94-651	N
PIASy	protein inhibitor of activated STAT protein gamma (PIASy)	AD, DBD	51588	Q8N2W9	100	5-510	N, C
p53	cellular tumor antigen p53	AD	7157	P04637	100	1-393	N
p53c	cellular tumor antigen p53 (C-terminus)	AD	7157	P04637	100	248-393	N
mp53	cellular tumor antigen p53 (mouse)	DBD	7157	P02340	100	73-390	N
PLIP	cPLA2 interacting protein	AD, DBD ¹	10524	O95624	100	5-461	N, pN
SETDB1	histone-lysine N-methyltransferase, H3 lysine-9 specific 4	AD, DBD ¹	9869	Q15047	100	1023-1291	N
SUMO-2	ubiquitin like protein SMT3A (SUMO-2)	AD	6612	P55854	100	1-103	C, N
SUMO-3	ubiquitin like protein SMT3B (SUMO-3)	AD, DBD	6613	P55855	100	1-95	C, N
ZHX1	zinc finger homeobox protein ZHX1	AD, DBD	11244	Q9UKY1	100	145-873	N
ZNF33B	zinc finger protein 33b	DBD	7582	Q8NDW3	100	527-778	N

Cellular organization and protein transport						
APP1	amyloid like protein 1 precursor	AD, DBD	333	P51693	100	243-555 PM, EC
CLH-17	clathrin heavy chain 1	DBD	1213	Q00610	100	1-289 PM, V
HP28	axonemal dynein light chain (hp28)	AD	7802	Q9BQZ6	100	3-258 CN
mHAP1	huntingtin associated protein 1 (mouse)	AD, DBD ²	9001	O35668	100	3-471 C, EE
HIP1	huntingtin interacting protein 1	AD, DBD ²	3092	O00291	100	245-631 C, GN
HMP	mitofilin	AD, DBD	10989	Q16891	100	212-758 Mit
KPNA2	karyopherin alpha-2 subunit	AD, DBD ²	3838	P52292	100	141-529 C, N
KPNB1	karyopherin beta-1 subunit	DBD	3837	Q14974	100	668-876 C, N
MAP1c3	microtubule associated proteins 1A/1B light chain 3	AD, DBD ²	84557	Q9H491	100	58-170 CN, MT
NEFL	light molecular weight neurofilament protein	AD, DBD	4747	Q8IU72	100	1-543 CN, IF
PFN2	profilin II	AD, DBD ¹	5217	P35080	100	1-139 CN
PTN	pleiotrophin precursor (exon 1 included)	AD, DBD	5764	P21246	100	1-168 PM, EC
SH3GL3	SH3 containing GRB2 like protein 3	AD, DBD ²	6457	Q99963	100	3-347 V
VIM	vimentin	DBD	7431	P08670	100	1-465 CN, IF
VIMc	vimentin (C-terminus)	AD	7431	P08670	100	189-465 CN, IF
Cell signaling and fate						
ALEX2	armadillo repeat protein ALEX2	AD, DBD	9823	O60267	100	127-632 C, PM
CLK1	protein kinase CLK1	DBD	1195	P49759	100	209-484 N
DRP-1	dihydropyrimidinase related protein 1 (C-terminus)	AD, DBD ¹	1400	Q14194	100	345-572 C
FEZ1	fasciculation and elongation protein zeta 1	AD, DBD ²	9638	Q99689	100	131-392 C, PM
GDF9	growth/differentiation factor 9	AD, DBD ¹	2661	O60383	100	276-454 C
GIT1	ARF GTPase activating protein GIT1 (9 aa insertion included)	AD, DBD ²	28964	Q9Y2X7	98	249-761 PM, V
PTPK	protein-tyrosine phosphatase kappa precursor	AD, DBD ¹	5796	Q15262	100	1227-1439 PM, AJ
Cellular metabolism						
GAPD	glyceraldehyde 3-phosphate dehydrogenase	DBD	2597	P04406	100	116-334 C
IMPD2	inosine-5'-monophosphate dehydrogenase 2	DBD	3615	P12268	100	34-514 C
TAL1	transaldolase	DBD	6888	P37837	100	3-337 C
Protein synthesis and turnover						
EF1A	translation elongation factor 1 alpha 1	AD, DBD ¹	1915	P04720	100	294-462 C, MT
EF1G	elongation factor 1 gamma	AD, DBD	1937	P26641	100	2-437 C, MT
EF1Gc	elongation factor 1 gamma (C-terminus)	AD	1937	P26641	100	123-437 C, MT
HIP2	ubiquitin conjugating enzyme E2-25 kDa	DBD	3093	P27924	100	1-200 C, N
MOV34	MOV34 isolog	AD, DBD ¹	10980	O15387	95	1-297 C, N
TCPG	T-complex protein 1, gamma subunit	DBD	7203	P49368	100	252-544 C

Uncharacterized proteins							
BAIP1	BARD1 interacting protein 1[similar to RIKEN cDNA 1810018M11]	AD	84289	Q9BS30	100	1-226	UN
BAIP2	BARD1 interacting protein 2 [hypothetical protein]	AD	84078	Q9H0I6	100	107-684	UN
BAIP3	BARD1 interacting protein 3 [hypothetical protein]	AD,DBD	55791	Q96HT4	100	152-436	UN
CGI-74	CGI-74 protein	AD	51631	Q9Y383	100	159-270	UN
CGI-125	CGI-125 protein	AD	51003	Q9Y3C7	100	1-131	UN
G45IP1	GADD45G interacting protein 1[hypothetical protein]	AD, DBD ²	84060	Q9H0V7	100	1-340	UN
G45IP2	GADD45G interacting protein 2 [B2 gene partial cDNA, clone B2E]	AD	9842	Q9NYA0	100	566-926	UN
G45IP3	GADD45G interacting protein 3 [OK/SW-CL.16]	AD, DBD	-	Q8NI70	100	3-134	UN
HIP5	huntingtin interacting protein 5 [hypothetical protein KIAA1377]	AD, DBD	57562	Q9P2H0	100	445-988	N, C
HIP11	huntingtin interacting protein 11[hypothetical protein]	AD, DBD ¹	1891	Q96EZ9	100	176-328	UN
HIP13	huntingtin interacting protein 13 [metastasis suppressor protein]	AD, DBD ¹	9788	Q96RX2	100	512-755	UN
HIP15	huntingtin interacting protein 15 [similar to KIAA0443 gene product]	AD	114928	Q96D09	100	663-838	UN
HIP16	huntingtin interacting protein 16 [similar to KIAA0266 gene product]	AD	10813	Q9BVJ6	100	585-771	UN
HSPC232	HSPC232	AD	51535	Q9P0P6	92	1-319	UN
LUC7B1	putative SR protein LUC7B1 (SR+89)	AD	55692	Q9NQ29	99	116-371	ER
MAGEH1	melanoma associated antigen H1	AD, DBD	28986	Q9H213	100	1-219	UN
Abbreviations: aa, amino acids; IDEN, identity; LOC, localization; LOCUS ID, NCBI LocusLink Identity, activation domain; DBD, DNA binding domain; DBD ¹ , DBD fusion proteins yielding no interactions; DBD ² , autoactive DBD fusion proteins; AJ, adherens junctions; C, cytosol; CN, cytoskeleton; EC, extracellular space; EE, early endosomes; ER, endoplasmic reticulum; IF, intermediate filaments; GN, Golgi network; Mit, mitochondria; MT, microtubules; N, nucleus; PM, plasma membrane; pN, perinuclear; UN, unknown; V, vesicles; [], database annotation.							

Abbreviations: aa, amino acids; IDEN, identity; LOC, localization; LOCUS ID, NCBI LocusLink Identity, activation domain; DBD, DNA binding domain; DBD¹, DBD fusion proteins yielding no interactions; DBD², autoactive DBD fusion proteins; AJ, adherens junctions; C, cytosol; CN, cytoskeleton; EC, extracellular space; EE, early endosomes; ER, endoplasmic reticulum; IF, intermediate filaments; GN, Golgi network; Mit, mitochondria; MT, microtubules; N, nucleus; PM, plasma membrane; pN, perinuclear; UN, unknown; V, vesicles; [], database annotation.

Table 8 New proteins in Huntington's disease interaction network

ID	NAME	FUSION	ACCESSION	IDEN	aa MATCH	LOC
Transcriptional control and DNA maintenance						
BARD1	BRCA1 associated ring domain protein 1	DBD	Q99728	99	1-379	N
CA150	putative transcription factor CA150	AD	O14776	93	299-629	N
Protein synthesis and turnover						
MOV34	MOV34 isolog	AD, DBD	O15387	95	1-297	C, N
Cell signaling and fate						
GIT1	ARF GTPase activating protein GIT1	AD	Q9Y2X7	98	249-761	PM, V
HSPC232	HSPC232	AD	Q9P0P6	92	1-319	UN
LUC7B1	putative SR protein LUC7B1 (SR+89)	AD	Q9NQ29	99	116-371	ER

Abbreviations: aa, amino acids; IDEN, identity; LOC, localisation; AD, activation domain; DBD, DNA binding domain; AJ, adherens junctions; C, cytosol; CN, cytoskeleton; EC, extracellular space; EE, early endosomes; ER, endoplasmic reticulum; IF, intermediate filaments; GN, Golgi network; Mit, mitochondria; MT, microtubules; N, nucleus; PM, plasma membrane; PN, perinuclear; UN, unknown; V, vesicles; [], database annotation

Table 9: New protein-protein interactions found

BAIT	PREY
SETDB1	SUMO-3
PIASy	SUMO-3
HZFH	SUMO-3
PIASy	HYP
HZFH	HYP
MAP1lc3	HYP
ZHX1	HYP
PIASy	HZFH
HZFH	HZFH
GIT1	HZFH
VIM	HZFH
PIASy	ZHX1
HZFH	ZHX1
VIM	ZHX1
FEZ1	HMP
HZFH	HMP
HMP	HMP
PIASy	HMP
HZFH	PTN
HIP15	PTN
PIASy	PTN
PTN	PTN
FEZ1	PTN
KPNA2	G45IP3
GIT1	G45IP3
BAIP1	G45IP3
FEZ1	G45IP3
SH3GL3	G45IP3
EF1A	APP1
SETDB1	APP1
HIP16	APP1
GDF9	APP1
G45IP1	APP1
BAIP1	APP1
HIP5	BAIP3
GIT1	BAIP3
BAIP2	BAIP3
APP1	BAIP3
FEZ1	BAIP3

NAG4	BAIP3
SETDB1	BAIP3
HBO1	BAIP3
HIP15	BAIP3
BAIP3	BAIP3
HZFH	BAIP3
PLIP	BAIP3
mHAP1	BAIP3
PIASy	BAIP3
HMP	BAIP3
NAG4	NEFL
HZFH	NEFL
VIM	NEFL
PIASy	NEFL
HMP	HIP5
PLIP	HIP5
mHAP1	HIP5
HBO1	HIP5
KPNA2	HIP5
VIM	HIP5
APP1	HIP5
HIP15	HIP5
NAG4	HIP5
GIT1	HIP5
BAIP1	HIP5
FEZ1	HIP5
CGI-74	HIP5
BAIP2	HIP5
ALEX2	ALEX2
PIASy	MAGEH1
KPNA2	MAGEH1
SETDB1	CA150
LUC7B1	CA150
HZFH	CA150
PIASy	CA150
PIASy	hADA3
BAIP1	hADA3
MAGEH1	hADA3
Ku70	hADA3
GIT1	BARD1
BAIP3	BARD1

SETDB1	BARD1
CA150	BARD1
NAG4	BARD1
HIP15	BARD1
HIP5	BARD1
PTN	BARD1
FEZ1	BARD1
IKAP	BARD1
BAIP1	BARD1
mHAP1	BARD1
HBO1	BARD1
BAIP2	BARD1
PLIP	BARD1
PIASy	BARD1
HZFH	BARD1
ZHX1	BARD1
HIP13	HDexQ20
CGI-125	HDexQ20
PFN2	HDexQ20
HP28	HDexQ51
HIP13	HDexQ51
HIP15	HDexQ51
PFN2	HDexQ51
CGI-125	HDexQ51
LUC7B1	GADD45G
GDF9	GADD45G
PTN	GADD45G
BAIP3	GADD45G
G45IP2	GADD45G
HIP16	GADD45G
G45IP3	GADD45G
CGI-125	GADD45G
G45IP1	GADD45G
HIP5	GADD45G
EF1G	GADD45G
EF1A	GADD45G
PLIP	GADD45G
PIASy	GADD45G
CGI-74	GADD45G
PTPK	GADD45G
MAP1lc3	PIASy

SUMO-2	PIASy
SUMO-3	PIASy
HIP16	HD1.7
DRP-1	HD1.7
HZFH	HD1.7
HIP13	HD1.7
CGI-125	HD1.7
HIP11	HD1.7
Ku70	HD1.7
IKAP	HD1.7
PFN2	HD1.7
FEZ1	HD1.7
GIT1	HD1.7
HIP5	HD1.7
PIASy	HD1.7
GIT1	HDd1.0
IKAP	HDd1.0
FEZ1	HDd1.0
PIASy	HDd1.3
IKAP	HDd1.3
HZFH	HDd1.3
Ku70	HDd1.3
PIASy	HIP2
Ku70	CLH-17
HZFH	mp53
ZHX1	mp53
p53	mp53
PIASy	mp53
PLIP	GAPD
PIASy	IMPD2
EF1G	EF1G
HIP11	EF1G
HZFH	TAL1
ZHX1	TAL1
Ku70	TCPG
PIASy	CLK1
mHAP1	ZNF33B
ZHX1	ZNF33B
HZFH	KPNB1
PIASy	KPNB1
PTN	KPNB1

ALEX2	VIM
SH3GL3	VIM
PIASy	VIM
HIP16	VIM
HZFH	VIM
HBO1	VIM
BAIP1	VIM
DRP-1	VIM
G45IP1	VIM
MOV34	VIM
VIM	VIM
NEFL	VIM
HSPC232	VIM
SETDB1	VIM
HIP15	HD1.7
HP28	HDexQ20

Supplementary Table 1: List of DBD proteins for 1st round of Y2H library screens

ID	NAME	ACCESSION	aa MATCH	PPIs
BARD1	BRCA1 associated ring domain protein 1	Q99728	1-379	3
CLH17	clathrin heavy chain 1	Q00610	1-289	1
CLK1	protein kinase CLK1	P49759	209-484	1
GADD45G	growth arrest and DNA-damage-inducible protein GADD45 gamma	O95257	18-159	6
hADA3	ADA3 like protein	O75528	235-432	1
HD1.7	huntingtin	P42858	1-506	5
HDd1.0	huntingtin	P42858	1-320	1
HDd1.3	huntingtin	P42858	166-506	2
HDexQ20	huntingtin	P42858	1-90	3
HDexQ51	huntingtin	P42858	1-82	4
HIP2	ubiquitin conjugating enzyme E2-25 kDa	P27924	1-200	1
IMPD2	inosine 5'-monophosphate dehydrogenase 2	P12268	34-514	1
KPNB1	karyopherin beta-1 subunit	Q14974	668-876	1
mp53	cellular tumor antigen p53 (mouse)	P02340	73-390	2
TAL1	transaldolase	P37837	3-337	1
TCPG	T-complex protein 1, gamma subunit	P49368	252-544	1
VIM	vimentin	P08670	1-465	6
ZNF33B	zinc finger protein 33b	Q8NDW3	527-778	1
14-3-3	14-3-3 protein epsilon	P42655	93-255	AA
DNAJ	DnaJ homolog subfamily A member 1	P31689	113-379	AA
HD513Q68	huntingtin	P42858	1-513	AA
HIP1	huntingtin interacting protein 1	O00291	245-631	AA
mAP2A1	α -adaptin A (mouse)	P17426	697-971	AA
mAP2A2	α -adaptin C (mouse)	P17427	697-938	AA
mHAP	huntingtin associated protein 1 (mouse)	O35668	3-471	AA
RFA	replication protein A 70 kDa DNA-binding subunit	P27694	262-616	AA
SH3GL3	SH3 containing GRB2 like protein 3	Q99963	3-347	AA
ZFR	ZNF259	O75312	29-460	AA
ACTG1	gamma-actin	P02571	182-375	-
ALBU	serum albumin precursor	P02768	1-249	-
ALDA	fructose-bisphosphate aldolase A	P04075	1-363	-
AMPL	cytosol aminopeptidase	P28838	46-487	-
ARF4L	ADP-ribosylation factor-like protein 4L	P49703	33-201	-
ASNS	glutamine-dependent asparagine synthetase	P08243	318-560	-
BCK	creatine kinase, B chain	P12277	92-381	-
CLH-17	clathrin heavy chain 1	Q00610	1165-1671	-
GAPDH	glyceraldehyde 3-phosphate dehydrogenase	P04406	1-334	-
HD-CT	huntingtin	P42858	2721-3144	-
LDHB	L-lactate dehydrogenase b chain	P07195	96-333	-
MDHM	malate dehydrogenase, mitochondrial precursor	P40926	1-338	-
MOV34	MOV34 isolog	O15387	76-297	-
NSFL1C	p97 cofactor p47	Q9UNZ2	201-370	-
PEBP	phosphatidylethanolamine-binding protein	P30086	1-186	-
PHGDH	D-3-phosphoglycerate dehydrogenase	O43175	1-553	-
PLD2	phospholipase D2	O14939	168-336	-
TIP49	49 kDa TBP-interacting protein	Q9Y265	1-456	-
TRFE	serotransferrin precursor	P02787	213-698	-
TUBA1	alpha-tubulin 1	P05209	1-451	-
TUBB4	tubulin beta-4 chain	Q13509	113-450	-
UBC1	polyubiquitin C	Q9UEF2	1-685	-

Abbreviations: aa, amino acids; DBD, DNA binding domain; PPIs, protein-protein interactions; AA, autoactivation of reporter gene.

Supplementary Table 2: Subcloned DBD proteins for 2nd round of library screens

Prey	Reason for selection	PPIs
HIP5	huntingtin interacting protein verified by <i>in vitro</i> binding assay	8
PIASy	huntingtin interacting protein verified by <i>in vitro</i> binding assay	3
CA150	huntingtin interacting protein, literature verified interaction [Holbert S. <i>et al. Proc. Natl Acad. Sci. USA</i> 98, 1811-1816 (2001)]	1
EF1G	part of ternary complex with EF1A, which is found in htt aggregates [Vanwetswinkel S. <i>et al. J Biol.Chem.</i> 278,43443-51 (2003)]	1
HYP A	huntingtin interacting protein, literature verified interaction [Faber, P.W. <i>et al. Hum. Mol. Genet.</i> 9, 1463-1474 (1998)]	1
FEZ1	huntingtin interacting protein verified by <i>in vitro</i> binding assay	AA
GIT1	huntingtin interacting protein verified by <i>in vitro</i> binding assay	AA
EF1A	htt aggregate-interacting protein [Mitsui K. <i>et al. J. Neurosci</i> 22,9267-9277 (2002)]	-
HIP11	huntingtin interacting protein verified by <i>in vitro</i> binding assay	-
NEFL	vimentin interacting protein, literature verified interaction [Carpenter, D.A. & Ip; W. <i>J. Cell. Sci.</i> 10, 2493-2498 (1996)]	-
p53	huntingtin interacting protein, literature verified interaction [Steffan, J.S. <i>et al. Proc. Natl. Acad. Sci. USA</i> 97, 6763-8 (2000)]	-
PLIP	BARD1 interacting protein, literature verified interaction [Dechend, R. <i>et al. Oncogene</i> 18, 3316-3323 (1999)]	-

Abbreviations: DBD, DNA binding domain; PPIs, protein-protein interactions; AA, autoactivation of reporter gene.

Supplementary Table 3: Reported interactions in Huntington's disease network

Reported interactions, found

Protein A	Protein B	Literature
CA150	HD1.7 HDexQ20 HDexQ51	Holbert S. <i>et al. Proc. Natl Acad. Sci. USA</i> 98 , 1811-1816 (2001). The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis.
HYP4	HD1.7 HDexQ20 HDexQ51	Faber, P.W. <i>et al. Hum. Mol. Genet.</i> 9 , 1463-1474 (1998). Huntingtin interacts with a family of WW domain proteins.
HIP1	HD1.7	Wanker, E.E. <i>et al. Hum. Mol. Genet.</i> 3 , 487-495 (1997). HIP-1: a huntingtin interacting protein isolated by the yeast two-hybrid system.
SH3GL3	HD1.7 HDexQ20 HDexQ51	Sittler, A. <i>et al. Mol. Cell</i> 4 , 427-436 (1998). SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polyglutamine-containing protein aggregates.
PIASy	mp53	Nelson, V., Davis, G.E. & Maxwell, S.A. <i>Apoptosis</i> 3 , 221-234 (2001). A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis.
p53	mp53	Chene, P. <i>Oncogene</i> 20 , 2611-2617 (2001). The role of tetramerization in p53 function. Leblanc V. <i>et al. Anal Biochem.</i> 308 , 247-54 (2002). Homogeneous time-resolved fluorescence assay for identifying p53 interactions with its protein partners, directly in a cellular extract.
PLIP	BARD1	Dechend, R. <i>et al. Oncogene</i> 18 , 3316-3323 (1999). The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
SUMO-2	PIASy	Sachdev, S. <i>et al. Genes Dev.</i> 15 , 3088-3103 (2001). PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.
SUMO-3	PIASy	Sachdev, S. <i>et al. Genes Dev.</i> 15 , 3088-3103 (2001). PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.
EF1G	EF1G	Mansilla, F. <i>et al. Biochem. J.</i> 365 , 669-676 (2002). Mapping the human translation elongation factor eEF1H complex using the yeast two-hybrid system.
NEFL VIMc	VIM	Carpenter, D.A. & Ip, W. <i>J. Cell. Sci.</i> 10 , 2493-2498 (1996). Neurofilament triplet protein interactions: evidence for the preferred formation of NF-L-containing dimers and a putative function for the end domains.

Reported interactions, not found

Protein A	Protein B	Literature
HAP1	HDexQ20 HDexQ51	Li, S.H. <i>et al. J. Biol. Chem.</i> 273 , 19220-19227 (1998) A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. Li, S.H. <i>et al. J. Neurosci.</i> 18 , 1261-1269. (1998) Interaction of huntingtin-associated protein with dynactin P150Glued.
HIP1	CLH-17	Henry, K.R. <i>et al. Mol. Biol. Cell</i> 13 , 2607-2625 (2002). Scd5p and clathrin function are important for cortical actin organization, endocytosis, and localization of sla2p in yeast. [interlogs paper] Metzler, M. <i>et al. J. Biol. Chem.</i> 276 , 39271-39276 (2001). HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. Waelter, S. <i>et al. Hum. Mol. Genet.</i> 10 , 1807-1817 (2001). The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis.
p53	HDexQ20 HDexQ51	Steffan, J.S. <i>et al. Proc. Natl. Acad. Sci. USA</i> 97 , 6763-6768 (2000). The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.
p53	hADA3	Wang, T. <i>et al. EMBO J.</i> 20 , 6404-6413 (2001). hADA3 is required for p53 activity.
p53	BARD1	Irminger-Finger, I. <i>et al. Mol. Cell</i> 6 , 1255-1266 (2001). Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis.
KPNA2	KPNB1	Chook, Y.M. & Blobel, G. <i>Curr. Opin. Struct. Biol.</i> 6 , 703-715 (2001). Karyopherins and nuclear import.

Supplementary Table 4: Reported huntingtin interacting proteins

ID	NAME	LOCUS ID	PubMed ID
Transcriptional control and DNA maintenance			
CA150	transcription elongation regulator 1 (TCERG1)	10915	11172033
CREB1	cAMP responsive element binding protein 1	1385	8643525
CREBBP	CREB binding protein (Rubinstein-Taybi syndrome)	1387	10823891
CTBP1	C-terminal binding protein 1	1487	11739372
HYPA	formin binding protein 3 (FNBP3)	55660	9700202
HYPB	huntingtin interacting protein B	29072	9700202
HYPB	huntingtin interacting protein B	29072	9700202
HYPB	huntingtin interacting protein B	29072	9700202
NCOR1	nuclear receptor corepressor 1	9611	10441327
NCOR1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	9611	10441327
NFKB1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	4790	12379151
PQBP1	polyglutamine binding protein 1	10084	10332029
REST	RE1-silencing transcription factor	5978	1288172
SAP30	sin3-associated polypeptide, 30kDa	8819	10823891;10441327
SP1	Sp1 transcription factor	6667	11988536
TAF4	TAF4 RNA polymerase II	6874	11988536
TBP	TATA box binding protein	6908	10410676
TP53	tumor protein p53 (Li-Fraumeni syndrome)	7157	10823891
Cellular organization and protein transport			
AP2A2	adaptor-related protein complex 2, alpha 2 subunit	161	9700202
DLG4	discs, large homolog 4 (Drosophila) (PSD95)	1742	11319238
HAP1	huntingtin-associated protein 1 (neuroan 1)	9001	9668110;9454836
HIP1	huntingtin interacting protein 1	3092	9147654
HIP14	huntingtin interacting protein 14	23390	9700202;12393793
OPTN	optineurin (FIP2)	10133	9700202;11137014
PACSL1	protein kinase C and casein kinase substrate in neurons 1	29993	12354780
SH3GL3	SH3-domain GRB2-like 3	6457	9809064
SYMPK	sympleskin	8189	9700202
TUBG1	tubulin, gamma 1	7283	11870213
Cell signaling and fate			
GRAP	GRB2-related adaptor protein	10750	8612237
GRB2	growth factor receptor-bound protein 2	2885	9079622
ITPR1	inositol 1,4,5-triphosphate receptor, type 1	3708	12873381
MAP3K10	mitogen-activated protein kinase kinase kinase 10	4294	10801775
PDE1A	phosphodiesterase 1A, calmodulin-dependent	5136	8643525
RASA1	RAS p21 protein activator (GTPase activating protein) 1	5921	8612237; 9079622
TGM2	transglutaminase 2	7052	11442349
TRIP10	thyroid hormone receptor interactor 10	9322	12604778
Cellular metabolism			
CBS	cystathionine-beta-synthase	875	9466992; 10434301;10823891
GAPD	glyceraldehyde-3-phosphate dehydrogenase	2597	8612237
TPH1	tryptophan hydroxylase 1	7166	12354289
Protein synthesis and turnover			
HIP2	huntingtin interacting protein 2	3093	8702625; 9700202
Uncharacterized proteins			
HYPE	huntingtin interacting protein E	11153	9700202
HYPK	huntingtin interacting protein HYPK	25764	9700202
HYPM	huntingtin interacting protein HYPM	25763	9700202
MAGEA3	melanoma antigen, family A, 3	4102	9700202

Abbreviations: ID, interacting protein gene symbol; LOCUS ID, NCBI LocusLink Identity; Pubmed ID, NCBI PubMed publication index; Reported htt interactors are presented according to databases: MINT, HPRD, BIND; Li & Li, *Trends Genet.* (2004), 20, 146-152 and Harjes & Wanker, *Trends. Biochem. Sci.* (2003), 28, 425-433.

Supplementary Table 5: Protein-protein interactions of the extended HD network

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference	Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
1	ABL1	25	CBL	867	literature	63	BRCA1	672	RBBP4	5928	literature
2	ABL1	25	PXN	5829	literature	64	BRCA1	672	RELA	5970	literature
3	ALEX2	9823	ALEX2	9823	this study	65	CA150	10915	LUC7B1	55692	this study
4	ALK	238	SHC1	6464	literature	66	CA150	10915	PIASy	51588	this study
5	AP2A2	161	SHC1	6464	literature	67	CBL	867	SRC	6714	literature
6	APP1	333	EF1A	1915	this study	68	CBL	867	VAV1	7409	literature
7	APP1	333	BAIP1	84289	this study	69	CBL	867	SH3KBP1	30011	literature
8	APP1	333	GDF9	2661	this study	70	CBL	867	LAT	27040	literature
9	APP1	333	SETBD1	9869	this study	71	CBL	867	SHC1	6464	literature
10	APP1	333	HIP16	10813	this study	72	CBL	867	PIK3R1	5295	literature
11	APP1	333	BAIP3	55791	this study	73	CBL	867	PLCG1	5335	literature
12	APP1	333	HIP5	57562	this study	74	CBL	867	FYN	2534	literature
13	APP1	333	G45IP1	84060	this study	75	CBL	867	PTK2B	2185	literature
14	AR	367	EP300	2033	literature	76	CBL	867	EGFR	1956	literature
15	AR	367	ESR1	2099	literature	77	CDC2	983	PCNA	5111	literature
16	AR	367	RELA	5970	literature	78	CDC2	983	FYN	2534	literature
17	AR	367	BRCA1	672	literature	79	CGI-74	51631	HIP5	57562	this study
18	AR	367	HDAC1	3065	literature	80	CHUK	1147	IKBKB	3551	literature
19	AR	367	NCOA1	8648	literature	81	CLH-17	1213	HGS	9146	literature
20	AR	367	JUN	3725	literature	82	CLH-17	1213	Ku70	2547	this study
21	AR	367	NCOA3	8202	literature	83	CLK1	1195	PIASy	51588	this study
22	AR	367	STAT3	6774	literature	84	CREB1	1385	BRCA1	672	literature
23	AR	367	NR3C1	2908	literature	85	CREB1	1385	NR3C1	2908	literature
24	BAIP1	84289	G45IP3	---	this study	86	CREBBP	1387	MSX1	4487	literature
25	BAIP3	55791	BAIP2	84078	this study	87	CREBBP	1387	RELA	5970	literature
26	BAIP3	55791	HIP15	114928	this study	88	CREBBP	1387	RBBP4	5928	literature
27	BAIP3	55791	BAIP3	55791	this study	89	CREBBP	1387	PTMA	5757	literature
28	BAIP3	55791	HIP5	57562	this study	90	CREBBP	1387	PPARG	5468	literature
29	BARD1	580	PLIP	10524	this study	91	CREBBP	1387	PML	5371	literature
30	BARD1	580	ZHX1	11244	this study	92	CREBBP	1387	MYOD1	4654	literature
31	BARD1	580	POU2F1	5451	literature	93	CREBBP	1387	JUN	3725	literature
32	BARD1	580	BRCA1	672	literature	94	CREBBP	1387	HNF4A	3172	literature
33	BARD1	580	CA150	10915	this study	95	CREBBP	1387	NR3C1	2908	literature
34	BARD1	580	GIT1	28964	this study	96	CREBBP	1387	EV1	2122	literature
35	BARD1	580	IKAP	8518	this study	97	CREBBP	1387	KLF5	688	literature
36	BARD1	580	HBO1	11143	this study	98	CREBBP	1387	SRC	6714	literature
37	BARD1	580	CDC2	983	literature	99	CREBBP	1387	BCL3	602	literature
38	BARD1	580	NAG4	29117	this study	100	CREBBP	1387	TP53	7157	literature
39	BARD1	580	BAIP2	84078	this study	101	CREBBP	1387	BRCA1	672	literature
40	BARD1	580	PIASy	51588	this study	102	CREBBP	1387	WT1	7490	literature
41	BARD1	580	BAIP3	55791	this study	103	CREBBP	1387	NCOA3	8202	literature
42	BARD1	580	HIP5	57562	this study	104	CREBBP	1387	NCOA1	8648	literature
43	BARD1	580	SETBD1	9869	this study	105	CREBBP	1387	KHDRBS1	10657	literature
44	BARD1	580	BCL3	602	literature	106	CREBBP	1387	HIPK2	28996	literature
45	BARD1	580	HAP1	9001	this study	107	CREBBP	1387	SREBF2	6721	literature
46	BARD1	580	PTN	5764	this study	108	CREBBP	1387	AR	367	literature
47	BARD1	580	HZFH	1107	this study	109	CTBP1	1487	HDAC2	3066	literature
48	BARD1	580	HIP15	114928	this study	110	CTBP1	1487	ZNFN1A1	10320	literature
49	BARD1	580	BAIP1	84289	this study	111	CTBP1	1487	HDAC1	3065	literature
50	BARD1	580	FEZ1	9638	this study	112	CTBP1	1487	EV1	2122	literature
51	BCL3	602	FYN	2534	literature	113	CTBP1	1487	BRCA1	672	literature
52	BCL3	602	RXRA	6256	literature	114	DLG4	1742	HGS	9146	literature
53	BCL3	602	JUN	3725	literature	115	DLG4	1742	FYN	2534	literature
54	BCL3	602	SHC1	6464	literature	116	DLG4	1742	PRKCA	5578	literature
55	BRCA1	672	HDAC2	3066	literature	117	DLG4	1742	DNCL1	8655	literature
56	BRCA1	672	EP300	2033	literature	118	DLG4	1742	ERBB2	2064	literature
57	BRCA1	672	ESR1	2099	literature	119	DRP-1	1400	Huntingtin	3064	this study
58	BRCA1	672	CDC2	983	literature	120	DRP-1	1400	VIM	7431	this study
59	BRCA1	672	HDAC1	3065	literature	121	EF1A	1915	GADD45G	10912	this study
60	BRCA1	672	STAT3	6774	literature	122	EF1A	1915	PLCG1	5335	literature
61	BRCA1	672	JUN	3725	literature	123	EF1G	1937	EF1G	1937	this study
62	BRCA1	672	MYC	4609	literature	124	EF1G	1937	GADD45G	10912	this study

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference	Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
125	EGFR	1956	SRC	6714	literature	190	GIT1	28964	BAIP3	55791	this study
126	EGFR	1956	PTK2	5747	literature	191	GIT1	28964	G45IP3	---	this study
127	EGFR	1956	PLCG1	5335	literature	192	GIT1	28964	HIP5	57562	this study
128	EGFR	1956	PIK3R1	5295	literature	193	GIT1	28964	PXN	5829	literature
129	EGFR	1956	ERBB2	2064	literature	194	GIT1	28964	PTK2	5747	literature
130	EGFR	1956	PDGFRB	5159	literature	195	GRAP	10750	EPOR	2057	literature
131	EGFR	1956	PTK2B	2185	literature	196	GRAP	10750	TNFSF6	356	literature
132	EGFR	1956	ESR1	2099	literature	197	GRAP	10750	KIT	3815	literature
133	EGFR	1956	SHC1	6464	literature	198	GRAP	10750	SOS1	6654	literature
134	EGFR	1956	SOS1	6654	literature	199	GRAP	10750	LAT	27040	literature
135	EP300	2033	ING1	3621	literature	200	GRB2	2885	TP73L	8626	literature
136	EP300	2033	NCOA1	8648	literature	201	GRB2	2885	PLCG1	5335	literature
137	EP300	2033	HNF4A	3172	literature	202	GRB2	2885	PTK2	5747	literature
138	EP300	2033	MDM2	4193	literature	203	GRB2	2885	SHC1	6464	literature
139	EP300	2033	PCNA	5111	literature	204	GRB2	2885	SOS1	6654	literature
140	EP300	2033	PTMA	5757	literature	205	GRB2	2885	LAT	27040	literature
141	EP300	2033	RELA	5970	literature	206	GRB2	2885	SRC	6714	literature
142	EP300	2033	STAT3	6774	literature	207	GRB2	2885	WAS	7454	literature
143	EP300	2033	ESR1	2099	literature	208	GRB2	2885	WASL	8976	literature
144	EPOR	2057	KIT	3815	literature	209	GRB2	2885	KHDRBS1	10657	literature
145	EPOR	2057	SHC1	6464	literature	210	GRB2	2885	SH3KBP1	30011	literature
146	EPOR	2057	VAV1	7409	literature	211	GRB2	2885	PIK3R1	5295	literature
147	EPOR	2057	PIK3R1	5295	literature	212	GRB2	2885	RASA1	5921	literature
148	ERBB2	2064	PTK2	5747	literature	213	GRB2	2885	VAV1	7409	literature
149	ERBB2	2064	SHC1	6464	literature	214	GRB2	2885	EGFR	1956	literature
150	ERBB2	2064	PTK2B	2185	literature	215	GRB2	2885	ABL1	25	literature
151	ERBB2	2064	SOS1	6654	literature	216	GRB2	2885	TNFSF6	356	literature
152	ESR1	2099	JUN	3725	literature	217	GRB2	2885	PDGFRB	5159	literature
153	ESR1	2099	MDM2	4193	literature	218	GRB2	2885	DNM1	1759	literature
154	ESR1	2099	PIK3R1	5295	literature	219	GRB2	2885	EPOR	2057	literature
155	ESR1	2099	SHC1	6464	literature	220	GRB2	2885	ERBB2	2064	literature
156	ESR1	2099	NCOA3	8202	literature	221	GRB2	2885	PTK2B	2185	literature
157	ESR1	2099	NCOA1	8648	literature	222	GRB2	2885	HRAS	3265	literature
158	EV1	2122	HDAC1	3065	literature	223	GRB2	2885	KIT	3815	literature
159	FEZ1	9638	HMP	10989	this study	224	GRB2	2885	CBL	867	literature
160	FEZ1	9638	BAIP3	55791	this study	225	GRB2	2885	FGFR1	2260	literature
161	FEZ1	9638	HIP5	57562	this study	226	hADA3	10474	EP300	2033	literature
162	FEZ1	9638	G45IP3	---	this study	227	hADA3	10474	TP53	7157	literature
163	FGFR1	2260	SHC1	6464	literature	228	hADA3	10474	BAIP1	84289	this study
164	FYN	2534	VAV1	7409	literature	229	hADA3	10474	PIASy	51588	this study
165	FYN	2534	SHC1	6464	literature	230	hADA3	10474	MAGEH1	28986	this study
166	FYN	2534	KHDRBS1	10657	literature	231	hADA3	10474	ESR1	2099	literature
167	FYN	2534	WAS	7454	literature	232	HAP1	9001	BAIP3	55791	this study
168	FYN	2534	PDGFRB	5159	literature	233	HAP1	9001	HGS	9146	literature
169	FYN	2534	PIK3R1	5295	literature	234	HAP1	9001	HIP5	57562	this study
170	FYN	2534	PLCG1	5335	literature	235	HBO1	11143	MCM2	4171	literature
171	FYN	2534	PXN	5829	literature	236	HBO1	11143	HIP5	57562	this study
172	FYN	2534	PTK2	5747	literature	237	HBO1	11143	BAIP3	55791	this study
173	G45IP2	9842	GADD45G	10912	this study	238	HBO1	11143	AR	367	literature
174	GADD45G	10912	G45IP1	84060	this study	239	HDAC1	3065	PML	5371	literature
175	GADD45G	10912	HIP5	57562	this study	240	HDAC1	3065	RELA	5970	literature
176	GADD45G	10912	LUC7B1	55692	this study	241	HDAC1	3065	PTMA	5757	literature
177	GADD45G	10912	RXRA	6256	literature	242	HDAC1	3065	PHB	5245	literature
178	GADD45G	10912	BAIP3	55791	this study	243	HDAC1	3065	MYOD1	4654	literature
179	GADD45G	10912	PIASy	51588	this study	244	HDAC1	3065	PCNA	5111	literature
180	GADD45G	10912	G45IP3	---	this study	245	HDAC1	3065	RBBP4	5928	literature
181	GADD45G	10912	PPARG	5468	literature	246	HDAC1	3065	ING1	3621	literature
182	GADD45G	10912	PCNA	5111	literature	247	HDAC1	3065	HDAC2	3066	literature
183	GADD45G	10912	ESR1	2099	literature	248	HDAC2	3066	PTMA	5757	literature
184	GADD45G	10912	CDC2	983	literature	249	HDAC2	3066	RBBP4	5928	literature
185	GADD45G	10912	CGI-125	51003	this study	250	HIP11	1891	EF1G	1937	this study
186	GADD45G	10912	CGI-74	51631	this study	251	HIP11	1891	Huntingtin	3064	this study
187	GAPD	2597	DNCL1	8655	literature	252	HIP16	10813	GADD45G	10912	this study
188	GAPD	2597	PLIP	10524	this study	253	HIP2	3093	PIASy	51588	this study
189	GDF9	2661	GADD45G	10912	this study	254	HIP2	3093	TP53	7157	literature

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
255	HIP5	57562	BAIP2	84078	this study
256	HIP5	57562	BAIP1	84289	this study
257	HIP5	57562	HIP15	114928	this study
258	HMP	10989	PIASy	51588	this study
259	HMP	10989	HIP5	57562	this study
260	HMP	10989	HMP	10989	this study
261	HMP	10989	BAIP3	55791	this study
262	HNF4A	3172	NCOA3	8202	literature
263	HNF4A	3172	SRC	6714	literature
264	HNF4A	3172	SREBF2	6721	literature
265	HRAS	3265	SOS1	6654	literature
266	HRAS	3265	VAV1	7409	literature
267	HRAS	3265	PIK3R1	5295	literature
268	HRAS	3265	MAPK8	5599	literature
269	Huntingtin	3064	TUBG1	7283	literature
270	Huntingtin	3064	RASA1	5921	literature
271	Huntingtin	3064	HYP	55660	this study
272	Huntingtin	3064	GRB2	2885	literature
273	Huntingtin	3064	HIP1	3092	this study
274	Huntingtin	3064	HIP2	3093	literature
275	Huntingtin	3064	ITPR1	3708	literature
276	Huntingtin	3064	REST	5978	literature
277	Huntingtin	3064	MAGEA3	4102	literature
278	Huntingtin	3064	SH3GL3	6457	this study
279	Huntingtin	3064	HAP1	9001	literature
280	Huntingtin	3064	SYMPK	8189	literature
281	Huntingtin	3064	TBP	6908	literature
282	Huntingtin	3064	SP1	6667	literature
283	Huntingtin	3064	NFKB1	4790	literature
284	Huntingtin	3064	PDE1A	5136	literature
285	Huntingtin	3064	TAF4	6874	literature
286	Huntingtin	3064	GAPD	2597	literature
287	Huntingtin	3064	TPH1	7166	literature
288	Huntingtin	3064	TP53	7157	literature
289	Huntingtin	3064	TGM2	7052	literature
290	Huntingtin	3064	MAP3K10	4294	literature
291	Huntingtin	3064	SAP30	8819	literature
292	Huntingtin	3064	CREB1	1385	literature
293	Huntingtin	3064	HIP15	114928	this study
294	Huntingtin	3064	PIASy	51588	this study
295	Huntingtin	3064	CGI-125	51003	this study
296	Huntingtin	3064	GIT1	28964	this study
297	Huntingtin	3064	HIP16	10813	this study
298	Huntingtin	3064	HIP13	9788	this study
299	Huntingtin	3064	FEZ1	9638	this study
300	Huntingtin	3064	IKAP	8518	this study
301	Huntingtin	3064	HP28	7802	this study
302	Huntingtin	3064	PFN2	5217	this study
303	Huntingtin	3064	HYPK	25764	literature
304	Huntingtin	3064	DLG4	1742	literature
305	Huntingtin	3064	HYPE	11153	literature
306	Huntingtin	3064	CREBBP	1387	literature
307	Huntingtin	3064	CA150	10915	this study
308	Huntingtin	3064	NCOR1	9611	literature
309	Huntingtin	3064	PACSLN1	29993	literature
310	Huntingtin	3064	HYPB	29072	literature
311	Huntingtin	3064	PQBP1	10084	literature
312	Huntingtin	3064	CTBP1	1487	literature
313	Huntingtin	3064	GRAP	10750	literature
314	Huntingtin	3064	TRIP10	9322	literature
315	Huntingtin	3064	HYPK	25766	literature
316	Huntingtin	3064	HIP14	23390	literature
317	Huntingtin	3064	HYPM	25763	literature
318	Huntingtin	3064	AP2A2	161	literature
319	Huntingtin	3064	CBS	875	literature

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
320	Huntingtin	3064	OPTN	10133	literature
321	HYP	55660	MAP1lc3	84557	this study
322	HZFH	1107	SUMO-3	6613	this study
323	HZFH	1107	VIM	7431	this study
324	HZFH	1107	HZFH	1107	this study
325	HZFH	1107	Huntingtin	3064	this study
326	HZFH	1107	BAIP3	55791	this study
327	HZFH	1107	HYP	55660	this study
328	HZFH	1107	PIASy	51588	this study
329	HZFH	1107	GIT1	28964	this study
330	HZFH	1107	ZHX1	11244	this study
331	HZFH	1107	NEFL	4747	this study
332	HZFH	1107	CA150	10915	this study
333	HZFH	1107	TP53	7157	this study
334	HZFH	1107	PTN	5764	this study
335	HZFH	1107	KPNB1	3837	this study
336	HZFH	1107	TAL1	6888	this study
337	HZFH	1107	HMP	10989	this study
338	IKAP	8518	CHUK	1147	literature
339	IKAP	8518	IKBKB	3551	literature
340	IKAP	8518	MAPK8	5599	literature
341	IMPD2	3615	PIASy	51588	this study
342	ING1	3621	PCNA	5111	literature
343	ING1	3621	RBBP4	5928	literature
344	JUN	3725	STAT3	6774	literature
345	JUN	3725	RELA	5970	literature
346	JUN	3725	MYOD1	4654	literature
347	JUN	3725	NCOA1	8648	literature
348	JUN	3725	MAPK8	5599	literature
349	KIT	3815	PIK3R1	5295	literature
350	KIT	3815	PLCG1	5335	literature
351	KPNA2	3838	G45IP3	—	this study
352	KPNA2	3838	MAGEH1	28986	this study
353	KPNA2	3838	DD5	51366	literature
354	KPNA2	3838	RELA	5970	literature
355	KPNA2	3838	PTMA	5757	literature
356	KPNA2	3838	TP53	7157	literature
357	KPNA2	3838	HIP5	57562	this study
358	KPNB1	3837	TP53	7157	literature
359	KPNB1	3837	PIASy	51588	this study
360	KPNB1	3837	PTN	5764	this study
361	KPNB1	3837	DD5	51366	literature
362	KPNB1	3837	PTMA	5757	literature
363	KPNB1	3837	FGFR1	2260	literature
364	Ku70	2547	HADA3	10474	this study
365	Ku70	2547	TCPG	7203	this study
366	Ku70	2547	Huntingtin	3064	this study
367	Ku70	2547	EGFR	1956	literature
368	Ku70	2547	PCNA	5111	literature
369	Ku70	2547	MAPK8	5599	literature
370	Ku70	2547	VAV1	7409	literature
371	Ku70	2547	PTTG1	9232	literature
372	Ku70	2547	WRN	7486	literature
373	Ku70	2547	ABL1	25	literature
374	MAGEH1	28986	PIASy	51588	this study
375	MAP3K10	4294	PHB	5245	literature
376	MAP3K10	4294	RACGAP1	29127	literature
377	MDM2	4193	PML	5371	literature
378	MEN1	4221	RELA	5970	literature
379	MYC	4609	MAPK8	5599	literature
380	MYC	4609	RELA	5970	literature
381	MYOD1	4654	RXRA	6256	literature
382	MYOD1	4654	STAT3	6774	literature
383	NAG4	29117	HIP5	57562	this study
384	NAG4	29117	BAIP3	55791	this study

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference	Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
385	NCOR1	9611	PML	5371	literature	450	PTK2B	2185	PIK3R1	5295	literature
386	NCOR1	9611	ESR1	2099	literature	451	PTK2B	2185	PXN	5829	literature
387	NCOR1	9611	PHB	5245	literature	452	PTK2B	2185	FYN	2534	literature
388	NCOR1	9611	PTMA	5757	literature	453	PTK2B	2185	SRC	6714	literature
389	NCOR1	9611	NCOA3	8202	literature	454	PTK2B	2185	VAV1	7409	literature
390	NCOR1	9611	AR	367	literature	455	PTN	5764	GADD45G	10912	this study
391	NCOR1	9611	NR3C1	2908	literature	456	PTN	5764	FEZ1	9638	this study
392	NEFL	4747	TSC1	7248	literature	457	PTN	5764	PTN	5764	this study
393	NEFL	4747	PRKCL1	5585	literature	458	PTN	5764	ALK	238	literature
394	NEFL	4747	PIASy	51588	this study	459	PTN	5764	PIASy	51588	this study
395	NEFL	4747	VIM	7431	this study	460	PTN	5764	HIP15	114928	this study
396	NEFL	4747	NAG4	29117	this study	461	PTPK	5796	GADD45G	10912	this study
397	NFKB1	4790	CHUK	1147	literature	462	PXN	5829	SRC	6714	literature
398	NFKB1	4790	AR	367	literature	463	RASA1	5921	PTK2B	2185	literature
399	NFKB1	4790	KLF5	688	literature	464	RASA1	5921	PIK3R1	5295	literature
400	NFKB1	4790	NR3C1	2908	literature	465	RASA1	5921	PDGFRB	5159	literature
401	NFKB1	4790	MEN1	4221	literature	466	RASA1	5921	HRAS	3265	literature
402	NFKB1	4790	IKBKB	3551	literature	467	RASA1	5921	FYN	2534	literature
403	NFKB1	4790	BRCA1	672	literature	468	RASA1	5921	PXN	5829	literature
404	NFKB1	4790	STAT3	6774	literature	469	RASA1	5921	ALK	238	literature
405	NR3C1	2908	NCOA1	8648	literature	470	RASA1	5921	SRC	6714	literature
406	NR3C1	2908	RELA	5970	literature	471	RASA1	5921	KHDRBS1	10657	literature
407	NR3C1	2908	MDM2	4193	literature	472	RELA	5970	STAT3	6774	literature
408	NR3C1	2908	STAT3	6774	literature	473	RXRA	6256	NCOA3	8202	literature
409	NR3C1	2908	JUN	3725	literature	474	SAP30	8819	ING1	3621	literature
410	PACSLN1	29993	WASL	8976	literature	475	SAP30	8819	HCFC1	3054	literature
411	PACSLN1	29993	DNM1	1759	literature	476	SAP30	8819	HDAC1	3065	literature
412	PCNA	5111	PTMA	5757	literature	477	SAP30	8819	HDAC2	3066	literature
413	PCNA	5111	WRN	7486	literature	478	SAP30	8819	RBBP4	5928	literature
414	PDGFRB	5159	PLCG1	5335	literature	479	SAP30	8819	NCOR1	9611	literature
415	PDGFRB	5159	SHC1	6464	literature	480	SETBD1	9869	CA150	10915	this study
416	PDGFRB	5159	PIK3R1	5295	literature	481	SETBD1	9869	BAIP3	55791	this study
417	PDGFRB	5159	PTK2	5747	literature	482	SH3GL3	6457	VIM	7431	this study
418	PIASy	51588	MAP1lc3	84557	this study	483	SH3GL3	6457	G45IP3	---	this study
419	PIASy	51588	BAIP3	55791	this study	484	SH3GL3	6457	CBL	867	literature
420	PIASy	51588	HYP4	55660	this study	485	SH3GL3	6457	SH3KBP1	30011	literature
421	PIK3R1	5295	SHC1	6464	literature	486	SOS1	6654	LAT	27040	literature
422	PIK3R1	5295	SRC	6714	literature	487	SOS1	6654	SH3KBP1	30011	literature
423	PIK3R1	5295	VAV1	7409	literature	488	SP1	6667	HNF4A	3172	literature
424	PIK3R1	5295	WAS	7454	literature	489	SP1	6667	HCFC1	3054	literature
425	PIK3R1	5295	HGS	9146	literature	490	SP1	6667	BRCA1	672	literature
426	PIK3R1	5295	KHDRBS1	10657	literature	491	SP1	6667	HDAC1	3065	literature
427	PIK3R1	5295	LAT	27040	literature	492	SP1	6667	HDAC2	3066	literature
428	PIK3R1	5295	PTK2	5747	literature	493	SP1	6667	JUN	3725	literature
429	PLCG1	5335	LAT	27040	literature	494	SP1	6667	MSX1	4487	literature
430	PLCG1	5335	WAS	7454	literature	495	SP1	6667	MYC	4609	literature
431	PLCG1	5335	SOS1	6654	literature	496	SP1	6667	MYOD1	4654	literature
432	PLCG1	5335	SRC	6714	literature	497	SP1	6667	PML	5371	literature
433	PLCG1	5335	VAV1	7409	literature	498	SP1	6667	POU2F1	5451	literature
434	PLCG1	5335	KHDRBS1	10657	literature	499	SP1	6667	RBBP4	5928	literature
435	PLIP	10524	BCL3	602	literature	500	SP1	6667	RXRA	6256	literature
436	PLIP	10524	AR	367	literature	501	SP1	6667	SHC1	6464	literature
437	PLIP	10524	STAT3	6774	literature	502	SP1	6667	SREBF2	6721	literature
438	PLIP	10524	GADD45G	10912	this study	503	SP1	6667	KLF4	9314	literature
439	PLIP	10524	BAIP3	55791	this study	504	SP1	6667	TP53	7157	literature
440	PLIP	10524	HIP5	57562	this study	505	SRC	6714	KHDRBS1	10657	literature
441	PML	5371	RELA	5970	literature	506	SRC	6714	WAS	7454	literature
442	PPARG	5468	RXRA	6256	literature	507	SRC	6714	STAT3	6774	literature
443	PPARG	5468	NCOA1	8648	literature	508	STAT3	6774	NCOA1	8648	literature
444	PQBP1	10084	AR	367	literature	509	STAT3	6774	KHDRBS1	10657	literature
445	PRKCA	5578	YWHAZ	7534	literature	510	SUMO-2	6612	PIASy	51588	this study
446	PTK2	5747	PXN	5829	literature	511	SUMO-3	6613	PIASy	51588	this study
447	PTK2	5747	SHC1	6464	literature	512	SUMO-3	6613	PML	5371	literature
448	PTK2	5747	SRC	6714	literature	513	SUMO-3	6613	SETBD1	9869	this study
449	PTK2B	2185	SHC1	6464	literature	514	TAF1B	9014	TAF1A	9015	literature

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
515	TAF1C	9013	TAF1B	9014	literature
516	TAF1C	9013	TAF1A	9015	literature
517	TAL1	6888	ZHX1	11244	this study
518	TBP	6908	TAF1B	9014	literature
519	TBP	6908	MSX1	4487	literature
520	TBP	6908	HMGB1	3146	literature
521	TBP	6908	NR3C1	2908	literature
522	TBP	6908	MCM2	4171	literature
523	TBP	6908	MDM2	4193	literature
524	TBP	6908	MYC	4609	literature
525	TBP	6908	RXRA	6256	literature
526	TBP	6908	NCOA3	8202	literature
527	TBP	6908	BCL3	602	literature
528	TBP	6908	TAF1C	9013	literature
529	TBP	6908	TP53	7157	literature
530	TBP	6908	TAF1A	9015	literature
531	TBP	6908	ZNFN1A1	10320	literature
532	TBP	6908	JUN	3725	literature
533	TBP	6908	NCOA1	8648	literature
534	TNFSF6	356	FYN	2534	literature
535	TNFSF6	356	SRC	6714	literature
536	TP53	7157	HMGB1	3146	literature
537	TP53	7157	YWHAZ	7534	literature
538	TP53	7157	NR3C1	2908	literature
539	TP53	7157	HNF4A	3172	literature
540	TP53	7157	ING1	3621	literature
541	TP53	7157	PIASy	51588	this study
542	TP53	7157	PML	5371	literature
543	TP53	7157	EP300	2033	literature
544	TP53	7157	MAPK8	5599	literature
545	TP53	7157	CHUK	1147	literature
546	TP53	7157	WT1	7490	literature
547	TP53	7157	MDM2	4193	literature
548	TP53	7157	TP73L	8626	literature
549	TP53	7157	TAF1C	9013	literature
550	TP53	7157	TAF1B	9014	literature
551	TP53	7157	TAF1A	9015	literature
552	TP53	7157	PTTG1	9232	literature
553	TP53	7157	KLF4	9314	literature
554	TP53	7157	HIPK2	28996	literature
555	TP53	7157	WRN	7486	literature
556	TP53	7157	BRCA1	672	literature
557	TP53	7157	ABL1	25	literature
558	TP53	7157	TP53	7157	this study
559	TP53	7157	ZHX1	11244	this study
560	TP53	7157	PRKCA	5578	literature
561	TP53	7157	CDC2	983	literature
562	TP73L	8626	HIPK2	28996	literature
563	TRIP10	9322	RXRA	6256	literature
564	TRIP10	9322	WAS	7454	literature
565	TSC1	7248	YWHAZ	7534	literature
566	TUBG1	7283	PIK3R1	5295	literature
567	TUBG1	7283	BRCA1	672	literature
568	TUBG1	7283	PXN	5829	literature
569	TUBG1	7283	RACGAP1	29127	literature
570	VAV1	7409	LAT	27040	literature
571	VIM	7431	MEN1	4221	literature
572	VIM	7431	PRKCL1	5585	literature
573	VIM	7431	TSC1	7248	literature
574	VIM	7431	DNCL1	8655	literature
575	VIM	7431	HIP16	10813	this study
576	VIM	7431	YWHAZ	7534	literature
577	VIM	7431	VIM	7431	this study
578	VIM	7431	SETBD1	9869	this study
579	VIM	7431	MOV34	10980	this study

Number	ID 1	LOCUSID 1	ID 2	LOCUSID 2	Reference
580	VIM	7431	HBO1	11143	this study
581	VIM	7431	ZHX1	11244	this study
582	VIM	7431	HSPC232	51535	this study
583	VIM	7431	PIASy	51588	this study
584	VIM	7431	HIP5	57562	this study
585	VIM	7431	G45IP1	84060	this study
586	VIM	7431	BAIP1	84289	this study
587	VIM	7431	ALEX2	9823	this study
588	ZHX1	11244	HYP4	55660	this study
589	ZHX1	11244	PIASy	51588	this study
590	ZNF33B	7558	HAP1	9001	this study
591	ZNF33B	7558	ZHX1	11244	this study

Abbreviations: ID, interacting protein gene symbol; LOCUS ID, NCBI LocusLink Identity. The presented list of protein-protein interactions is computed from databases: MINT, HPRD, BIND; Li & Li, *Trends Genet.* (2004), **20**, 146-152 and Harjes & Wanker, *Trends. Biochem. Sci.* (2003), **28**, 425-433.

The figures show:

Figure 1 Identification of two-hybrid interactions connected to HD. a, Schematic representation of the screening strategy. b, Identification of interactions by systematic interaction mating. Upper panel: Selection of diploid yeast clones by transfer on minimal medium lacking leucine and tryptophan (SDII). Lower panel: Two-hybrid selection of interactions on minimal medium lacking leucine, tryptophan, histidine and uracil (SDIV) after 5 days of growth at 30°C. The prey proteins HP28 (A5), SH3GL3 (A7), CA150 (B9), HIP15 (B10), PFN2 (B11), HIP13 (C1), CGI125 (C12) and HYPA (D1) were identified as HDexQ51 interactors.

Figure 2 Protein interaction network for Huntington's disease. a, Matrix of 117 two-hybrid interactions between 21 bait and 49 prey proteins. b, Yeast two-hybrid interactions depicted as network using the software Pivot 1.0. In total, 96 interactions and 61 distinct proteins are depicted. In addition, dimers of EF1G, VIM and p53 are shown.

Figure 3 Systematic validation of two-hybrid interactions by *in vitro* binding experiments. GST-fusion proteins (baits) immobilised on glutathione agarose beads were incubated with COS1 cell extracts containing HA-tagged prey proteins. After extensive washing of the beads, bound proteins were eluted and analysed by SDS-PAGE and immunoblotting using anti-HA antibody.

Figure 4 Identification of network proteins stimulating htt aggregation. a, Filter retardation assay. Protein extracts were prepared from HEK293 cells coexpressing HD169Q68 and network proteins as indicated. The aggregated proteins retained on the filter were detected with anti-htt antibody (CAG53b) and anti-GIT1 antibody. b, Coimmunoprecipitation of HD510Q68 and GIT1 from COS1 cell extracts. Extracts were incubated with anti-GIT1 or preimmune serum. Immunoprecipitated material was analysed by immunoblotting using htt- antibody 4C8 and anti-HA antibody. c, Coimmunoprecipitation of htt and GIT1 from human brain extracts. Protein complexes containing GIT1 were pulled-down with increasing amounts of anti-htt antibodies, but not with corresponding preimmune sera. d, Analysis of subcellular localisation of HD510Q68 and GIT1 by immunofluorescence microscopy. COS1 cells were transfected with the indicated constructs and immunolabelled with 4C8 anti-htt

antibody coupled to Cy3-conjugated antibody (red) and with anti-HA antibody coupled to FITC-conjugated antibody (green). Nuclei were counterstained with Hoechst (blue). Colocalisation of HD510Q68 and GIT1 is illustrated by yellow colour of the insoluble aggregates. Scale bars, 10 μ m.

- 5 **Figure 5** Detection of GIT1 in brains of R6/1 transgenic mice and HD patients. a, Sections of striatum and cortex of R6/1 mice brains labelled with anti-GIT1 and anti-htt (EM48) antisera. Arrows point to nuclear inclusions. b, Inclusions in cortex of HD patients are labelled with anti-htt (2B4) and anti-GIT1 antibodies. Arrows indicate neuronal inclusions, recognized by anti-htt (2B4) and anti-GIT1 antibodies. Scale bars, 20 μ m. c, Colocalisation of GIT1 and htt in the cortex of HD patients detected by immunofluorescence microscopy.

Figure 6 Amino acid sequence of the interacting proteins of the PPI of huntingtin.

- Figure 7** Identification of Y2H interactions connected to HD. A, The screening strategy. B, Identification of interactions by systematic interaction mating. Upper panel: Selection of diploid yeast clones on SDII minimal medium. Lower panel: Two-hybrid selection of interactions on SDIV minimal medium. The prey proteins HP28 (A5), SH3GL3 (A7), CA150 (B9), HIP15 (B10), PFN2 (B11), HIP13 (C1), CGI125 (C12), and HYPA (D1) were identified as HDexQ51 interactors.

- 20 **Figure 8** A protein interaction network for Huntington's disease. A, Matrix of 186 Y2H interactions between 35 bait and 51 prey proteins. Interactions reported previously (30), or verified in pull down assays (35) are indicated. B, A comprehensive PPI network for htt. Y2H interactors identified in this study (red diamonds), previously published interactors (blue squares), interactors identified from databases HRPD, MINT and BIND, bridging any two proteins in the extended network (green triangles, Suppl. Table 5). Htt interactors previously reported and found in our screens (CA150, HYPA, HIP1, and SH3GL3), depicted as red squares.

- 25 **Figure 9** Validation of Y2H interactions by *in vitro* binding experiments. GST-fusion proteins immobilized on glutathione agarose beads were incubated with COS-1 cell extracts containing HA-tagged proteins. After extensive washing, pulled proteins
30 were eluted and analyzed by SDS-PAGE and immunoblotting using anti-htt 4C8 or anti-HA antibodies.

Figure 10 GIT1 enhances and is critical for htt aggregation. A, Filter retardation assay for the identification of GIT1 as a promoter of htt aggregation. 48 h post transfection, protein extracts were prepared from HEK293 cells coexpressing HD169Q68 and GIT1-CT (aa 249-770). Aggregated proteins retained on the filter were detected with anti-htt (CAG53b) or anti-C-GIT1 antibody. B, Effect of full-length GIT1 on HD169Q68 aggregation analyzed by the filter retardation assay. C, Analysis of HD169Q68 aggregation in cells overexpressing GIT1-CT by indirect immunofluorescence microscopy. a, HD169Q68 (red). b, GIT1-CT (green). c, Colocalization of GIT1 with the endosomal marker EEA1 is indicated in yellow. d-f, Colocalization of HD169Q68 (red) and GIT1-CT (green) in COS-1 cells. D, Silencing of endogenous GIT1 expression. HEK293 cells transfected with the siRNA-GIT1 were analyzed after 48 h by immunoblotting using anti-C-GIT1 and anti-GAPDH antibodies. E, Silencing of endogenous GIT1 prevents the accumulation of insoluble htt aggregates. siRNA-GIT1 treated and untreated cells expressing HD169Q68 were analyzed 72 h post transfection by filtration.

Figure 11 Verification of the htt-GIT1 interaction. A, Coimmunoprecipitation of HD510Q68 and HA-GIT1-CT from COS-1 cell extracts using anti-C-GIT1 antibody. Immunoprecipitated material was analyzed by immunoblotting, using the anti-HA 12CA5 antibody detecting recombinant GIT1 (upper blot) and the htt-4C8 antibody (lower blot). B, Coimmunoprecipitation of htt and GIT1 from human brain extracts. C, Subcellular localization of GIT1 and htt in differentiated PC12 cells (a-c) and SH-SY5Y cells (d-f) by confocal immunofluorescence microscopy. Colocalization of htt and GIT1 shown in yellow (panel c and f). Arrow points to cytoplasmic structures recognized by both antibodies. In addition, specific GIT1 labeling was detected at the tip of neurite-like extensions in adhesion foci (arrowheads). Scale bars, 10 μ m.

Figure 12 Detection of GIT1 in brains of transgenic mice and HD patients. A, Sections of striatum and cortex of R6/1 mice brain labeled with anti-C-GIT1 and anti-htt EM48 antibodies. Arrows point to nuclear inclusions. B, Neuronal inclusions (arrows) in cortex of HD patients recognized by anti-htt 2B4 and anti-C-GIT1 antibodies. Scale bars, 20 μ m. C, Colocalization of GIT1 and htt in the cortex of HD

patients, detected by immunofluorescence microscopy. D, Detection of N-terminally truncated GIT1 degradation products in HD patient brain cortex.

Figure 13 Specificity of GIT1 antibodies. A, Scheme indicating the regions of GIT1, which were used for the production of antibodies. NT-GIT1 antibody recognizes the N-terminal part (aa 1-100), C-GIT1 the central part (aa 368-587) and CT-GIT1 the C-terminal part (aa 664-770) of GIT1. B, Analysis of the specificity of the GIT1 antibodies. All three antibodies specifically recognize GIT1, but not the homologous protein GIT2 (Premont et al., 2000). After expression of full length HAGIT1 and HA-GIT2 15 µg of total COS-1 cell extract was subjected to SDS-PAGE. Immunoblotting was performed with anti-NT-GIT1 (1:500), anti-C-GIT1 (1:500) and anti-CT-GIT1 (1:500) antibodies. Expression of HA-GIT1 and HA-GIT2 was detected with an anti-HA antibody (1:1000).

The examples illustrate the invention:

PART I: ESTABLISHING THE PROTEIN-INTERACTION NETWORK OF HUNTINGTIN

Examples 1: Particular methods and material used in the Examples

• Antibodies, strains and plasmids

A polyclonal antibody (pAb) against GIT1 was generated by injection of affinity purified His₆-tagged GIT1 (residues 368-587) into a rabbit. The htt-specific pAb CAG53b and HD1 were described^{13,14}. Commercially available antibodies were anti-GST pAb (Amersham Pharmacia), anti-GIT1 pAb (Santa Cruz Biotechnology), anti-HA monoclonal antibody 12CA5 (mAb) (Roche Diagnostics), anti-htt pAb EM48⁴⁷, anti-htt mAb 2B4⁴⁸ and anti-htt mAb 4C8 (Chemicon). As secondary antibodies for immunofluorescence microscopy Cy3- and FITC-conjugated IgGs (Jackson ImmunoResearch) were used. The yeast strains used as two-hybrid reporters were L40ccua [MATa his3Δ200 trp1-901 leu2-3,112 LYS2::(*lexAop*)₄-HIS3 ura3::(*lexAop*)₈-lacZ ADE2::(*lexAop*)₈-URA3 GAL4 gal80 can1 cyh2] and L40ccα [MATα his3Δ200 trp1-910 leu2-3,112 ade2 LYS2::(*lexAop*)₄-HIS3 URA3::(*lexAop*)₈-lacZ GAL4 gal80 can1 cyh2]. Both strains are derivatives of L40c¹⁷. Plasmids pHD510Q17 and pHD510Q68 were generated by insertion of fragments coding for HD510Q17 and HD510Q68 into pcDNA-I (Invitrogen). pHD169Q68 was derived from pHD510Q68 by deletion of the XhoI- XhoI fragment encoding aa 170-510 of human htt.

• Library screening

Plasmids encoding bait proteins were transformed into the strain L40ccua, tested for the absence of reporter gene activity and cotransformed with a human fetal brain cDNA library (Clontech). For each transformation 1 x 10⁶ independent transformants were plated onto minimal medium lacking tryptophan, leucine, histidine and uracil (SDIV medium) and incubated at 30°C for 5 to 10 days. Clones were picked into microtitre plates using a picking robot and grown over night in liquid minimal medium lacking tryptophan and leucine (SDII medium). Then, they were spotted onto nylon or nitrocellulose membranes placed on SDIV medium plates. After incubation for 4 days

membranes were subjected to a β -galactosidase (β -GAL) assay. Plasmids were prepared from positive clones and characterised by restriction analyses and sequencing. For retransformation assays plasmids encoding bait and prey proteins were cotransformed in the yeast strain L40ccua and plated onto SDIV medium.

5 • Array mating screen

Plasmids encoding bait and prey proteins were transformed into strains L40ccua and L40cc α , respectively. L40cc α clones were arrayed in 96-well microtitre plates and mixed with a single L40ccua clone for interaction mating. Diploid cells were transferred by a robot (Beckman, Biomek® 2000) onto YPD medium plates and, after
10 incubation for 24 h at 30°C, onto SDII medium plates for additional 72 h at 30°C. For two-hybrid selection diploid cells were transferred onto SDIV medium plates with and without nylon or nitrocellulose membranes and incubated for 5 days at 30°C. The nylon or nitrocellulose membranes were subjected to the β -GAL assay. Positive clones were verified by cotransformation assays using plasmids encoding respective
15 bait and prey proteins.

• Protein expression and verification assays

For verification experiments cDNA fragments encoding baits and preys were subcloned into pGEX derivatives (Stratagene) or pTL-HA¹⁸. GST fusion proteins were expressed in *E. coli* BL21-codon PlusTM RP (Stratagene) and affinity purified
20 on glutathione agarose beads (Sigma) using standard protocols¹⁷. COS1 cells were transfected with mammalian expression plasmids and lysed as described¹⁸. For *in vitro* binding assays, 30 μ g of GST or GST fusion protein were immobilized on glutathione agarose beads and incubated with 500 μ g protein extract prepared from COS1 cells expressing a HA-tagged fusion protein for 2 h at 4°C in binding buffer [50
25 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1 % NP-40, 1 mM EDTA, 20 mM NaF, 1 mM DTT, 0.1 % Triton X-100, protease inhibitors (Roche Diagnostics)]. After centrifugation and extensive washing of the beads bound proteins were eluted and analysed by SDS-PAGE and Western blotting. Coimmunoprecipitation experiments were performed as described by Sittler *et al.*¹⁸. For immunofluorescence microscopy
30 COS1 cells were grown on cover slips and cotransfected with pcDNA-HD510Q68 and pTL-HA-GIT1. 40 h post transfection cells were fixed with 2% paraformaldehyde.

Standard protocols for staining with appropriate primary and secondary antibodies were used ¹⁸.

- **Filter Retardation Assay**

HEK293 cells coexpressing HD169Q68 and GIT1, PIASy, HIP5, HP28, PFN2, FEZ1 or BARD1 were harvested 48 h post transfection. Cells were lysed as described ¹⁸ and boiled in 2% SDS, 100 mM DTT for 5 min. Aliquots containing 50, 25 and 12.5 µg of total protein were used for filtration on a cellulose acetate membrane ¹⁴. SDS-resistant aggregates were detected using anti-CAG53b or anti-GIT1 antibodies.

- **Immunocytochemistry**

10 Mice were deeply anaesthetised and perfused through the left cardiac ventricle with 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were removed and postfixed overnight in 4% paraformaldehyde. Sections were processed for immunocytochemistry as described ⁴⁷. pAb EM48 (1:1000) and affinity purified anti-GIT1 pAb (1:100) were used as primary antibodies.

15 Six human HD and 5 control brains were used in this study. Two HD cases were classified as grade 3 and four cases as grade 4 of neuropathological severity. For immunolabelling standard protocols were used ⁴⁸. 2B4 mAb (1:200) and affinity purified GIT1 pAb (1:50) were used as primary antibodies.

Example 2: Two-hybrid screens and data management

20 To generate a PPI network for HD we used a combination of library and matrix yeast two-hybrid screens (Fig. 1a). First, 50 selected cDNAs encoding proteins potentially involved in HD including 10 different htt fragments were cloned into a DNA binding domain vector for expression of LexA fusion proteins (baits). The resulting plasmids were introduced into yeast strain L40ccua, which carries three reporter genes, *HIS3*,
25 *URA3* and *lacZ*, for two-hybrid interaction analyses. Forty baits did not activate the reporters by themselves and were used individually for cotransformation screening of a human fetal brain cDNA library expressing GAL4 activation domain hybrids (preys). In each screen, 1×10^6 auxotrophic transformants were tested on selective plates, and 1-50 positive colonies were typically obtained. Restriction analyses and

sequencing identified preys that together with their respective baits repeatedly activated the reporter genes. Starting with 40 baits in the first round of cotransformation screens we identified 34 PPIs for 10 baits (Table 1).

In the second round of screens, 12 cDNA fragments encoding preys identified in the first screen were subcloned into a DNA binding domain vector. The resulting baits were tested for autoactivation and 10 were screened against a human fetal brain cDNA library. Four of the 10 proteins revealed additional 13 PPIs.

Finally, an array mating screen was performed to connect all baits and preys identified in the transformation screens. For this assay, MAT α yeast cultures were transformed with plasmids encoding prey proteins and arrayed in 96-well microtitre plates for interaction mating with individual MAT α strains expressing bait proteins. Using this strategy each bait was individually tested for interaction with every prey in the array. Diploid yeast clones, formed by mating on YPD plates, were selected on agar SDII plates, and further transferred by a spotting robot on SDIV plates to select for Y2H interactions (Fig. 1b). We examined 3500 pairwise combinations of baits and preys in the mating assay and identified additional 70 PPIs. These interactions could be confirmed in cotransformation assays (Table 5).

Table 5:

Summary of two-hybrid screens

	baits	preys	baits yielding	interactions
Screen	screened	screened	interactions	identified
1st transformation screen	40	4×10^7	10	34
2nd transformation screen	10	1×10^7	4	13
Array mating screen	50	70	21	70

Thus, the combination of cDNA library and array mating screens proved powerful in establishing a highly connected PPI network linked to htt.

Sequence analysis of the cDNAs encoding bait and prey proteins revealed ORFs ranging from 82 to 728 amino acids in size (Table 2). In a systematic Blast search 60 out of the 67 proteins identified were identical to a SwissProt or TrEMBL protein entry (<http://us.expasy.org/sprot/>). The remaining 7 proteins showed 75-99 % identity to its best fit and either contained single amino acid substitutions, variable polyQ lengths or small regions of sequence variation. Uncharacterised proteins were named according to their interaction partners. Each ORF was further examined for consensus protein domains using the FprintScan, HMMPfam, HMMSmart, ProfileScan, and BlastProDom programs providing useful hints to protein function. For example, the protein BAIP1 (BARD1 interacting protein 1) possesses a Zn-finger-like PHD finger that is believed to be important for chromatin-mediated transcriptional regulation. Similarly, domain searches for BAIP2 (BARD1 interacting protein 2) revealed a BTB/POZ domain, a motif found in developmentally regulated zinc finger proteins of the Kelch family of actin-associated proteins. Thus, BAIP2 could potentially mediate the association of BARD1 with the actin cytoskeleton.

Example 3: Analysis and functional assignment of the two-hybrid data

Our two-hybrid screens identified a total of 117 PPIs between 70 protein fragments. As a result of the iterative two-hybrid strategy all interactions could be depicted in a single large network. The number of interactions identified for each bait varied from 1 to 18, with each protein having 1.6 interaction partners on average. In order to display the PPI data, both matrix and network representations were used (Fig. 2). The matrix shows, in addition to the two-hybrid interactions, previously reported interactions and interactions verified by independent methods (Fig. 2a). In comparison, the network view allows to immediately recognize local PPI patterns and paths connecting two proteins in the network (Fig. 2b). Interestingly, proteins such as htt, BARD1, GADD45G, HIP5, PIASy or VIM interact with more than 11 other proteins forming nodes within the HD network, while 30 proteins have only one interaction partner and thus are located at the periphery of the network (Fig. 2b). Indeed, all other proteins are embedded in many bi-fan motifs and multiple circular interaction clusters that have been interpreted to be an indication for biological relevance^{11,19}. Schwikowski et al.²⁰ defined network proteins, which are separated

by no more than two other proteins, as being part of a functional cluster. In this respect all proteins in our network form a functional cluster with htt.

We assigned a subcellular localisation to each protein by examining various sources of literature and based on available experimental data we grouped the proteins into six broad functional categories (Fig. 2a, Table 2).

Eighteen proteins in the HD network are involved in transcriptional regulation or DNA maintenance (Fig. 2a). The second largest group, 14 proteins, includes mainly cytoskeletal and transport proteins. We assigned 5 proteins to cellular signalling and fate, another 4 proteins to protein synthesis and turnover, and 3 proteins to cellular metabolism. Being part of 41 interactions, 16 proteins of unknown function were identified.

For the analysis of htt PPIs, as much as 40 out of 117 interactions (34,2%) included a htt fragment (Fig. 2a). In total, 19 different htt interacting partners from various functional groups were detected, 4 proteins had been previously described and 6 involved proteins of unknown function. Surprisingly, most htt partners (6) are involved in transcriptional regulation and DNA maintenance, but others function in cell organization and transport (4), cellular signalling (2), or cellular metabolism (1), suggesting that htt functions in different subcellular processes.

The current hypothesis that htt has a function in transcriptional regulation is inferred from its interactions with transcriptional activators, coactivators or repressors²¹. In agreement with previous reports, binding of htt to CA150²² and HYPA²³ has been detected in our screens. In addition, new connections to nuclear proteins such as SETBD1, PLIP and HBO1 were found. These multidomain proteins act on histones and are known modulators of chromatin structure and gene expression. Similarly, the zinc finger bromo domain containing proteins BARD1, NAG4, HZFH, ZHX1, ZNF33B play a role in transcriptional control. The protein IKAP directly interacts with htt and was recently shown to be part of a complex regulating RNA polymerase II activity²⁴. Htt also interacts with PIASy, which inhibits transcription factor STAT-mediated gene activation²⁵. PIASy functions as SUMO E3 ligase for the Wnt-responsive transcription factor LEF1, inhibiting its activity via sumoylation²⁶. This suggests that PIASy catalysed sumoylation of transcription factors could represent a general

mechanism in repression of gene expression. The binding of PIASy to htt indicates that htt may itself be a substrate for sumoylation. Alternatively, it could influence the sumoylation of other transcription factors. Thus, our data extend the nuclear role of htt and provide additional leads for its involvement in transcriptional regulation.

- 5 Another large group of htt interactors identified here are proteins that function in cellular organization and vesicle transport. We report a new interaction between htt and dynein light chain (HP28), a component of the dynein/dynactin motor protein complex. Interestingly, the p150^{Glued} subunit of dynactin is linked to the htt-associated protein HAP1^{16,27}. Our observation that htt directly binds to HP28 underscores the
10 potential scaffolding role of htt/HAP1 in dynein/dynactin driven retrograde vesicle transport along microtubules in axons.

- The htt interacting protein HIP1 anchors clathrin-coated vesicles to the cytoskeleton via its actin-binding domain, a link crucial for synaptic vesicle endocytosis²⁸. Here, a new PPI between htt and profilin II (PFN2)²⁹ was detected. PFN2, a protein enriched
15 in neurons, modulates actin polymerization *in vitro* and is involved in endocytosis via association with scaffolding proteins²⁹. The htt-PFN2 connection adds support to a potential role of htt in modulation of both actin polymerization and vesicle transport processes.

- Currently, for the function of 6 htt interactors, including HIP5, no genetic or
20 biochemical evidence is available (Table 2). We found that HIP5 binds to htt as well as to karyopherin α (KPNA2). KPNA2 serves as an adapter for karyopherin β (KPNB1), which transports NLS-tagged proteins into the nucleus³⁰. Thus, HIP5 might take this route to the nucleus. Interestingly, HEAT or armadillo (ARM) repeats, forming α -helical structures in KPNA2 and KPNB1 are also present in htt³¹.
25 Therefore, the complexes between KPNA2 and HIP5 as well as between htt and HIP5 could be similar in terms of protein structure. It is tempting to further speculate that htt participates in nucleocytoplasmic transport.

Example 3: Verification of PPIs

- Comparison with literature-cited interactions revealed that more than 80% of the two-
30 hybrid interactions identified here are novel. For all network bait and prey proteins only 24 PPIs have been reported previously using two-hybrid methods,

coimmunoprecipitations or affinity chromatography-based techniques; 18 of these were confirmed in our Y2H assays (Fig 2a, Table 2). Failure to detect interactions may result from the high stringency of our particular two-hybrid system. However, in most cases the occurrence of false negatives can be explained by the lack of essential domains in one of the protein fragments used. For example, an interaction between p53 and hADA3 has been described ³², with the first 214 amino acids of hADA3 being essential for this interaction. It escaped our two-hybrid analysis, because a C-terminal hADA3 fragment (amino acids 235-432) was used. For the same reason, an interaction between p53 and BARD1 or between KPNA2 and KPNB1 was not observed.

Beside false negatives, the two-hybrid assay is also prone to create false positive results ⁹. Addressing this issue we performed a series of pull-down and overlay assays and thereby confirmed several of the two-hybrid PPIs independently. Proteins were expressed as GST-fusions in *E. coli* and as HA-fusions in COS1 cells. After immobilization of the GST-fusion protein to beads or nitrocellulose membranes the respective partner was affinity-purified from a COS1 cell extract and binding was detected by immunoblotting. Using these assays, 22 physical interactions, central to the HD network, were verified (Fig. 2a). The results of some *in vitro* GST pull-down assays are shown in Fig. 3. For example HD510Q17 interacts with HIP1, GIT1, PIASy, FEZ1 and HIP11, and HIP5 binds to HD510Q68, GIT1, HBO1, PLIP and FEZ1 (Fig. 3). In total, 35 two-hybrid interactions were verified independently either in previous studies or by our *in vitro* binding assays (Fig. 2a).

Example 4: GIT1 promotes htt aggregation *in vivo*

The formation of insoluble polyQ-containing protein aggregates is a pathological hallmark of HD. Several lines of evidence link htt aggregation to disease progression and the development of motor symptoms. We screened network proteins for their potential to enhance htt aggregation in a cell-based aggregation assay ¹⁴. In this assay, formation of SDS-insoluble htt aggregates in mammalian cells, that have been cotransfected with constructs encoding an N-terminal htt fragment with 68 glutamines (HD169Q68) and a network protein of interest, is monitored by filter retardation ¹⁴. HD169Q68 *per se* has only a low propensity to form insoluble aggregates in HEK293 cells. However, as shown in Fig. 4a coexpression of the htt-interacting protein GIT1

strongly promotes the formation of HD169Q68 aggregates, whereas coexpression of PIASy, HIP5, HP28, PFN2, FEZ1 and BARD1 has no discernable effect. Thus, GIT1 is a potential modifier of HD pathogenesis, which may influence the rate of formation of insoluble htt aggregates *in vivo*.

5 Furthermore, probing of the insoluble HD169Q68 aggregates with an anti-GIT1 antibody revealed that GIT1 does not only stimulate aggregation but is also an integral part of the insoluble aggregates (Fig. 4a). This suggests that GIT1 promotes aggregation through direct binding to mutant htt.

10 The interaction between GIT1 and htt was confirmed by coimmunoprecipitation from COS1 cells transfected with constructs encoding HD510Q68 and HA-GIT1. Forty hours post transfection cell extracts were prepared and treated with antiserum against GIT1. HD510Q68 and HA-GIT1 were detected in the immunoprecipitate on Western blots with anti-htt antibody 4C8 and anti-HA antibody 12CA5, respectively (Fig. 4b).

15 The GIT1-htt interaction was also detected in human brain. Protein extracts prepared from human cortex were treated with the anti-htt antibodies CAG53b and HD1, and the precipitate was probed for the presence of GIT1 (Fig. 4c). Full length GIT1, migrating at about 90 kDa ³³, was precipitated by both anti-htt antibodies in a concentration dependent manner, indicating the existence of a complex between htt
20 and GIT1 in neurons.

Finally, we performed colocalisation studies of htt and GIT1 in COS1 cells using immunofluorescence microscopy. In cells expressing HD510Q68 or GIT1 alone a diffuse cytoplasmic staining was observed for each protein (Fig. 4d). However, when
25 GIT1 and mutant htt were coexpressed, large perinuclear structures, most likely reflecting protein aggregates, appeared almost exclusively. These structures contained both GIT1 and htt. The images further substantiate the findings that GIT1 and htt bind to each other and that GIT1 is a potent enhancer of mutant htt aggregation.

**Example 5: GIT1 localises to htt aggregates in HD transgenic mouse and
30 patient brains**

The finding of colocalisation of htt and GIT1 within aggregates in transfected COS1 cells suggests that GIT1 might also be a component of htt aggregates *in vivo*. To investigate this possibility we first assessed the distribution of GIT1 in brains of R6/1 transgenic mice expressing a human htt exon 1 protein with 150 glutamines ³⁴. In wildtype mice, GIT1 immunoreaction product was found diffuse in the cytoplasm and nuclei of neurons throughout the brain. In R6/1 brains, in addition to the diffuse staining, GIT1 immunoreactivity was also present in large nuclear and cytoplasmic puncta similar to htt aggregates (Figure 5a). To further confirm these data, we examined the subcellular distribution of GIT1 in cortex from HD patient brains and healthy individuals (Fig. 5b). In patient brains, GIT1 antibodies labelled neuronal nuclear inclusions as well as neuropil aggregates characteristic of HD brains ³⁵. In contrast, neurons from control brains only showed a diffuse nuclear and cytoplasmic GIT1 immunostaining. In fact, in colocalisation studies performed in HD brain sections, GIT1 positive aggregates were also labelled with anti-htt antibody 2B4, indicating that both proteins coaggregated *in vivo* (Fig. 5c). This observation raises the possibility that an alteration of the neuronal GIT1 subcellular distribution contributes to HD pathogenesis.

PART II: VERIFICATION AND FURTHER RESULTS

Example 6: Experimental Procedures

• Antibodies

A polyclonal antibody (pAb) against GIT1 was generated by injection of purified His6-tagged GIT1 (aa 368-587) into a rabbit. The resulting GIT1 pAb (C-GIT1) was affinity purified using immobilized GIT1 protein. The pAb NT-GIT1 recognizes the first 100 aa of GIT1 (Santa Cruz Biotechnology), the monoclonal antibody (mAb) CT-GIT1 (Transduction Laboratories) is specific for the last 10⁶ amino acids of GIT1. For all three Abs, no cross-reaction with GIT2 was observed (Fig. 13). The pAbs against GAPDH (Wanker et al., 1997) and htt [CAG53b (Davies et al., 1997) and HD1 (Scherzinger et al., 1997)] were described. Commercially available antibodies were anti-GST pAb (Amersham Pharmacia), anti-HA mAb 12CA5 (Roche Diagnostics), anti-htt pAb EM48 (Gutekunst et al., 1999), anti-htt mAb 2B4 (Lunkes et al., 2002), anti-htt mAb 4C8 (Chemicon) and anti-EEA1 pAb (Santa Cruz Biotechnology). As

secondary antibodies for immunofluorescence microscopy, Cy3- (dianova) and Alexa 488- (MoBiTec) conjugated IgGs were used.

• Strains and plasmids

- 5 The yeast strains used for two-hybrid analysis were L40ccua [MATa his3D200 trp1-901 leu2-3,112 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-lacZ ADE2::(lexAop)8- URA3 GAL4 gal80 can1 cyh2] and L40cca [MATa his3D200 trp1-910 leu2-3,112 ade2 LYS2::(lexAop)4-HIS3 URA3::(lexAop)8-lacZ GAL4 gal80 can1 cyh2].

10 Plasmids pHD510Q17 and pHD510Q68 were generated by insertion of fragments coding for HD510Q17 and HD510Q68 into pcDNA-I (Invitrogen). pHD169Q68 was derived from pHD510Q68 by deletion of the XhoI-XhoI fragment encoding aa 170-510 of human htt. pV5-HD169Q68 was generated by inserting the EcoRI-XhoI fragment from pHD510Q68 into pcDNA3.1/V5-HIS (Invitrogen). Full-length GIT1 (aa 1-770) was amplified by PCR from the cDNA clone IMAGp958H111245Q2 (RZPD, 15 Germany) using the primers GIT1-F/GIT1-R and subcloned into the EcoRI-BglII site of pTL-HA (HA-GIT1). The GIT2 cDNA (aa 1-759) was PCR amplified with the primers GIT2-F / GIT2-R and subcloned into the XhoI-NotI site of pTL-HA (HA-GIT2). The primer sequences were as follows: GIT1-F (5'-CGGAATTCATGTCCCGAAAGGGGCCGCG-3'), GIT1-R (5'-GGAAGATCTGGTCACTGCTTCTTCTCTCGGG-3'), GIT2-F (5'-ACGCGTCGACCATGTGCGAAA 20 CGGCTCCG-3') and GIT2-R (5'-ATAAGAATGCGGCCGCGCCCTGCCCTTGCTAGTTG -3').

• Library screening

- 25 Plasmids encoding baits were transformed into L40ccua, tested for the absence of reporter gene activity and cotransformed with a human fetal brain cDNA library (Clontech). For each transformation, 1×10^6 independent transformants were plated onto minimal medium lacking tryptophan, leucine, histidine and uracil (SDIV medium) and incubated at 30°C for 5 to 10 days. Clones were picked into microtitre plates and

grown overnight in liquid minimal medium lacking tryptophan and leucine (SDII medium). Then, they were spotted onto nylon membranes placed on SDIV agar plates. After incubation for 4 days, the membranes were subjected to a b-galactosidase (b-GAL) assay. Plasmids were prepared from positive clones and characterized by sequencing. For retransformation assays, plasmids encoding baits and preys were cotransformed into L40ccua and plated onto SDIV medium.

• Array mating screen

Plasmids encoding baits and preys were transformed into strains L40ccua and L40cca, respectively. L40cca clones were arrayed in 96-well microtitre plates and mixed with a single L40ccua clone for interaction mating. Diploid cells were transferred onto YPD medium plates and, after incubation for 24 h at 30°C, onto SDII medium plates for additional 72 h at 30°C. For two-hybrid selection, diploid cells were transferred onto SDIV medium plates with and without nylon membranes and incubated for 5 days at 30°C. The nylon membranes were subjected to the b-GAL assay. Positive clones were verified by cotransformation assays.

• Protein expression and verification assays

For verification experiments, cDNA fragments encoding baits and preys were subcloned into pGEX derivatives (Stratagene) or pTL-HA (Sittler et al., 1998). GST-fusion proteins were expressed in *E. coli* BL21-codon PlusTM RP (Stratagene) and affinity purified on glutathione agarose beads (Sigma) (Wanker et al., 1997). COS-1 cells were transfected with mammalian expression plasmids and lysed as described (Sittler et al., 1998). For in vitro binding assays, 30 µg of GST or GST fusion protein were immobilized on glutathione agarose beads and incubated with 500 µg COS-1 cell extract containing HA-tagged fusion protein for 2 h at 4°C, in binding buffer [50 mM HEPES-KOH pH 7.4, 150 mM NaCl, 10% glycerol, 1% NP-40, 1 mM EDTA, 20 mM NaF, 1 mM DTT, 0.1% Triton X-100, protease inhibitors (Roche Diagnostics)]. After centrifugation and extensive washing, bound proteins were eluted and analyzed by SDS-PAGE and Western blotting.

Coimmunoprecipitation experiments were performed as previously described (Sittler et al., 1998). For immunofluorescence microscopy, COS-1 cells were grown on cover slips and cotransfected with plasmids encoding N-terminal htt V5-HD169Q68 and/or C-terminal HA-GIT1-CT. 40 h post-transfection, cells were treated with 2% paraformaldehyde. Immunolabeling was performed with anti-C-GIT1 (1:500) and with anti-V5 (1:300) Abs. Nuclei were counterstained with Hoechst. For subcellular localization of endogenous GIT1 and htt, differentiated PC12 and SH-SY5Y cells were used. PC12 cells were treated with 50 ng/ml NGF and grown on cover slips for 6 d. SH-SY5Y cells were serum starved for 24 h and then differentiated with 10 nM IGF-I for 30 min. Cells were labeled with C-GIT1 (1:20) and 4C8 (1:20) Abs and viewed with a confocal microscope LSM510 (Zeiss).

• Filter Retardation Assay

HEK293 cells coexpressing HD169Q68 and selected network proteins were harvested 48 h post-transfection. Cell lysates were boiled in 2% SDS, 50 mM DTT for 5 min. Aliquots containing 12.5, 25 or 50 µg of total protein were used for filtration on cellulose acetate membranes (Scherzinger et al., 1997). SDS-resistant aggregates were detected using anti-CAG53b or anti C-GIT1 pAbs.

• Inhibition of GIT1 expression by siRNA

For silencing of endogenous GIT1 expression, HEK293 cells were transfected with the siRNA duplex siRNA-GIT1 (5'-AAGCCTGGATGGAGACCTA GA-3') using TransMessenger (Qiagen) or Lipofectamin 2000 (Invitrogen) transfection reagents. 48 h post transfection, cell lysates were analyzed for GIT1 expression by immunoblotting using C-GIT1 Ab. To examine the effect of endogenous GIT1 silencing on htt aggregation, HEK293 cells were cotransfected with pHD169Q68 and siRNA-GIT1 and subjected to filtration after 72 h.

• Detection of GIT1 in R6/1 mouse and human HD brains

For immunocytochemistry, mice were deeply anaesthetized and perfused through the left cardiac ventricle with 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were removed and postfixed overnight in 4% paraformaldehyde. Sections were processed for immunocytochemistry as described (Gutekunst et al., 1999). EM48 (1:1000) and C-GIT1 (1:100) pAbs were used.

Tissues from 8 human HD and 7 control brains were used in this study. Two HD cases were classified as grade 3 of neuropathological severity, six cases as grade 4. Standard protocols were used (Lunkes et al., 2002) for immunolabeling with 2B4 mAb (1:200) and C-GIT1 pAb (1:50). For Western analysis of total protein lysates from frontal cortex, the C-GIT1 pAb (1:300) was used.

Example 7: Two-hybrid screens

To generate a PPI network for HD, we used a combination of library and matrix yeast two-hybrid screens (Fig. 7A). Previous studies have shown that htt potentially participates in clathrin-mediated endocytosis, apoptosis, vesicle transport, cell signaling, morphogenesis and transcriptional regulation (Harjes and Wanker, 2003; Li and Li, 2004). For this reason, we selected 50 cDNAs encoding proteins involved in these processes, including 5 different N-terminal htt fragments, as well as proteins known to interact with htt, for subcloning into a DNA binding domain vector to express LexA fusion proteins as baits (Suppl. Table 1). The resulting plasmids were sequenced and introduced into yeast strain L40ccua, which carries three reporter genes, HIS3, URA3 and lacZ, for two-hybrid interaction analysis.

Forty of these baits did not activate the reporters by themselves and were used individually for cotransformation screening of a human fetal brain cDNA library expressing GAL4 activation domain (AD) hybrids as preys. In each screen, 1×10^6 auxotrophic transformants were tested on selective plates, and 1-50 positive colonies were typically obtained. Restriction analysis and sequencing revealed that about 12% of all positive clones expressed preys with correct in-frame sequences, while 88% of the clones contained plasmids with out-of-frame sequences or sequences from non-protein-encoding regions, which were discarded. 27 preys were identified only once, while the other 11 were found up to four times as independent AD fusions. Plasmids

with the longest coding regions were used for subsequent studies. The preys identified by the library two-hybrid screens were tested together with their respective baits for activation of reporter gene expression in cotransformation assays. Only prey/bait combinations that activated the reporter gene expression in two independent cotransformation assays were selected for further two-hybrid studies and in vitro pull-down assays (Fig. 9). Starting with 40 baits in the library and subsequent cotransformation screens, we identified 41 PPIs among 18 bait and 38 prey proteins.

For a second round of two-hybrid screens, cDNAs encoding 12 prey proteins were selected from literature verified interactions and from interactions confirmed by in vitro binding experiments (Suppl. Table 2), and subcloned into a DNA binding domain vector. The resulting baits were tested for autoactivation, and 10 were screened against a human fetal brain cDNA library as described above. We identified another 14 PPIs among 5 bait and 13 prey proteins. Nine preys were found once and 4 were discovered multiple times as independent AD fusions. All interactions were confirmed by cotransformation assays.

Finally, an array-mating screen was performed to connect bait and prey proteins identified in the cDNA library transformation screens (Fig. 7A). L40cca yeast cultures were transformed with plasmids encoding the 51 prey proteins obtained in the first and second round of cDNA library screens and arrayed in 96-well microtiter plates. Prey cDNAs were also subcloned into DNA binding domain vectors and introduced into an L40ccua strain to generate additional baits for interaction mating. Including the ones already used for the library screens, we arrived at 46 baits, which did not autoactivate the reporter genes (Table 7). These baits were used individually for mating against the matrix of prey proteins. Diploid yeast clones, formed on YPD plates, were selected on agar SDII plates, and further transferred by a spotting robot onto SDIV plates to select for Y2H interactions (Fig. 7B). We examined 2346 (51x46) pair wise combinations of baits and preys in the mating assay reproducing all 55 two-hybrid interactions, which had been found in the library screens. In addition, 131 new PPIs were found by interaction mating and subsequently reproduced in cotransformation assays. Using this combination of library and matrix two-hybrid

screens, a total of 186 PPIs among 35 bait and 51 prey proteins could be identified (Fig. 8A).

Sequence analysis of the cDNAs revealed ORFs ranging from 82 to 728 amino acids in size (Table 7). In a systematic Blast search, 77 of the 86 bait and prey protein fragments were identical to a SwissProt or TrEMBL protein entry (<http://us.expasy.org/sprot/>). Nine proteins showed 75-99% identity to their best respective database hit and either contained single amino acid substitutions, variable polyQ lengths or small regions of sequence variation. Uncharacterized proteins were named according to their interaction partners.

This chapter describes the whole yeast two hybrid screening procedure and obtained fundamental data. A full description of our final datasets are shown in tables 6 to 9. Table 6 contains a compilation of all found protein-protein interactions in the Huntington's disease protein network. Some of these interactions are already known and literature-cited. A dataset which describes only new identified interactions will be found in Table 9. Table 7 characterizes all proteins involved in the protein network. Most of these proteins are known from different databases but some proteins are still unknown (Table 8). Nucleic acid and amino acid sequence data for all network-proteins are available from Figure 6.

Example 8: Functional assignment of yeast two-hybrid data

To chart two-hybrid interactions identified in this study, previously reported, or verified by independent methods, a matrix representation was used (Fig. 8A). We assigned a subcellular localization to each network protein by examining various sources of literature and, based on the experimental data, we grouped the proteins into six broad functional categories (Fig. 8A, Table 7). 18 proteins in the HD network are involved in transcriptional regulation or DNA maintenance; 14 proteins mainly participate in cytoskeletal and transport processes. We assigned 7 proteins to cellular signaling and fate, another 5 to protein synthesis and turnover, and 3 proteins to cellular metabolism. 16 proteins of unknown function were identified, participating in 72 interactions. The number of interactions identified for each protein varied from 1 to 24, with 2.6 interaction partners on average. Interestingly, proteins such as htt,

BARD1, GADD45G, HIP5, HZFH, PIASy, BAIP3 or VIM interact with more than 15 other proteins, forming hubs in the HD network, while 15 proteins have only one interaction partner.

For htt, 19 different interacting partners from various functional groups were identified, of which HIP1, CA150, SH3GL3 and HYPA had been described previously (Harjes and Wanker, 2003). 6 of the htt partners are involved in transcriptional regulation and DNA maintenance, 4 function in cellular organization and transport and 3 in cellular signaling, supporting the hypothesis that htt is involved in these processes. Moreover, we have detected 6 novel htt interacting proteins of unknown function termed HIP5, HIP11, HIP13, HIP15, HIP16, and CGI-125.

Using 5 different N-terminal htt fragments as baits, the potential htt-binding sites of 13 interaction partners were mapped (Fig. 8A). For the proteins CA150, HYPA, PNF2, SH3GL3, CGI-125 and HIP13, however, a conclusive determination of the htt binding region was not possible with the two-hybrid assay, because these proteins bound to HDexQ20, HDexQ51 and HD1.7, but not to HDd1.0 (Fig. 8A). We suggest that these proteins bind to the htt exon 1 fragment, but this binding region might be masked in the HDd1.0 protein, while it is accessible in the HD1.7 fragment. Interestingly, we found that HP28 and HIP15 bind to HDexQ51, but not to HDexQ20, HD1.7 and HD1.0, indicating that the interaction of these proteins with htt is enhanced by the expanded polyQ repeat. Thus, HP28 and HIP15 may be disease specific htt interactors.

To generate a more comprehensive HD interaction map, we supplemented our two-hybrid network (red diamonds) with all 38 known direct htt interaction partners (Suppl. Table 4 and Fig. 8B, blue squares). Furthermore, we added 83 human proteins (green triangles), identified from protein interaction databases HPRD, MINT, and BIND that bridge any two proteins in our extended network. Using this approach, we obtained an interaction network for htt containing a total of 181 proteins and 591 PPIs (Fig. 8B and Suppl. Table 5).

Example 9: Verification of PPIs

Comparison with literature-cited interactions revealed that more than 89% of the two-hybrid interactions identified are unknown. 30 PPIs have been reported previously using two-hybrid methods, coimmunoprecipitations or affinity chromatography-based techniques; 21 of these were detected in our Y2H assays (Fig. 8A, Suppl. Table 3).

5 In most cases, the occurrence of false negatives can be explained by the lack of essential domains in one of the protein fragments. For example, an interaction between p53 and hADA3 has been described (Wang et al., 2001), with the first 214 amino acids of hADA3 being essential for this interaction. It escaped our two-hybrid analysis, because a C-terminal hADA3 fragment (amino acids 235-432) was used.

10 Failure to detect interactions may also result from the high stringency of our two-hybrid assay, which can be attributed to low protein expression levels and the simultaneous use of three reporters. Our system is particularly designed to minimize false positives, which are known to occur frequently in two-hybrid assays (von Mering et al., 2002). To determine the rate of false positives in our system, we directly
15 assessed 54 interactions from the two-hybrid network by in vitro pull-down experiments, mainly focusing on htt and its immediate interaction partners. Proteins were expressed as GST-fusions in *E. coli*, and their interacting partners as HA-fusions in COS-1 cells. After immobilization of GST-fusion proteins to beads, the potential interaction partners were pulled down from COS-1 cell extracts. Binding
20 was detected by SDS-PAGE and immunoblotting. Using this assay, 35 interactions representing 32 different protein pairs were verified successfully (Fig. 9). Failure to detect an interaction by GST pull-down assays could be due to low protein expression levels or the lack of appropriate protein modifications. Therefore, the 19 non-verified protein-protein interactions are still valid until further experiments show
25 contradictory results. The rate of 64.8% verified interactions suggests that in our Y2H network false positives might appear less frequently than described for other PPI studies (von Mering et al., 2002).

Example 10: GIT1 promotes htt aggregation

30 Several lines of evidence indicate that aggregation of mutant htt is linked to disease progression and the development of motor symptoms (Davies et al., 1997; Sanchez

et al., 2003). Therefore, cellular proteins that influence aggregate formation are potential modulators of disease pathogenesis. In order to identify such proteins, we screened all 19 direct htt interaction partners (Fig. 8A) for their ability to enhance htt aggregation in a cell-based assay (Sittler et al., 1998). In this assay, HEK293 cells were cotransfected with constructs encoding an aggregation prone N-terminal htt fragment with 68 glutamines (HD169Q68) and a network protein. After 48 h, formation of SDS-insoluble htt aggregates was analyzed by a filter retardation assay (Scherzinger et al., 1997). In this time period HD169Q68 by itself formed only few aggregates. In comparison, coexpression of the C-terminal GIT1 fragment found in the Y2H screens (GIT1-CT) increased the amount of htt aggregates 3-fold (Fig. 10A). Coexpression of HD169Q68 with other htt-interacting proteins, on the other hand, did not enhance htt aggregation (data not shown).

It has been described previously that GIT1 and its homologue p95-APP1 are able to form homo- and heterodimers in vitro and in vivo (Kim et al., 2003; Paris et al., 2003). Therefore, we wondered whether GIT1-CT by itself is able to form SDS-insoluble protein aggregates in mammalian cells. As shown in Fig. 10A, we did not detect aggregates in the filter retardation assay upon transient overexpression of GIT1-CT. However, in cells coexpressing HD169Q68 and GIT1-CT, stable SDS-resistant aggregates immunoreactive with the anti-C-GIT1 antibody were formed, indicating that both proteins coaggregate in cells, and that GIT1-CT is an integral part of the insoluble htt aggregates (Fig. 10A).

Next, we tested whether full-length GIT1 is able to accelerate htt aggregation in mammalian cells. Analysis by filter retardation assay revealed that full-length GIT1 enhances htt aggregation in a dose dependent manner (Fig. 10B). However, compared to GIT1-CT, it was less efficient in stimulating HD169Q68 aggregation in the cell model, indicating that the N-terminally truncated GIT1 fragment is a more potent enhancer of htt aggregation than the full-length protein.

As previous studies have shown that the expression of C-terminal GIT1/p95-APP1 fragments induces the formation of large vesicular structures in mammalian cells (Di Cesare et al., 2000; Matafora et al., 2001), we analyzed the effect of GIT1-CT on HD169Q68 aggregation by indirect immunofluorescence microscopy. We found that expression of GIT1-CT alone induced the accumulation of large vesicular structures

in the perinuclear region (Fig. 10Cb). In comparison, when HD169Q68 was expressed alone, the protein was distributed in the cytoplasm, and no large aggregates or inclusion bodies were observed (Fig. 10Ca). However, when HD169Q68 and GIT1-CT were coexpressed (Fig. 10Cd-f), htt was almost exclusively detected in the perinuclear vesicles (Fig. 10Cd), indicating that GIT1-CT overexpression induces the relocalization of htt to membranous structures. A similar effect was observed when full-length GIT1 and HD169Q68 were coexpressed in COS1 cells, however, the rate of vesicle formation and htt recruitment was lower, compared to GIT1-CT/HD169Q68 expressing cells (data not shown). The colocalization of GIT1 with the early endosomal marker EEA1 is shown in Fig. 10Cc. Together, these results suggest that the enhancement of HD169Q68 aggregation in mammalian cells is due to the recruitment of mutant htt into vesicular structures induced by overexpression of GIT1 or GIT1-CT.

Example 11: GIT1 is crucial for the formation of htt aggregates in mammalian cells

Next, we investigated whether endogenous GIT1 promotes htt aggregation in mammalian cells. In order to reduce endogenous GIT1 levels in HEK293 cells, we employed the short-interfering RNA (siRNA) technology (Elbashir et al., 2001). Cells were cotransfected with HD169Q68 and GIT1-specific siRNA, and silencing of endogenous GIT1 was monitored 48 h post transfection by Western blot analysis (Fig. 10D). We found that siRNA treatment specifically reduced endogenous GIT1 by ~80% and caused a strong decrease of HD169Q68 aggregate formation (Fig. 10E). After incubation for 72 h, SDS-resistant HD169Q68 aggregates were detected in untreated, but not in siRNA treated cells. This indicates that physiological levels of GIT1 are critical for htt aggregation in mammalian cells, and that an inhibition of GIT1 expression dramatically slows down aggregate formation. A similar effect was also obtained when GIT1-specific siRNA was applied to cells overexpressing GIT1-CT and HD169Q68 proteins (data not shown).

Example 12: Verification of the htt-GIT1 interaction

The interaction between GIT1-CT and htt was confirmed by coimmunoprecipitation from COS-1 cells transfected with constructs encoding the first 510 amino acids of htt with 68 glutamines (HD510Q68) and an N-terminally truncated hemagglutinin (HA) tagged HA-GIT1-CT (aa 249-770) protein. 40 h post-transfection, cell extracts were prepared and treated with GIT1 antiserum. HD510Q68 and HA-GIT1-CT were detected in the immunoprecipitates on Western blots with anti-htt antibody 4C8 and anti-HA antibody 12CA5, respectively (Fig. 11A).

The GIT1-htt interaction was also detected in healthy human brain. Protein extracts prepared from cortex were treated with the anti-htt antibodies CAG53b and HD1, and the precipitate was probed for the presence of GIT1 (Fig. 11B) with a GIT1 specific antibody (NT-GIT1; Fig. 13). Full length GIT1, migrating at about 95 kDa (Vitale et al., 2000), was precipitated by both anti-htt antibodies in a concentration dependent manner, indicating that a protein complex containing htt and GIT1 is formed under physiological conditions.

Next, we examined the colocalization of endogenous htt and GIT1 in differentiated PC12 cells by confocal immunofluorescence microscopy. Both proteins were mainly detected in the cytoplasm, but were also present in the neurite-like extensions (Fig. 11Cab). Colocalization, indicated in yellow, was visible in cytoplasmic complexes in the perinuclear region (Fig. 11Cc) as well as in a number of intracellular structures scattered throughout the neuritic extensions. GIT1 was also detected in adhesion-like structures at the tip of the extensions, as previously reported (Di Cesare et al., 2000; Manabe Ri et al., 2002). These regions, however, did not contain htt protein. Similar results were obtained when the endogenous localization of GIT1 and htt was analyzed in differentiated neuroblastoma SH-SY5Y cells using confocal immunofluorescence microscopy (Fig. 11Cd-f).

Example 13: GIT1 localizes to htt aggregates in patient brain

Our findings suggest that GIT1 might also be a component of neuronal inclusions containing htt aggregates in brain of HD patients and transgenic animals (Davies et al., 1997; DiFiglia et al., 1997). To investigate this possibility, we first assessed the distribution of GIT1 in brain slices of R6/1 transgenic mice expressing a human htt

exon 1 protein with 150 glutamines (Mangiarini et al., 1996). In wild type mice, GIT1 specific immunoreactivity was diffused in the cytoplasm and nuclei of neurons throughout the brain. In R6/1 brain, however, in addition to a diffuse staining, GIT1 immunoreactivity was also present in large nuclear and cytoplasmic puncta containing htt aggregates (Fig. 12A). To further confirm these data, we examined the subcellular distribution of GIT1 in HD patient and healthy cortex (Fig. 12B). In patient brain, GIT1 specific antibodies labeled neuronal nuclear inclusions as well as the neuropil aggregates characteristic of HD (DiFiglia et al., 1997). In contrast, neurons from control tissue showed only diffuse nuclear and cytoplasmic GIT1 immunostaining. Fig. 12C shows colocalization of htt and GIT1 in neuronal nuclear inclusions.

Example 14: GIT1 is degraded in HD patient brain

The presence of GIT1 in protein extracts from HD affected and unaffected cortex was also analyzed by SDS-PAGE and immunoblotting. As shown in Fig. 12D, full-length GIT1 protein migrating at about 95 kDa was detected in healthy brain (Fig. 12D), but was significantly reduced in HD. Interestingly, in HD, but not in control brain, prominent GIT1 degradation products migrating at about 25-50 kDa were detected with the C-terminal GIT1 antibody C-GIT1 (Fig. 12D). In strong contrast, no such products were observed when the N-terminal GIT1 antibody NT-GIT1 directed against the ARF-GAP domain was used (data not shown). This indicates the formation of large amounts of N-terminally truncated GIT1 fragments in HD brain, which may be a significant factor in disease pathogenesis.

Additional references:

1. Tucker, C. L., Gera, J. F. & Uetz, P. Towards an understanding of complex protein networks. *Trends Cell. Biol.* **11**, 102-106 (2001).
- 5 2. Alberts, B. The cell as a collection of protein machines: preparing the next generation of molecular biologists. *Cell* **92**, 291-294 (1998).
3. Legrain, P., Wojcik, J. & Gauthier, J. M. Protein--protein interaction maps: a lead towards cellular functions. *Trends Genet.* **17**, 346-352 (2001).
- 10 4. Fields, S. & Song, O. A novel genetic system to detect protein-protein interactions. *Nature* **340**, 245-246 (1989).
5. Uetz, P. et al. A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* **403**, 623-627 (2000).
6. Ito, T. et al. A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc. Natl Acad. Sci. USA* **98**, 4569-74 (2001).
- 15 7. Rain, J. C. et al. The protein-protein interaction map of *Helicobacter pylori*. *Nature* **409**, 211-5 (2001).
8. Bader, G. D. & Hogue, C. W. Analyzing yeast protein-protein interaction data obtained from different sources. *Nature Biotechnol.* **20**, 991-997 (2002).
- 20 9. von Mering, C. et al. Comparative assessment of large-scale data sets of protein-protein interactions. *Nature* **417**, 399-403 (2002).
10. Walhout, A. J. et al. Integrating Interactome, Phenome, and Transcriptome Mapping Data for the *C. elegans* Germline. *Curr. Biol.* **12**, 1952-1958 (2002).
11. Walhout, A. et al. Protein interaction mapping in *C. elegans* using proteins involved in vulval development. *Science* **287**, 116-122 (2000).
- 25 12. Fromont-Racine, M., Rain, J. & Legrain, P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. *Nature Genet.* **16**, 277-282 (1997).
13. Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* **90**, 537-548 (1997).
- 30 14. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. *Cell* **90**, 549-558 (1997).
15. Cattaneo, E. et al. Loss of normal huntingtin function: new developments in Huntington's disease research. *Trends Neurosci.* **24**, 182-188 (2001).
- 35 16. Li, X. et al. A huntingtin-associated protein enriched in brain with implications for pathology. *Nature* **378**, 398-402 (1995).
17. Wanker, E. et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. *Hum. Mol. Genet.* **3**, 487-495 (1997).

18. Sittler, A. et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polyglu-containing protein aggregates. *Mol. Cell* **4**, 427-436 (1998).
- 5 19. Milo, R. et al. Network motifs: simple building blocks of complex networks. *Science* **298**, 824-7 (2002).
20. Schwikowski, B., Uetz, P. & Fields, S. A network of protein-protein interactions in yeast. *Nature Biotechnol.* **17**, 1030-1032 (2000).
21. Cha, J. H. Transcriptional dysregulation in Huntington's disease. *Trends Neurosci.* **23**, 387-392 (2000).
- 10 22. Holbert, S. et al. The Glu-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. *Proc. Natl Acad. Sci. USA* **98**, 1811-1816 (2001).
- 5 23. Faber, P. et al. Huntingtin interacts with a family of WW domain proteins. *Hum. Mol. Genet.* **7**, 1463-1474 (1998).
24. Hawkes, N. A. et al. Purification and characterization of the human elongator complex. *J. Biol. Chem.* **277**, 3047-3052 (2002).
- 20 25. Liu, B., Gross, M., ten Hoeve, J. & Shuai, K. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. *Proc. Natl Acad. Sci. USA* **98**, 3203-3207 (2001).
26. Sachdev, S. et al. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. *Genes Dev.* **15**, 3088-3103 (2001).
- 25 27. Engelender, S. et al. Huntingtin-associated protein 1 (HAP1) interacts with the p150^{Glued} subunit of dynactin. *Hum. Mol. Genet.* **6**, 2205-2212 (1997).
28. Waelter, S. et al. The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. *Hum. Mol. Genet.* **10**, 1807-1817 (2001).
- 30 29. Witke, W. et al. In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. *EMBO J.* **17**, 967-976 (1998).
30. Chook, Y. & Blobel, G. Karyopherins and nuclear import. *Curr. Opin. Struct. Biol.* **11**, 703-715 (2001).
31. Andrade, M. A., Petosa, C., O'Donoghue, S. I., Muller, C. W. & Bork, P. Comparison of ARM and HEAT protein repeats. *J. Mol. Biol.* **309**, 1-18 (2001).
- 35 32. Wang, T. et al. hADA3 is required for p53 activity. *EMBO J.* **20**, 6404-6413 (2001).
33. Vitale, N. et al. GIT proteins, A novel family of phosphatidylinositol 3,4, 5-trisphosphate-stimulated GTPase-activating proteins for ARF6. *J. Biol. Chem.* **275**, 13901-13916 (2000).
- 40 34. Mangiarini, L. et al. Exon 1 of the Huntington's disease gene containing a highly expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* **87**, 493-506 (1996).

35. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* **277**, 1990-1993 (1997).
36. Aebersold, R. & Mann, M. Mass spectrometry-based proteomics. *Nature* **422**, 198-207 (2003).
- 5 37. Bernstein, C., Bernstein, H., Payne, C. M. & Garewal, H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. *Mutat. Res.* **511**, 145-178 (2002).
- 10 38. Becher, M. W. et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and *IT15* CAG triplet repeat length. *Neurobiol. Dis.* **4**, 387-397 (1998).
39. Hernandez-Deviez, D. J., Casanova, J. E. & Wilson, J. M. Regulation of dendritic development by the ARF exchange factor ARNO. *Nature Neurosci.* **5**, 623-624 (2002).
- 5 40. Di Cesare, A. et al. p95-APP1 links membrane transport to Rac-mediated reorganization of actin. *Nature Cell Biol.* **8**, 521-530 (2000).
41. Zhang, H., Webb, D. J., Asmussen, H. & Horwitz, A. F. Synapse formation is regulated by the signaling adaptor GIT1. *J. Cell. Biol.* **161**, 131-142 (2003).
- 20 42. Graveland, G. A., Williams, R. S. & DiFiglia, M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. *Science* **227**, 770-773 (1985).
43. Ko, J. et al. Interaction between liprin-alpha and GIT1 is required for AMPA receptor targeting. *J. Neurosci.* **23**, 1667-1677 (2003).
- 25 44. Cha, J. H. et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. *Proc. Natl Acad. Sci. USA* **95**, 6480-6485 (1998).
45. Kim, S. et al. The GIT family of proteins forms multimers and associates with the presynaptic cytomatrix protein Piccolo. *J. Biol. Chem.* **278**, 6291-6300 (2003).
- 30 46. Scherzinger, E. et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. *Proc. Natl Acad. Sci. USA* **96**, 4604-4609 (1999).
47. Gutekunst, C. A. et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. *J. Neurosci.* **19**, 2522-2534 (1999).
- 35 48. Lunkes, A. et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. *Mol. Cell* **10**, 259-269 (2002).
- 40 49. Davy A., Bello P., Thierry-Mieg N., Vaglio P., Hitti J., Doucette-Stamm L., Thierry-Mieg D., Reboul J., Boulton S., Walhout A.J., Caux O., Vidal M. A protein-protein interaction map of the *Caenorhabditis elegans* 26S proteasome. *EMBO Rep.* **2001**, Sep; 2(9) : 821-8.

50. Albertinazzi, C., Za, L., Paris, S., and De Curtis, I. (2003). ADP-Ribosylation Factor 6 and a Functional PIX/p95-APP1 Complex Are Required for Rac1B-mediated Neurite Outgrowth. *Mol Biol Cell* 14, 1295-1307.
51. Alberts, B. (1998). The cell as a collection of protein machines: preparing the next generation of molecular biologists. *Cell* 92, 291-294.
52. Bader, G. D., and Hogue, C. W. (2002). Analyzing yeast protein-protein interaction data obtained from different sources. *Nature Biotechnol* 20, 991-997.
53. Becher, M. W., Kotzuk, J. A., Sharp, A. H., Davies, S. W., Bates, G. P., Price, D. L., and Ross, C. A. (1998). Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. *Neurobiol Dis* 4, 387-397.
54. Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F., and Sipione, S. (2001). Loss of normal huntingtin function: new developments in Huntington's disease research. *Trends Neurosci* 24, 182-188.
55. Claing, A., Perry, S. J., Achiriloaie, M., Walker, J. K., Albanesi, J. P., Lefkowitz, R. J., and Premont, R. T. (2000). Multiple endocytic pathways of G protein-coupled receptors delineated by GIT1 sensitivity. *Proc Natl Acad Sci USA* 97, 1119-1124.
56. Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., and Bates, G. P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 90, 537-548.
57. de Curtis, I. (2001). Cell migration: GAPs between membrane traffic and the cytoskeleton. *EMBO Rep* 2, 277-281.
58. Di Cesare, A., Paris, S., Albertinazzi, C., Dariozzi, S., Andersen, J., Mann, M., Longhi, R., and de Curtis, I. (2000). p95-APP1 links membrane transport to Rac-mediated reorganization of actin. *Nature Cell Biol* 8, 521-530.
59. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* 277, 1990-1993.
60. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411, 494-498.
61. Ge, H., Walhout, A. J., and Vidal, M. (2003). Integrating 'omic' information: a bridge between genomics and systems biology. *Trends Genet* 19, 551-560.
62. Graveland, G. A., Williams, R. S., and DiFiglia, M. (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. *Science* 227, 770-773.
63. Gutekunst, C. A., Li, S. H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., and Li, X. J. (1999). Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. *J Neurosci* 19, 2522-2534.

64. Harjes, P., and Wanker, E. E. (2003). The hunt for huntingtin function: interaction partners tell many different stories. *Trends Biochem Sci* 28, 425-433.
65. Harper, P. S. (1996). *Huntington's disease* (London, W.B.Saunders Ltd.).
- 5 66. Jimenez-Sanchez, G., Childs, B., and Valle, D. (2001). Human disease genes. *Nature* 409, 853-855.
67. Kim, S., Ko, J., Shin, H., Lee, J., Lim, C., Han, J., Altmann, W., Garner, C., Gundelfinger, E., Premont, R., et al. (2003). The GIT family of proteins forms multimers and associates with the presynaptic cytomatrix protein Piccolo. *J Biol Chem* 278, 6291-6300.
- 10 68. Li, S.-H., and Li, X.-J. (2004). Huntingtin-protein interactions and the pathogenesis of Huntington's disease. *Trends Genet* 20, 146-154.
69. Lunkes, A., Lindenberg, K. S., Ben-Haiem, L., Weber, C., Devys, D., Landwehrmeyer, G. B., Mandel, J. L., and Trottier, Y. (2002). Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. *Mol Cell* 10, 259-269.
- 5 70. Manabe Ri, R., Kovalenko, M., Webb, D. J., and Horwitz, A. R. (2002). GIT1 functions in a motile, multi-molecular signaling complex that regulates protrusive activity and cell migration. *J Cell Sci* 115, 1497-1510.
- 20 71. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., and Bates, G. P. (1996). Exon 1 of the Huntington's disease gene containing a highly expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87, 493-506.
- 25 72. Matafora, V., Paris, S., Dariozzi, S., and de Curtis, I. (2001). Molecular mechanisms regulating the subcellular localization of p95-APP1 between the endosomal recycling compartment and sites of actin organization at the cell surface. *J Cell Sci* 4, 4509-4520.
- 30 73. Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D., and Alon, U. (2002). Network motifs: simple building blocks of complex networks. *Science* 298, 824-827.
74. Paris, S., Longhi, R., Santambrogio, P., and de Curtis, I. (2003). Leucine-zipper-mediated homo- and hetero-dimerization of GIT family p95-ARF GTPase-activating protein, PIX-, paxillin-interacting proteins 1 and 2. *Biochem J* 372, 391-398.
- 35 75. Perutz, M. F. (1999). Glutamine repeats and neurodegenerative diseases: molecular aspects. *Trends Biochem Sci* 24, 58-63.
76. Sanchez, I., Mahlke, C., and Yuan, J. (2003). Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. *Nature* 421, 373-379.
- 40 77. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Höllenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. *Cell* 90, 549-558.

78. Schwikowski, B., Uetz, P., and Fields, S. (2000). A network of protein-protein interactions in yeast. *Nature Biotechnol* 17, 1030-1032.
79. Sittler, A., Walter, S., Wedemeyer, N., Hasenbank, R., Scherzinger, E., Eickhoff, H., Bates, G., Lehrach, H., and Wanker, E. (1998). SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. *Mol Cell* 4, 427-436.
80. Turner, C., West, K., and Brown, M. (2001). Paxillin-ARF GAP signaling and the cytoskeleton. *Curr Opin Cell Biol* 13, 593-599.
81. Vitale, N., Patton, W. A., Moss, J., Vaughan, M., Lefkowitz, R. J., and Premont, R. T. (2000). GIT proteins, A novel family of phosphatidylinositol 3,4,5-trisphosphate-stimulated GTPase-activating proteins for ARF6. *J Biol Chem* 275, 13901-13916.
82. von Mering, C., Krause, R., Snel, B., Cornell, M., Oliver, S. G., Fields, S., and Bork, P. (2002). Comparative assessment of large-scale data sets of protein-protein interactions. *Nature* 417, 399-403.
83. Wang, T., Kobayashi, T., Takimoto, R., Denes, A., Snyder, E., el-Deiry, W., and Brachmann, R. (2001). hADA3 is required for p53 activity. *EMBO J* 20, 6404-6413.
84. Wanker, E., Rovira, C., Scherzinger, E., Hasenbank, R., Walter, S., Tait, D., Colicelli, J., and Lehrach, H. (1997). HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. *Hum Mol Genet* 3, 487-495.
85. Witke, W., Podtelejnikov, A., Di Nardo, A., Sutherland, J., Gurniak, C., Dotti, C., and Mann, M. (1998). In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. *EMBO J* 17, 967-976.
86. Zhang, H., Webb, D. J., Asmussen, H., and Horwitz, A. F. (2003). Synapse formation is regulated by the signaling adaptor GIT1. *J Cell Biol* 161, 131-142.
87. Zhao, Z., Manser, E., Loo, T., and Lim, L. (2000). Coupling of PAK-interacting exchange factor PIX to GIT1 promotes focal complex disassembly. *MolCell Biol* 20, 6354-6363.